



## **Companion Document**

# Table of Contents

Chapter 1 Process: Management.....	3
Chapter 2 Process: Device Marketing Authorization and Facility Registration.....	13
Chapter 3 Process: Measurement, Analysis and Improvement.....	22
Chapter 4 Process: Medical Device Adverse Events and Advisory Notices Reporting.....	37
Chapter 5 Process: Design and Development.....	45
Chapter 6 Process: Production and Service Controls.....	61
Chapter 7 Process: Purchasing.....	86

# Medical Device Single Audit Program

## Chapter 1

### Process: Management

The intent of the **Management process** is to provide adequate resources for device design, manufacturing, quality assurance, distribution, installation, and servicing activities; to assure the quality management system is functioning properly and effectively; and to monitor the quality Management system and make necessary adjustments. A quality management system that has been implemented effectively and is monitored to identify and address existing and potential problems is more likely to produce medical devices that function as intended.

The **management representative** is responsible for ensuring that the requirements of the quality management system have been effectively defined, documented, implemented, and maintained. Prior to the review of any process, interview the management representative (or designee) to obtain an overview of the process and a feel for management's knowledge and understanding of the process.

The Management process is the first process to be audited per the MDSAP audit sequence.

### Auditing the Management Process

**Purpose:** The purpose of auditing the Management process is to verify top management ensures an adequate and effective quality management system has been established and maintained. The audit should commence and end with the management process.

**Outcomes:** As a result of the audit of the Management process, objective evidence will show whether the organization has:

- A) Identified processes needed for the quality management system, their application throughout the organization, and their sequence and interaction
- B) Defined, documented, and implemented procedures and instructions to ensure the development and maintenance of an effective quality management system
- C) Established quality objectives at relevant functions and levels within the organization consistent with the quality policy and ensured that these are periodically reviewed for continued suitability
- D) Determined the criteria and methods needed to ensure the operation and control of quality management system processes, including the identification and management of interrelated processes
- E) Committed the appropriate personnel and resources for infrastructure to the quality management system
- F) Assigned responsibility and authority to personnel and established the organizational structure to ensure processes assuring quality are not compromised
- G) Performed risk management planning and ongoing review of the effectiveness of risk management activities to ensure that policies, procedures and practices are established for analyzing, evaluating and controlling risk
- H) Ensured the continued effectiveness of the quality management system and its processes
- I) Established a quality management system which is capable of producing devices that are safe, effective

and suitable for their intended use.

**Links to Other Processes:** Measurement, Analysis and Improvement; Design and Development; Purchasing; Production and Service Controls; Device Marketing Authorization and Facility Registration

## **Audit Tasks and Links to Other Processes:**

### **1. Verify that a quality manual, management review, and quality management system procedures and instructions have been defined and documented.**

*Clause and Regulation:* [ISO 13485:2003: 4.1, 4.2.1, 4.2.2, 5.4.2; TG(MD)R Sch3 P1 1.4(4); RDC ANVISA 16/2013: 2.1, 2.2.1, 2.2.6; MHLW MO169: 5, 6, 7, 14; 21 CFR 820.20]

*Additional country-specific requirements:*

*United States (FDA):*

Confirm the organization has established a quality plan which defines the quality practices, resources, and activities relevant to devices that are designed and manufactured [21 CFR 820.20(d)].

*Assessing conformity:*

### **Quality management system**

Manufacturers of medical devices are required to establish a quality management system (including quality system procedures and instructions) that is tailored to the medical devices they are manufacturing or designing. The manufacturer's quality management system must properly implement all applicable requirements of Medical devices – Quality management systems – Requirements for regulatory purposes (ISO 13485:2003), Brazilian Good Manufacturing Practices (RDC ANVISA 16/2013), Japanese QMS Ordinance (MHLW MO 169), the Quality System Regulation (21 CFR Part 820) and specific requirements of medical device regulatory authorities participating in the MDSAP program, as well as other necessary controls to assure its finished devices, the design and manufacturing processes, and all related activities conform to approved specifications.

### **Quality system procedures and instructions**

The organization may refer to these as Level 1 documents. They are typically high-level, non-product and non-process specific documents and can usually be found in the Quality Manual. These procedures and instructions may contain information on the sequence and interaction of various quality management system processes. The Quality Manual is to outline the structure of the documentation and to describe the interaction of processes (e.g. the processes for identifying nonconformities and corrections and the processes for investigating nonconformities to determine root cause and corrective actions).

### **Management review procedures**

Management reviews are one of the basic tenants of a good quality management system. It is important that the organization establish procedures for conducting management reviews.

## Quality plan

The Quality System Regulation (21 CFR 820) requires that the organization establish a quality plan(s). A quality plan should include quality practices, resources, and activities relevant to the medical devices being designed and manufactured. It must be specifically relevant to devices. Elements of the quality plan are typically found in the organization's quality management system documentation (e.g., the Quality Manual, records, production procedures, quality system procedures, measurement, analysis and improvement procedures, and design and development procedures). A quality plan may be specific to one device or specific to overall systems. In effect, the quality plan serves as a roadmap of the quality management system. The plan can reference the applicable quality management system documents and indicate how they apply to the device that is the subject of the plan.

- 2. Confirm top management has documented the appointment of a management representative. Verify the responsibilities of the management representative include ensuring that quality management system requirements are effectively established and maintained, reporting to top management on the performance of the quality management system, and ensuring the promotion of awareness of regulatory requirements throughout the organization.**

*Clause and Regulation:* [ISO 13485:2003: 5.5.2; TG(MD)R Sch3 P1 1.4(5)(b); RDC ANVISA 16/2013: 2.2.5; MHLW MO169: 16; 21 CFR 820.20(b)]

*Additional country-specific requirements:* None

*Assessing conformity:*

### Management representative

It is important to confirm that top management has appointed a management representative and that the responsibilities and authorities of the management representative have been defined, documented, and implemented. The appointment of the management representative must be documented.

### Confirm appointment

The organization may document the appointment of a management representative in an organizational chart, Quality Manual, memorandum to file, position description, or other appropriate manner. The appointment of the management representative may be made by name or title.

### Evaluate responsibility and authority

Confirm that the management representative has established responsibility and authority for ensuring that the quality management system is effectively defined, documented, implemented, and maintained. The management representative must also have established responsibility and authority for reporting to top management on the performance of the quality management system. Confirmation can be accomplished by interviewing the management representative and top management and reviewing the Quality Manual, the management representative's position description, or similar documents.

### Other examples

Additional examples of evidence of the management representative's responsibilities and authorities may include:

- Sign-off authority for changes to procedures, processes, designs, etc.
- Authority to act on behalf of top management during the audit
- Authority to place products or processes on hold
- Responsibility for managing quality audit functions
- Responsibility for contributing to corrective and preventive action activities, complaint handling, and the handling of nonconforming product, etc.

## Training

Where the activities performed personally by the management representative result in a determination of whether product meets requirements, including regulatory requirements, the management representative must be competent to perform such activities. In such cases, verify that training and experience includes the relevant regulatory requirements.

### **3. Verify that a quality policy and objectives have been set at relevant functions and levels within the organization. Ensure the quality objectives are measurable and consistent with the quality policy. Confirm appropriate measures are taken to achieve the quality objectives.**

*Clause and Regulation:* [ISO 13485:2003: 5.3, 5.4.1; TG(MD)R Sch3 P1 1.4(5)(a); RDC ANVISA 16/2013: 2.2.1; MHLW MO169: 12, 13; 21CFR 820.20(a)]

*Additional country-specific requirements:* None

*Assessing conformity:*

## Quality policy

A quality policy is comprised of one or more statements of the organization's intentions and direction with respect to quality. Top management must establish the quality policy and ensure quality objectives are established that are consistent with the quality policy. Top management must ensure that the quality policy is understood and communicated at all levels of the organization. An assessment of whether the organization's quality system is satisfying the established quality policy and objectives should be a topic addressed during management reviews.

## Quality objectives

An effective way of determining whether quality objectives have been implemented is to ask for examples of quality objectives and the status of these objectives. Typically, a quality objective is expressed as a measurable target or goal. An example of an organization's quality objective could be "to have all essential components meet specifications at a defined reliability rate or better." To accomplish this objective, the organization will have to identify, evaluate, and approve reliable suppliers or bring the manufacturing of that component in-house.

### **4. Review the manufacturer's organizational structure and related documents to verify that they include provisions for responsibilities, authorities (e.g., management representative), personnel, resources for infrastructure, competencies, and training to ensure that personnel have the necessary competence to design and manufacture devices in accordance with the planned arrangements and applicable regulatory requirements.**



*Clause and Regulation:* [ISO 13485:2003: 5.1, 5.5.1, 5.5.2, 6.1, 6.2; TG(MD)R Sch3 P1 1.4(5)(b)(ii); RDC ANVISA 16/2013: 2.2.2, 2.2.3, 2.2.4, 2.3; MHLW MO169: 10, 15, 16, 21, 22, 23; 21 CFR 820.20(b), 820.25]

*Additional country-specific requirements:* None

*Assessing conformity:*

## **Responsibility and authority**

Methods for completing this audit task include reviewing the organizational chart(s) and asking authority and responsibility questions. The responsibilities and authorities of various individuals within the organization are also typically described within the Quality Manual, position descriptions, and job postings.

## **Resources**

Top management is responsible for ensuring that resources necessary to maintain an effective quality management system are provided. Resources include money, equipment, supplies, and personnel. One method for confirming that adequate resources are made available is to ask the management representative to provide several examples of recent requests for different types of resources and describe the outcomes of these requests.

### **5. Determine the extent of outsourcing of processes that may affect the conformity of product with specified requirements and verify the proper documentation of controls in the quality management system.**

*Clause and Regulation:* [ISO 13485:2003: 4.1, 4.2.1; RDC ANVISA 16/2013: 2.5; MHLW MO169: 5, 6; 21 CFR 820.50]

*Additional country-specific requirements:*

#### *Australia (TGA):*

If an Australian Sponsor undertakes an activity that is preferred by the manufacturer, or required, to be under the control of the manufacturer, verify that the roles and responsibilities of the Australian Sponsor are documented in the manufacturer's quality management system and that the Sponsor is qualified and controlled as a supplier. For example, but not limited to; a labeling activity to ensure that the name and address of the Australian Sponsor accompanies the device [TG(MD)R Reg 10.2], the installation of a device, or the servicing of a device.

#### *Canada (HC):*

Verify that the roles and responsibilities of any regulatory correspondents, importers, distributors, or providers of a service are clearly documented in the organization's quality management system and are qualified as suppliers and controlled.

*Assessing conformity:*

## **Outsourcing**

Most organizations outsource at least some products (including services) that affect the ability of the medical device to conform to specified requirements. Some organizations outsource the majority of products. During interview of the management representative, ascertain the extent to which the organization outsources processes essential for the proper functioning of the finished medical device. Process performance and product conformity, including the performance of supplied product, must be included in management review. The organization must ensure control over outsourced products and processes that affect product conformance with specified requirements.

**Link: Purchasing**

During audit of the organization's Purchasing process, ensure that management has assured the appropriate level of control over suppliers, including an assessment of the relationship between supplied products and product risk.

- 6. Confirm the organization has determined the necessary competencies for personnel performing work affecting product quality, provided appropriate training, and made personnel aware of the relevance and importance of their activities on product quality and achievement of the quality objectives. Ensure records of training and competencies are maintained.**

*Clause and Regulation:* [ISO 13485:2003: 4.2.1, 6.2.2; RDC ANVISA 16/2013: 2.2.3, 2.2.4, 2.3; MHLW MO169: 6, 23; 21 CFR 820.25]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Confirm that the manufacturer ensures that any consultant who gives advice regarding design, purchasing, manufacturing, packaging, labeling, storage, installation, or servicing of medical devices has proper qualification to perform such tasks. Those consultants shall be contracted as a formal service supplier, according to purchasing controls defined by the manufacturer [RDC ANVISA 16/2013: 2.3.3].

*United States (FDA):*

Verify that resources include the assignment of trained personnel to meet the requirements of 21 CFR Part 820, including management, performance of work, assessment activities, and internal quality audits [21 CFR 820.20(b)(2)].

*Assessing conformity:*

**Training**

A review of employee training records can be performed to ensure that employees have been trained regarding the organization's quality policy and objectives. In particular, this should be done for employees involved in key operations that affect product realization and product quality.

**Link: Production and Service Controls**

During the audit of the Production and Service Controls process, ensure that employees who are involved in key operations that affect product realization and product quality have been trained in their specific job tasks, as well as the quality policy and objectives. When appropriate, review the training records for those employees whose activities have contributed to process nonconformities.

- 7. *Verify that management has committed to and has responsibility for overall risk management planning, including ongoing review of the effectiveness of risk management activities ensuring that policies, procedures and practices are established and documented for analyzing, evaluating and controlling product risk throughout product realization.***

*Clause and Regulation:* [ISO 13485:2003: 7.1; TG(MD)R Sch1 P1 2; RDC ANVISA 16/2013: 2.4; MHLW MO169: 26; 21 CFR 820.30(g)]

*Additional country-specific requirements:* None

*Assessing conformity:*



## Commitment to risk management

Confirm that top management has shown commitment to the risk management process by ensuring the provision of adequate resources and the assignment of qualified personnel for risk management activities. Risk-based decisions occur throughout the various quality management system processes. Top management is responsible for defining and documenting the policy for determining criteria for risk acceptability. Additionally, ensure top management reviews the suitability of the risk management process. This review may be part of the management review. Previously unidentified risks discovered during the production and post-production of the medical device may indicate a need to improve the risk management process. Each organization must decide how much risk is acceptable.

When appropriate, assess the role of top management when risk-based decisions are made that appear to justify levels of risk that do not meet the organization's previously established risk-acceptance criteria.

### ***Link: Design and Development***

Risk management usually starts in conjunction with the design and development planning process at a point in the development when the results of risk analysis can affect the design process. During audit of the Design and Development process, evaluate top management's commitment to risk management activities. Evidence of commitment to risk management may include the implementation of new or more stringent controls, external controls (e.g. additional supplier-related controls), or design changes to maintain an acceptable level of product risk.

## **8. Verify that procedures have been defined, documented, and implemented for the control of documents and records required by the quality management system. Confirm the organization retains records and at least one obsolete copy of controlled documents for a period of time at least equivalent to the lifetime of the device, but not less than two years from the date of product release.**

*Clause and Regulation:* [ISO 13485:2003: 4.2.1, 4.2.3, 4.2.4; RDC ANVISA 16/2013: 3.1; MHLW MO169: 6, 8, 9; 21 CFR 820.40, 820.180]

*Additional country-specific requirements:*

### *Australia (TGA):*

Confirm that Quality Management System documentation and records in relation to a device are retained by the manufacturer for at least 5 years [TG(MD)R Sch3 P1 1.9].

### *Brazil (ANVISA):*

Verify that change records include a description of the change, identification of the affected documents, the signature of the approving individual(s), the approval date, and when the change becomes effective [RDC ANVISA 16/2013: 3.1.5].

Confirm that the manufacturer maintains a master list of the approved and effective documents [RDC ANVISA 16/2013: 3.1.5].

Verify that electronic records and documents have backups [RDC ANVISA 16/2013: 3.1.6].

### *Japan (MHLW):*

Confirm that Quality Management System documentation and records in relation to a device are retained by the Registered Manufacturing Site for the following periods [MHLW MO169: 8.4, 9.3, 67, 68]:

1. 15 years for “specially designated maintenance control required medical devices” [or one year plus the shelf life for products when the shelf life or the expiry date (hereinafter simply referred to as the “shelf life”) plus one year exceeds 15 years]
2. 5 years for the products other than the ‘specially designated maintenance control required medical devices’ (or one year plus the shelf life for the products of which the shelf life plus one year exceeds 5 years).
3. 5 years for training records and documentation

Note: PMD Act 2.8 defines the term “specially designated maintenance control required medical device” as: A medical device designated by the Minister of Health, Labour and Welfare after hearing the opinion of the Pharmaceutical Affairs and Food Sanitation Council as those whose potential risk to the diagnosis, treatment or prevention of disease is significant without proper control since this kind of equipment requires expert knowledge and skill in examination for maintenance and inspection, repair and other management.

*United States (FDA):*

Confirm that approved changes to documents are communicated to the appropriate personnel in a timely manner [21 CFR 820.40(b)].

*Assessing conformity:*

## **Implementation of document and records procedures**

Confirm that the organization has defined, documented, and implemented procedures for control of quality management system documents and records. Evidence that these controls are effective can be ascertained through the audit of the other quality management system processes. For example, evidence that the document controls process is ineffective might be the observation of obsolete procedures being used or required records being unavailable.

Ensure at least one copy of obsolete controlled documents is maintained.

## **9. Verify that management reviews are being conducted at planned intervals and that they include a review of the suitability and effectiveness of the quality policy, quality objectives, and quality management system to assure that the quality management system meets all applicable regulatory requirements.**

*Clause and Regulation:* [ISO 13485:2003: 5.6; TG(MD)R Sch3 P1 1.4(5)(b)(iii); RDC ANVISA 16/2013: 2.2.6; MHLW MO169: 18, 19, 20; 21 CFR820.20(c)]

*Additional country-specific requirements:* None

*Assessing conformity:*

## **Verify implementation of management review procedures**

It is important to verify that the organization has implemented effective management review procedures. Top management must review the suitability, adequacy and effectiveness of the organization’s quality management system at defined intervals and with sufficient frequency to ensure that the quality management system satisfies applicable requirements of Medical devices – Quality management systems – Requirements for regulatory purposes (ISO 13485:2003), Brazilian Good Manufacturing Practices (RDC ANVISA 16/2013), Japanese QMS Ordinance (MHLW MO 169), the Quality System Regulation (21 CFR Part 820) and specific requirements of medical device regulatory authorities participating in the MDSAP program, in addition to the organization’s own established quality policy and objectives. The dates and results of the management reviews must be documented. These documentation requirements must be included in the management review procedure.

Other requirements commonly seen in management review procedures include a fixed agenda of topics to be discussed (with flexibility for unique agenda items to be added), the necessary attendees who are to participate in the management review, and how action items resulting from the management review are to be addressed and input into the Measurement, Analysis and Improvement process when necessary. Ensure that the quality policy and objectives have been reviewed for continued suitability and that any changes to regulatory requirements have been identified. Other inputs to management review include results of internal and external audits, customer feedback, process performance and product conformity, status of preventive and corrective actions, follow-up actions from previous management reviews, changes that could affect the quality management system, and recommendations for improvement.

***Link: Measurement, Analysis and Improvement***

During audit of the Measurement, Analysis and Improvement process, confirm when necessary that action items resulting from Management review are considered for corrective or preventive action.

**10. Confirm that management has identified and ensured the applicable device marketing authorization and facility registration processes have been followed and that appropriate documents have been submitted to the applicable regulatory authorities in the markets in which the devices are offered for commercial distribution.**

*Clause and Regulation:* [ISO 13485:2003: 4.2.1, 7.2.1]

*Additional country-specific requirements:*

*Australia (TGA):*

Medical device market authorization, facility registration, and the submission of appropriate documentation to the TGA, are responsibilities of the Australian Sponsor. Australian manufacturers are also, by definition, Australian Sponsors.

*For manufacturers located outside of Australia:*

Confirm that the manufacturer is aware of the Australian Sponsor's entries in the Australian Register of Therapeutic Goods (ARTG).

Confirm that the manufacturer has a written agreement with the Australian Sponsor to ensure that information about the compliance of a device included in the ARTG, with the Essential Principles through the application of a relevant conformity assessment procedure, and information concerning adverse events, advisory notices and recalls is readily available to the Sponsor or the TGA. The agreement must also require the Australian Sponsor to provide the manufacturer with any information in relation to the manufacturer's obligations under the conformity assessment procedures and any information in relation to whether the medical device complies with the Essential Principles [TG Act s41FD, s41FN(3)(e), TG(MD)R Sch3 P1 Cl1.4(3), Cl1.7].

*Brazil (ANVISA):*

For domestic manufacturers, confirm that the establishment has ANVISA's authorization to manufacture medical devices (AFE - Autorização de Funcionamento da Empresa). For domestic and international manufacturers, verify that the products already distributed in the Brazilian market, are registered/notified with ANVISA [Brazilian Federal Law 6360/76].

*Canada (HC):*

Verify that the manufacturer has defined, documented, and implemented processes to ensure that devices are licensed prior to sale [CMDR Sections 26, 32, 34, 43].

Verify that the manufacturer has defined, documented and implemented processes to ensure that any new

or modified quality management system certificate issued to the manufacturer for regulatory purposes is submitted to the Minister within 30 days after it is issued [CMDR Section 43.1].

*Japan (MHLW):*

Confirm that the products distributed in the Japanese market, are approved/ certified/ notified with PMDA/ Registered Certification Bodies [PMD Act: 23-2-5(1), 23-2-23(1), 23-2-12(1)].

For a manufacturing site which conducts primary design, primary assembly, sterilization, domestic storage until final release of products, confirm that the site is registered by MHLW. [PMD Act: 23-2-3, 23-2-4]

*United States (FDA):*

Confirm the establishment is registered with FDA and devices marketed to the United States are listed.

Confirm the manufacturer has submitted a pre-market notification or approval (as applicable) to FDA prior to marketing the device in the United States [21 CFR 807].

*Assessing conformity:*

## **Responsibilities and authorities of personnel**

During audit of the Management process, ascertain the responsibilities and authorities of employees responsible for ensuring proper registration, licensing, notification and listing information is accurately submitted to regulatory authorities or authorized representatives (e.g. Australian Sponsor) participating in the MDSAP. Confirm the appropriate information is submitted to regulatory authorities or authorized representatives during the review of the Device Marketing Authorization and Facility Registration process. Preliminary review of Device Marketing Authorization and Facility Registration can be made during audit of the Management process, followed by comprehensive coverage for specific medical devices selected for review under the Design and Development process.

***Link: Device Marketing Authorization and Facility Registration***

- 11. At the conclusion of the audit, a decision should be made as to whether top management has demonstrated the necessary commitment to ensure a suitable and effective quality management system is in place and being maintained and whether the effectiveness of the system has been communicated to personnel.**

*Clause and Regulation:* [ISO 13485:2003: 5.1, 5.5.3; RDC ANVISA 16/2013: 2.2.1; MHLW MO169: 10, 17; 21 CFR 820.20(a), 820.5]

*Assessing conformity:*

## **Audit the other processes**

During the audit of the other MDSAP processes, the audit team will have the opportunity to assess whether management is appropriately carrying out its responsibilities; whether the quality policy is understood, implemented, and maintained at all levels of the organization; if the necessary resources are being provided to maintain an effective quality management system; if the management representative has the necessary responsibilities and authorities; the adequacy of the organizational structure; and whether management reviews and quality audits are effective, etc.

Remember that a quality management system that has been implemented effectively, monitored to identify and address existing and potential problems, and has an integrated risk management process utilizing risk-based decision-making is more likely to produce medical devices that function as intended.

# Medical Device Single Audit Program

## Chapter 2

### Process: Device Marketing Authorization and Facility Registration

The Device Marketing Authorization and Facility Registration process may be audited as a linkage from the Management process and/or the Design and Development process.

**Purpose:** The purpose of auditing the Device Marketing Authorization and Facility Registration process is to verify that the organization has performed the appropriate activities regarding device marketing authorization and facility registration with regulatory authorities participating in the MDSAP.

**Outcomes:** As a result of the audit of the Device Marketing Authorization and Facility Registration process, objective evidence will show whether the organization has:

- A) Complied with requirements to register and/or license device facilities
- B) Submitted device listing information to regulatory authorities when applicable
- C) Obtained device marketing authorization in the appropriate jurisdictions
- D) Arranged for assessment of changes (where applicable) and obtained marketing authorization for changes to devices or the quality management system which require amendment to existing marketing authorization

#### ***Links to Other Processes: Management, Design and Development***

#### **Audit Tasks and Links to Other Processes:**

1. Verify the organization has complied with regulatory requirements to register and/or license device facilities and submit device listing information in the appropriate jurisdictions where the organization markets or distributes their devices.

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.2.1; see the country-specific requirements below]

*Country specific requirements:*

*Australia (TGA):*

Manufacturer of a medical device is the person who is responsible for the design, production, packaging and labeling of the device before it is supplied under the person's name, whether or not it is the person, or another person acting on the person's behalf, who carries out those operations.

Australian importers (Sponsors) are required to include (register) medical devices from non-Australian manufacturers in the Australian Register of Therapeutic Goods (ARTG). To assist the Australian sponsor, non-Australian manufacturers must undertake the following tasks to demonstrate that they have met the obligations on manufacturers who wish to supply to Australia;

- Classify the device using the Australian classification rules
- Identify an Australian conformity assessment procedure that is to be applied in accordance with the classification of the device
- Obtain 3rd party assessment of their QMS and the device in accordance with the selected conformity assessment procedure or an equivalent EU MDD, AIMD or IVDD procedure



- Prepare an Australian Declaration of Conformity in accordance with the requirements of the Conformity Assessment Procedure that has been applied [TG(MD)R Sch 3 P1 C11.8].
- Either provide to the Australian Sponsor, or enter into a written agreement with the Sponsor that requires the manufacturer to provide to the Sponsor, or the TGA, on request;
  - o Evidence that their device complies with the Australian Essential Principles
  - o Evidence that the manufacturer has applied an Australian Conformity Assessment Procedure, or equivalent MDD / AIMD / IVDD conformity assessment procedure.
  - o Information about reportable adverse events, advisory notices or recalls
  - o Permit the TGA to inspect the manufacturer's premises at any reasonable time, to inspect medical devices of any kind on those premises and to examine, take measurements of, conduct tests on, require tests to be conducted on or take samples of medical devices of any kind on those premises or anything on those premises that relates to medical devices of any kind. While on those premises, to make any still or moving image or any recording of those premises or anything on those premises; and
  - o If requested to do so by an authorized person, produce to the person such documents relating to devices of the kind included in the Register as the person requires and allow the person to copy the documents
  - o That the manufacturer will comply with any conditions imposed on the manufacture of devices
  - o That the Sponsor provide the manufacturer with information in relation to the manufacturer's obligations under a conformity assessment procedure and information in relation to whether the devices comply with the Essential Principles [TG Act 41FN(3)(e)].

*Refer to:*

- *Therapeutic Goods Act 1989*
  - o Part 4-2 – Essential Principles and medical device standards
  - o Part 4-3 – Conformity Assessment Procedures
  - o Section 41FD – Matters to be certified
  - o Section 41FN – Conditions applying automatically
  - o Section 41FO – Conditions imposed when kinds of medical devices are included in the Register
  - o Section 41FP – Conditions imposed after kinds of medical devices are included in the Register
- *Therapeutic Goods (Medical Devices) Regulations 2002*
  - o Regulation 3.5 – Medical devices manufactured outside Australia
  - o Schedule 1 – Essential Principles
  - o Schedule 2 – Classification Rules
  - o Schedule 3 – Conformity Assessment Procedures

*Brazil (ANVISA):*

For a domestic manufacturer, confirm that the establishment has ANVISA's authorization to manufacture medical devices (AFE – Autorização de Funcionamento da Empresa). For domestic and international manufacturers, verify that the products already distributed in the Brazilian market are registered/notified with ANVISA [Brazilian Federal Law nº 6360/76].



Manufacturer means any person who designs, manufactures, assembles or processes finished devices, including those who only perform sterilization process, labeling and packaging [RDC ANVISA 16/2013: 1.2.9].

According Brazilian Legislation, the Good Manufacturing Practice (GMP) certification is a prerequisite for medical device registration. Therefore, the facility site inspection precedes the device registration request. Medical devices subject to notification do not need the GMP certificate, but even not being certified, their manufacturers shall comply with the GMP requirements.

- Medical devices registration/notification:

Device marketing authorization shall be requested to ANVISA by the domestic manufacturer or importer (legal representative) formally established in Brazil.

Registration is a comprehensive process for market authorization, applied to medical devices in classes III and IV, and some class I and II devices, listed on an exception list [ANVISA IN nº 03/2011].

Notification is a simplified market authorization process, applied to medical device classes I and II, and not listed on the exception list [ANVISA IN nº 03/2011].

Both registration and notification are valid for 5 years – renewal of these authorizations shall be requested upon time defined at Brazilian Law 6360/1976.

- Establishment license:

Domestic manufacturer: shall be authorized by ANVISA, at a minimum, as a manufacturer of medical devices. This license includes authorization to store and distribute medical devices.

Importer: the importer is considered the legal representative of the international manufacturer in Brazil and shall be authorized by ANVISA to import, store, and distribute medical devices. In the case of outsourcing the storage, the importer does not need authorization for this activity.

#### *Canada (HC):*

Manufacturer means a person who sells a medical device under their own name, or under a trade-mark, design, trade name or other name or mark owned or controlled by the person, and who is responsible for designing, manufacturing, assembling, processing, labeling, packaging, refurbishing or modifying the device, or for assigning to it a purpose, whether those tasks are performed by that person or on their behalf [CMDR 1].

No person shall import or sell a Class II, III or IV medical device unless the manufacturer of the device holds a license in respect of that device or, if the medical device has been subjected to a change described in section 34, an amended medical device license [CMDR 26].

An application for a medical device license shall be submitted to the Minister by the manufacturer of the medical device in a format established by the Minister [CMDR 32].

An application for a medical device license shall include a copy of a quality management system certificate certifying that the quality management system under which the medical device is manufactured (class II) or designed and manufactured (class III or IV) satisfies National Standard of Canada CAN/CSA-ISO 13485:2003. [CMDR 32(2)(f); 32(3)(j); 32(4)(p)].

#### *Japan (MHLW):*

“Marketing Authorization Holder” means a person who resides in Japan and is granted a license for marketing from a prefectural government [PMD Act: 23-2].

Application or Notification for marketing:

- 1) Class 2, class 3, and class 4 medical devices except for the devices specified by the requirement of PMD Act: 23-2-23 (1):

An “Application for Marketing Approval” shall be submitted to PMDA by the Marketing Authorization Holder to receive authorization for marketing a medical device in Japan. [PMD Act: 23-2-5 (1)] An “Application for QMS Audit” shall also be submitted to PMDA by the Marketing Authorization Holder, when

they do not have an effective QMS Certificate for the device. [PMD Act: 23-2-5 (6), (7)]

2) Class 2 and class 3 medical devices which are specified by the requirement of PMD Act: 23-2-23 (1):

An “Application for Marketing Certification” shall be submitted to a Registered Certification Body (RCB) by the Marketing Authorization Holder to receive authorization for marketing a medical device in Japan. [PMD Act: 23-2-23 (1)] An “Application for QMS Audit” shall also be submitted to an RCB by the person, when the person does not have a valid QMS Certificate for the device. [PMD Act: 23-2-23 (3), (4)].

3) Class 1 medical devices:

A “Notification for Marketing” shall be submitted to PMDA by the Marketing Authorization Holder for marketing a class 1 device in Japan [PMD Act: 23-2-12 (1)]. A class 1 medical device doesn’t need any QMS Certificate for marketing.

Facility Registration (Registered Manufacturing Site):

A medical device manufacturing site which conducts one of the designated manufacturing processes listed below shall be registered:

- a) Primary Designing,
- b) Primary assembly,
- c) Sterilization, and
- d) Domestic storage before final release.

These medical device manufacturing sites are called “Registered Manufacturing Sites”. Sites performing the cited activities must submit an application to PMDA for registration [PMD Act: 23-2-3, 23-2-4].

*United States (FDA):*

21 CFR 807 - Establishment Registration and Device Listing for Manufacturers and Initial Importers of Devices:

Establishment means a place of business under one management at one general physical location at which a device is manufactured, assembled, or otherwise processed.

Owner or operator means the corporation, subsidiary, affiliated company, partnership, or proprietor directly responsible for the activities of the registering establishment.

Owner or operator must register the establishment and submit listing information to Food and Drug Administration (FDA) for those devices in commercial distribution, regardless of classification—

The registration and listing requirements must pertain to any person who:

- (1) Initiates or develops specifications for a device that is to be manufactured by a second party for commercial distribution by the person initiating specifications;
- (2) Manufactures for commercial distribution a device either for itself or for another person; regardless of whether the manufacturer places the device into commercial distribution or returns the device to the customer;
- (3) Repackages or relabels a device;
- (4) Acts as an initial importer;
- (5) Manufactures components or accessories which are ready to be used for any intended health-related purpose and are packaged or labeled for commercial distribution for such purpose;
- (6) Acts as a contract sterilizer, whether the contract sterilizer places the devices into commercial distribution or returns the devices to the customer;

- (7) Acts as a complaint file establishment; or
- (8) Is a device establishment located in a foreign trade zone

**Link: Management**

During audit of the Management process, confirm that management is aware of and has made arrangements for device marketing authorization and facility registration.

**2. Confirm the organization has received appropriate marketing clearance or approval in the regulatory jurisdictions where the organization markets their devices.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.2.1; see the country-specific requirements below]

*Country specific requirements:*

*Australia (TGA):*

Marketing authorization (inclusion in the Australian Register of Therapeutic Goods [ARTG]) is granted to the Australian Sponsor. Non-Australian manufacturers will need to assist the Sponsor through the provision of information. A Sponsor is not permitted to import a device until market authorization has been granted.

A non-Australian manufacturer's procedures should ensure that product is not released for export and supply to Australia unless the Australian Sponsor has been issued with a "Certificate of Inclusion in the Australian Register of Therapeutic Goods" that identifies each kind of medical device that has been approved for supply to the Australian market [TG Act s41FJ].

*Brazil (ANVISA):*

In Brazil there are two kinds of marketing clearance, registration and notification:

Device market clearance shall be requested to ANVISA by the domestic manufacturer or importer (legal representative) formally established in Brazil.

Registration is a comprehensive process for market authorization, applied to medical devices in classes III and IV, and some class I and II devices, listed on an exception list [ANVISA IN nº 03/2011].

Notification is a simplified market authorization process, applied to medical devices classes I and II, not listed on the exception list [ANVISA IN nº 03/2011].

Both registration and notification are valid for 5 years – renewal of these authorizations shall be requested upon time defined at Brazilian Law 6360/1976.

*Canada (HC):*

No person shall import or sell a Class II, III or IV medical device unless the manufacturer of the device holds a license in respect of that device or, if the medical device has been subjected to a change described in section 34, an amended medical device license [CMDR 26].

*Japan (MHLW):*

Any person who intends to market a medical device in Japan shall for a commercial purpose have a license for marketing granted by the prefectural government. This person is called a "Marketing Authorization Holder" (MAH) and shall reside in Japan [PMD Act: 23-2]. The person has to submit an Application for Marketing Approval/Certification (class 2, 3 or 4 medical device) or a Notification for Marketing (class 1 medical device) to receive marketing clearance for the medical device. No person shall market a medical device in Japan, unless the Marketing Authorization Holder of the device has been granted the marketing clearance [PMD Act: 23-2-5 (1), 23-2-23 (1), 23-2-12].

*United States (FDA):*

21 CFR 807.81- When a pre-market notification is required:

Each person who is required to register his establishment pursuant to 807.20 must submit a premarket notification submission to the Food and Drug Administration at least 90 days before he proposes to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of a device intended for human use which meets any of the following criteria:

- (1) The device is being introduced into commercial distribution for the first time; that is, the device is not of the same type as, or is not substantially equivalent to, (i) a device in commercial distribution before May 28, 1976, or (ii) a device introduced for commercial distribution after May 28, 1976, that has subsequently been reclassified into class I or II.
- (2) The device is being introduced into commercial distribution for the first time by a person required to register

21 CFR 814 – Premarket Approval

A Premarket approval is required for any FDA class III device that was not on the market (introduced or delivered for introduction into commerce for commercial distribution) before May 28, 1976, and is not substantially equivalent to a device on the market before May 28, 1976, or to a device first marketed on, or after that date, which has been classified into class I or class II.

***Link: Management, Design and Development***

During the audit of the Management and Design and Development processes, ensure that management is aware of requirements for device marketing authorization and facility registration, and that these are considered when designing the device. Confirm that management obtains marketing authorization in the appropriate jurisdictions prior to commercial distribution of the device.

**3. Verify the organization has identified changes to marketed devices or the quality management system which require notification to regulatory authorities.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.2.1; see the country-specific requirements below]

*Country specific requirements:*

*Australia (TGA):*

The manufacturer is required to notify their assessment body of:

A proposed substantial change to their QMS

A proposed change to the kinds of medical devices to which the system is to be applied

For Class III or AIMD, a proposed change to design, or intended performance of the device

Refer to:

Therapeutic Goods (Medical Devices) Regulations 2002

Regulation 3.5 – Medical devices manufactured outside Australia

Schedule 3 - The relevant conformity assessment procedure chosen by the manufacturer

Note: An entry in the Australian Register of Therapeutic Goods (inclusion) in the name of the Australian Sponsor is in effect until cancelled.

### *Brazil (ANVISA):*

Changes involving medical devices already approved by ANVISA, shall be submitted for a new approval [Brazilian Law nº 6360/76 - Art. 13]. Changes/modifications that shall be submitted are those ones classified as significant change, which affects: a) features of safety and effectiveness, including measures to communicate information (ex. residual risk); b) identification of the device or its manufacturer or manufacturing site; c) indication for use, including its purpose, patient type (adult, pediatric, newborn) or environment to be used (domestic, hospital, ambulance, etc.); d) device classification; e) technical specification of the device, including composition and other operational/technical/physical features; f) manufacturing method.

Examples of modifications that may require a new submission include, but are not limited to, the following:

- Sterilization method;
- Structural material / composition;
- New or additional manufacturer;
- Manufacturing method;
- Manufacturing site;
- Operating parameters or conditions for use;
- Patient or user safety features;
- Sterile barrier packaging material;
- Stability or expiration claims;
- Design;
- Labels and instructions of use (if modification is regarding information);
- Commercial name;
- Indication for use;
- New software version;
- Commercial presentation;
- Inclusion of a new device in a family of medical devices already approved;
- Inclusion of new accessories.

### *Canada (HC):*

If the manufacturer proposes to make one or more changes, the manufacturer shall submit to the Minister, in a format established by the Minister, an application for a medical device license amendment including the information and documents set out in section 32 that are relevant to the change [CMDR 34].

Every manufacturer of a licensed medical device shall, annually before November 1 and in a form authorized by the Minister, furnish the Minister with a statement signed by the manufacturer or by a person authorized to sign on the manufacturer's behalf describing any change to the information and documents supplied by the manufacturer with respect to the device, other than those to be submitted under section 34 or 43.1 [CMDR 43].

If the holder of a medical device license discontinues the sale of the medical device in Canada, the licensee shall inform the Minister within 30 days after the discontinuance, and the license shall be cancelled at the time that the Minister is informed [CMDR 43(3)].

Subject to section 34, if a new or modified quality management system certificate is issued in respect of a

licensed medical device, the manufacturer of the device shall submit a copy of the certificate to the Minister within 30 days after it is issued [CMDR 43.1].

*Japan (MHLW):*

A change to a medical device which is approved/certified by PMDA/a Registered Certification Body may require the Marketing Authorization Holder to submit a change application or a change notification [PMD Act 23-2-5 (1), 23-2-5 (11), 23-2-5 (12), 23-2-23 (1), 23-2-23 (6), 23-2-23 (7)]. Changes that require a change application or a change notification are those which directly impact the safety and efficacy of the device; and/or the intended use, materials, etc. approved during marketing approval / certification.

The Registered Manufacturing Site shall communicate changes with the Marketing Authorization Holder when the Registered Manufacturing Site plans such changes. This allows the Marketing Authorization Holder to take any necessary regulatory actions mentioned above [MHLW MO169; 29].

Examples of changes that may require an application or a notification include, but are not limited to:

- Design;
- Composition;
- Raw material;
- Sterilization method;
- Manufacturing method;
- Manufacturing site;
- Patient or user safety features;
- Operating parameters or conditions for use;
- Indication for use;
- Shelf life;
- Performance specification.

*United States (FDA):*

21 CFR 807 - Establishment Registration and Device Listing for Manufacturers and Initial Importers of Devices:

Update the device listing information during each June and December or, at its discretion, at the time the change occurs. Conditions that require updating and information to be submitted for each of these updates are as follows:

- (1) If an owner or operator introduces into commercial distribution a device identified with a classification name not currently listed by the owner or operator
- (2) If an owner or operator discontinues commercial distribution of all devices in the same device class

Update registration if changes in individual ownership, corporate or partnership structure, or location of at the time of annual registration, or by letter if the changes occur at other times. This information must be submitted within 30 days of such changes. Changes in the names of officers and/or directors of the corporation(s) must be filed with the establishment's official correspondent and must be provided to the Food and Drug Administration upon receipt of a written request for this information.

21 CFR 807.81(a)(3) - When a premarket notification submission is required:



A new complete 510(k) application is required for changes or modifications to an existing device, where the modifications could significantly affect the safety or effectiveness of the device or the device is to be marketed for a new or different indication. All changes in indications for use require the submission of a 510(k).

Examples of modifications that may require a 510(k) submission include, but are not limited to, the following:

- Sterilization method;
- Structural material;
- Manufacturing method;
- Operating parameters or conditions for use;
- Patient or user safety features;
- Sterile barrier packaging material;
- Stability or expiration claims;
- Design.

#### 21 CFR 814.39 – PMA Supplements

After FDA's approval of a PMA, an applicant shall submit a PMA supplement for review and approval by FDA before making a change affecting the safety or effectiveness of the device for which the applicant has an approved PMA. While the burden for determining whether a supplement is required is primarily on the PMA holder, changes for which an applicant shall submit a PMA supplement include, but are not limited to, the following types of changes if they affect the safety or effectiveness of the device:

- (1) New indications for use of the device
- (2) Labeling changes
- (3) The use of a different facility or establishment to manufacture, process, or package the device
- (4) Changes in sterilization procedures
- (5) Changes in packaging
- (6) Changes in the performance or design specifications, circuits, components, ingredients, principle of operation, or physical layout of the device
- (7) Extension of the expiration date of the device based on data obtained under a new or revised stability or sterility testing protocol that has not been approved by FDA

#### ***Link: Design and Development***

During the audit of the Design and Development process, the audit team should confirm the organization has considered regulatory requirements for device marketing authorization and facility registration; and has complied with these requirements prior to marketing the changed device in the applicable regulatory jurisdictions.

# Medical Device Single Audit Program

## Chapter 3

### Process: Measurement, Analysis and Improvement

One of the most important activities in the quality management system is the identification of existing and potential causes of product and quality problems. Such causes must be identified so that appropriate and effective corrective or preventive actions can take place. These activities are carried out under the Measurement, Analysis and Improvement process.

The purpose of an organization's Measurement, Analysis and Improvement process is to collect and analyze information, identify and investigate existing and potential causes of product and quality problems, and take appropriate and effective corrective or preventive action to prevent recurrence or occurrence. It is essential that an organization verify or validate these actions, communicate corrective and preventive action activities to responsible people, provide relevant information for management review, and document these activities. These activities will help the organization deal effectively with existing or potential product and quality problems, prevent their recurrence and/or occurrence, and prevent or minimize device failures or other quality problems.

The **management representative** is responsible for ensuring that the requirements of the quality management system have been effectively defined, documented, implemented, and maintained. Prior to the audit of any process, interview the management representative (or designee) to obtain an overview of the process and a feel for management's knowledge and understanding of the process.

The Measurement, Analysis and Improvement process is the second primary process to be audited per the MDSAP audit sequence. When applicable, information regarding device or identified quality management system nonconformities observed during the audit of the Measurement, Analysis and Improvement process should be used to make decisions as to design projects or design changes to assess during audit of the Design and Development process, suppliers to evaluate during audit of the Purchasing process, and processes to review during audit of the Production and Service Controls process.

### Auditing the Measurement, Analysis and Improvement Process

**Purpose:** The purpose of auditing the Measurement, Analysis and Improvement process is to verify that the manufacturer's processes ensure that information related to products, processes, or the quality management system is collected and analyzed to identify actual and potential product, process, or quality system nonconformities, that problems and potential problems are investigated, and that appropriate and effective corrective actions and preventive actions are taken.

**Outcomes:** As a result of the audit of the Measurement, Analysis and Improvement process, objective evidence will show whether the organization has:

- A) Defined, documented, and implemented procedures for measurement, analysis and improvement that address the requirements of the quality management system standard and participating MDSAP regulatory authorities
- B) Identified, analyzed, and monitored appropriate sources of quality data to identify nonconformities or potential nonconformities and determined the need for corrective or preventive action

- C) Ensured investigations are conducted to identify the underlying cause(s) of nonconformities and potential nonconformities, where possible
- D) Implemented appropriate corrective action to eliminate the recurrence or preventive action to prevent the occurrence of product or quality system nonconformities, commensurate with the risks associated with the nonconformities or potential nonconformities encountered
- E) Reviewed the effectiveness of corrective action and preventive action
- F) Utilized information from the analysis of production and post-production quality data to amend the analysis of product risk, as appropriate

**Links to Other Processes:** Design and Development; Production and Service Controls; Purchasing; Medical Device Adverse Events and Advisory Notices Reporting; Management

### **Audit Tasks and Links to Other Processes:**

- 1. Verify that procedures for measurement, analysis and improvement which address the requirements of the quality management system standard and regulatory authorities have been established and documented. Confirm the organization maintains and implements procedures to monitor and measure product conformity throughout product realization, as well as procedures that provide for mechanisms for feedback to provide early warnings of quality problems and the implementation of corrective action and preventive action.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 8.2.1, 8.2.4.1, 8.5; TG(MD)R Sch3 P1 1.4(5)(b)(iii), Sch3 P1 Cl 1.4(5)(f); RDC ANVISA 16/2013: 5.3.1, 7.1, 7.2; MHLW MO.169: 6, 55, 58, 62; 21 CFR 820.100(a)]

*Additional country-specific requirements:*

*United States (FDA):*

Verify that procedures are in place for verifying or validating the corrective and preventive action to ensure the action is effective and does not adversely affect the finished device [21 CFR 820.100(a)(4)].

Verify procedures ensure that information related to quality problems or nonconforming product is disseminated to those directly responsible for assuring the quality of such product or the prevention of problems [21 CFR 820.100(a)(6)].

Confirm procedures provide for the submission of relevant information on identified quality problems, as well as corrective and preventive actions, for management review [21 CFR 820.100(a)(7)].

*Assessing conformity:*

### **Procedures**

Each organization must establish and maintain procedures for analyzing data and implementing corrective action and preventive action. The procedures must include requirements for:

- a) Analyzing feedback, conformity to product requirements, characteristics and trends of processes and products (including opportunities for preventive action), and conformity of suppliers
- b) Reviewing nonconformities, including customer complaints
- c) Evaluating the need for action to prevent recurrence or occurrence of nonconformities

- d) Recording the results of any investigations and of actions taken
- e) Identifying the action(s) needed to correct and prevent recurrence or occurrence of nonconforming product and other quality problems
- f) Ensure that action is effective and does not adversely affect the finished device
- g) Implementing and recording changes in methods and procedures needed to correct and prevent identified quality problems
- h) Ensuring that information related to quality problems or nonconforming product is disseminated to those directly responsible for assuring the quality of such product or the prevention of such problems

**2. Determine if appropriate sources of quality data have been identified for input into the measurement, analysis and improvement process, including customer complaints, feedback, service records, returned product, internal and external audit findings, and data from the monitoring of products, processes, nonconforming products, and suppliers. Confirm that data from these sources are accurate and analyzed using valid statistical methods (where appropriate) to identify existing and potential product and quality management system nonconformities that may require corrective or preventive action.**

Clause and regulation: [ISO 13485:2003: 4.2.1, 8.1, 8.4, 8.5; TG(MD)R Sch3 P1 CI 1.4(3); RDC ANVISA 16/2013: 7.1.1.1, 9.1; MHLW MO169: 6, 54, 61, 62; 21 CFR 820.100(a)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Verify that the organization has established and maintained procedures for identifying valid statistical techniques required for verifying the quality system performance and process capability for achieving established specifications [RDC ANVISA 16/2013: 9.1].

*United States (FDA):*

Where appropriate, verify the organization has established and maintained procedures for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics [21 CFR 820.250(a)].

*Assessing conformity:*

## **Quality data sources**

Complaints, records of acceptance activities and concessions, nonconformities identified in internal audits, service records, acceptability of supplied product and supplier performance, and data presented in management review are common quality data sources that are useful in identifying quality problems, among others.

Some sources of quality data that may be useful in identifying potential problems are acceptance activities, such as component, in-process, or finished device testing; environmental monitoring, and statistical process control (SPC). Results of acceptance activities may indicate an unfavorable trend that left unattended may result in product nonconformity.

During the audit of the Measurement, Analysis and Improvement process, it is recommended that the auditor(s) review the previous audit report if there is one for the organization. If this information

is available, the audit team should use the information in the report when selecting some quality data sources to review during the audit. For example, if service records were reviewed during the previous audit and the organization was handling the data appropriately, the audit team may wish to select a different data source for review during the audit. However, if the previous audit documented that the data from service records were not being entered into the Measurement, Analysis and Improvement process appropriately, the audit team should consider reviewing service records again to determine whether the previous deficiency was effectively addressed.

Select some sources of quality data. Determine if the data from these sources were entered into the organization's Measurement, Analysis and Improvement process for analysis and whether the information was complete, accurate, and entered in a timely fashion. Be mindful of quality problems that appear in more than one data source. For example, device nonconformities noted in complaints should be compared with similar nonconformities noted during the organization's analysis of data from other data sources such as product reject reports, or nonconforming product or process reports. This comparison will help the organization and the audit team understand the full extent of the quality problem.

### **Analysis of data**

An organization should use data from a variety of quality data sources to identify the causes of existing product and quality problems. Not all organizations will have the same sources of quality data. For example, service records and installation reports are quality data sources that may not be found at every device manufacturer. As the audit team is conducting the audit, determine what sources of quality data the organization has identified. The audit team will also determine whether the sources identified by the organization are appropriate and if the organization is analyzing quality data from these sources to identify existing product problems as well as existing problems within its quality system. Later in the evaluation of the Measurement, Analysis and Improvement process, the audit team will be sampling raw quality data to determine how the organization analyzed the quality data and responded to the results of its analysis.

An organization should also use data from a variety of quality data sources to identify the causes of potential product and quality problems. The organization should be looking for trends or other indications of potential problems before the problems actually occur. The organization may choose to perform analysis of competing devices, including reviewing advisory notices related to competing devices, to determine whether similar nonconformities could occur in the organization's devices. Determine whether the organization can identify potential product and quality problems that may require preventive action.

An organization has the flexibility to use whatever methods of analysis are appropriate to identify existing and potential causes of nonconforming product or other quality problems. However, an organization must use appropriate statistical methodology where necessary to detect recurring quality problems. An organization must also use appropriate statistical tools when it is necessary to use statistical methodology. It should not misuse statistics in an effort to minimize the problem or avoid addressing the problem.

#### ***Link: Purchasing***

During the audit of the Measurement, Analysis and Improvement process, the audit team may encounter data involving product nonconformities, including complaints involving finished devices, where the underlying cause of the quality problem has been traced to a supplied product. During the audit of the Purchasing process, the audit team should consider selecting suppliers to audit that have corrective action indicators of nonconformities with supplied components or processes.



**3. Determine if investigations are conducted to identify the underlying cause(s) of detected nonconformities, where possible. *Confirm investigations are commensurate with the risk of the nonconformity.***

*Clause and regulation:* [ISO 13485:2003: 8.5.2; TG(MD)R Sch1 P1 2; RDC ANVISA 16/2013: 2.4, 6.5.1, 7.1.1.2; MHLW MO169: 63; 21 CFR 820.100 (a)(2)]

*Additional country-specific requirements:* None

*Assessing conformity:*

### **Investigations of nonconformities**

The depth of the organization's investigation of a process, product, or other quality system nonconformity should be commensurate with the significance and risk of the nonconformity. The process for determining the extent of an investigation may be linked to the organization's risk management system and the design outputs essential to the proper functioning of the device.

A correction is not the same as a corrective action. In order for an organization to take a corrective action (i.e., action taken to prevent recurrence of an existing nonconformity), an investigation must be conducted to determine the cause of the nonconformity. Often an organization will only make a correction to handle the immediate problem (e.g. relabeling a lot of mislabeled finished devices). Determining the cause of the lot of mislabeled finished devices is more difficult and may be overlooked. Where possible, the organization should identify the underlying cause or causes of the nonconformity so that appropriate corrective action can be taken.

### **Selecting records**

When selecting records of investigations to review, be mindful of the risk of the nonconformity to the product or process. Select records of investigations where the nonconformity has a higher risk of adversely affecting the ability of the finished device to meet its essential design outputs or the nonconformity affects the safety and efficacy of the product.

**4. Determine if investigations are conducted to identify the underlying cause(s) of potential nonconformities, where possible. *Confirm investigations are commensurate with the risk of the potential nonconformity.***

*Clause and regulation:* [ISO 13485:2003: 8.5.3; TG(MD)R Sch1 P1 2; RDC ANVISA 16/2013: 2.4, 7.1.1.1; MHLW MO169: 64; 21 CFR 820.100(a)(2)]

*Additional country-specific requirements:* None

*Assessing conformity:*

### **Investigations of potential nonconformities**

The depth of the organization's investigation into potential process, product, or other quality system nonconformities should be commensurate with the risk of the nonconformity if it were to occur. The process for determining the extent of an investigation may be linked to the organization's risk management system and outputs essential to the proper functioning of the device.



## Selecting records

When selecting records of investigations to review, be mindful of the risk of the potential nonconformity to the product or process. Select records of investigations where the potential nonconformity has a higher risk of adversely affecting the ability of the finished device to meet its essential design outputs or the potential nonconformity could affect the safety and efficacy of the product.

### 5. Confirm that corrections, corrective actions, and preventive actions were determined, implemented, documented, effective, and did not adversely affect finished devices. Ensure corrective action and preventive action is appropriate to the risk of the non-conformities or potential nonconformities encountered.

*Clause and regulation:* [ISO 13485:2003: 8.2.2, 8.2.3, 8.3, 8.5.2, 8.5.3; TG(MD)R Sch1 P1 2; Sch3 P1 1.4(5)(b)(iii), Sch3 P1 1.4(5)(f); RDC ANVISA 16/2013: 2.4, 6.5, 7.1.1.3, 7.1.1.4, 7.1.1.5; MHLW MO169: 56, 57, 60, 63, 64; 21 CFR 820.100(a)(3), 820.100 (a)(4), 820.100(a)(6), 820.100(b)]

*Additional country-specific requirements:* None

*Assessing conformity:*

## Determining the extent of actions

Corrective actions taken by an organization can vary depending on the situation. Corrective actions are intended to correct and also prevent recurrence of not only nonconforming product but also poor practices, such as inadequate training.

In developing corrective action addressing nonconforming product, the organization should consider corrections to be taken regarding the effected products, whether distributed or not. Corrections and corrective actions must be commensurate with the risk associated with the nonconformity.

The audit team may encounter situations where a quality problem has been identified, but the organization's management has decided not to undertake corrective actions. Confirm that the organization's decision not to take corrective action has been made using appropriate risk-based decision making, including a determination that the finished device meets risk acceptability criteria.

## Determining the effectiveness of actions

During the audit of the Measurement, Analysis and Improvement process, review the mechanisms by which the organization assessed effectiveness of the corrective and preventive actions. Compare the records of significant and/or higher risk corrective actions and preventive actions to the organization's product and quality data analyses, such as trend results. Look for product or quality problems or trends that continued or began after the actions were implemented. This may indicate that the corrective actions or preventive actions were not effective.

Review how the organization has determined that the actions do not adversely affect the finished device(s).

### ***Link: Medical Device Adverse Events and Advisory Notices Reporting***

Determine whether any of the organization's corrective actions require reporting to participating MDSAP authorities.

**6. *When a corrective or preventive action results in a design change, verify that any new hazard(s) and any new risks are evaluated under the risk management process.***

*Clause and regulation:* [ISO 13485:2003: 7.1; TG(MD)R Sch1 P1 2; RDC ANVISA 16/2013: 2.4, 4.1.10; MHLW MO169: 26; 21 CFR 820.30(i), 820.30(g)]

*Additional country-specific requirements:* None

*Assessing conformity:*

### **Design change**

Completing this audit task may involve linkages to other subsystems. Verification and validation are important elements in assuring that corrective actions and preventive actions that result in design changes are effective and do not introduce new hazards.

#### **Link: Design and Development**

If the corrective action or preventive action involves changing the design, design controls should be applied to the change where applicable. When necessary, confirm that design controls were applied to the change according to the organization's procedures. In addition, design changes should be evaluated under the organization's risk management process to ensure that changes do not introduce new hazards.

**7. *When a corrective or preventive action results in a process change, confirm that the process change is assessed to determine if any new risks to the product are introduced. Verify the manufacturer has performed revalidation of processes where appropriate.***

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.1, 7.5.2; TG(MD)R Sch1 P1 2; Sch3 P1 1.5(4); RDC ANVISA 16/2013: 2.4, 5.6, 7.1.1.4; MHLW MO169: 6, 26, 45, 46; 21 CFR 820.100(a)(4), 820.100(a)(5), 820.70(b), 820.75(c)]

*Additional country-specific requirements:*

#### *Australia (TGA):*

Confirm that when a manufacturer plans to make a substantial change to a critical process (e.g. sterilization, processing materials of animal origin, processing materials of microbial or recombinant origin, or processes that incorporate a medicinal substance in a medical device), the manufacturer notifies the auditing organization who will determine if an assessment of the change is required before implementation [TG(MD)R Sch3 P1 1.5(2)].

#### *Canada (HC):*

Verify that the manufacturer has a process or procedure for identifying a "significant change" to a class III or IV device. Verify that information about "significant changes" is submitted in a medical device license amendment application [CMDR 1, 34].

#### *Japan (MHLW):*

Confirm that when the Registered Manufacturing Site plans to make a significant change to a manufacturing processes (e.g. sterilization site change, manufacturing site change), the Registered Manufacturing Site notifies the Marketing Authorization Holder so as the Marketing Authorization Holder can take appropriate regulatory actions. [MHLW MO169: 29]

*Assessing conformity:*

### **Process changes**

Completing this audit task may involve linkages to other quality management system processes. Production processes require at least some degree of qualification, verification, or validation. If the change involves a validated process, review the organization's evaluation of the process change

to determine if revalidation is needed.

***Links: Production and Service Controls, Purchasing***

If the corrective action or preventive action involves changing a production process, the audit team should consider selecting this change for evaluation during audit of Production and Service Controls.

For changes to production processes that are performed by suppliers, the audit team should consider selecting those suppliers for evaluation during audit of the Purchasing process. In cases where the organization makes a change to a validated process performed by a supplier, the audit team should evaluate whether re-validation is required. If re-validation of production processes is required, confirm the results show the process meets the planned result.

**8. Verify that controls are in place to ensure that product which does not conform to product requirements is identified and controlled to prevent its unintended use or delivery. Confirm that an appropriate disposition was made, justified, and documented.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 8.3; TG(MD)R Sch3 P1 1.4(5)(b)(iii); RDC ANVISA 16/2013: 6.5; MHLW MO169: 6, 60; 21CFR 820.90(a)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Confirm that the evaluation of non-conforming product includes a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformity. The evaluation and any investigation must be documented [RDC ANVISA 16/2013: 6.5.1].

*United States (FDA):*

Confirm that the evaluation of non-conforming product includes a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformity. The evaluation and any investigation must be documented [21 CFR 820.90(a)].

*Assessing conformity:*

**Nonconforming product**

The audit team should review procedures and controls for preventing the unintended distribution of nonconforming product. The auditor(s) may choose to select a sample of records involving nonconforming product that was in stock or returned to review how the procedures and controls were applied to control the nonconforming product.

Confirm the organization has established and maintained procedures that define the responsibility for review and the authority for the disposition of nonconforming product, as well as the execution of the review and disposition process. Disposition of nonconforming product must be documented.

The audit team may encounter situations where the organization's management has decided to authorize the use of nonconforming product under concession. Documentation must include the justification for use of nonconforming product and the signature of the individual(s) authorizing the use. Confirm that the organization's decision to use nonconforming product under concession has been made using appropriate risk-based decision making, including a determination that the finished device meets specified requirements. Be mindful of instances where the use of nonconforming product under concession has led to devices not meeting specifications.

## Selecting records

When selecting records of nonconforming products to review, be mindful of the risk of the nonconformity to the finished device and the patient or user. Select records of nonconforming products to review where the nonconformity has a higher risk of adversely affecting the ability of the finished device to meet its essential design outputs or the nonconformity affects the safety and efficacy of the product.

### 9. Confirm that when nonconforming product is detected after delivery or use, appropriate action is taken *commensurate with the risk, or potential risks*, of the nonconformity.

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 8.3, 8.5.1; TG(MD)R Sch1 P1 2; RDC ANVISA 16/2013: 2.4, 7.1.1.8; MHLW MO169: 6, 60, 62; 21 CFR 820.100(a)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Verify that the manufacturer has procedures to determine the product recall and other field actions that are relevant in the case of products already distributed [RDC ANVISA 16/2013: 7.1.1.8].

*Assessing conformity:*

## Control and action based on risk

During this audit task, confirm that the organization has determined the control and actions to be taken on nonconforming products detected after delivery or use, commensurate with the risk associated with a product failure.

While it may not be necessary for the organization to recall nonconforming product from distribution as part of its identified actions needed to correct and prevent recurrence of the problem, confirm that the decision is made using an adequate risk justification.

### ***Link: Medical Device Adverse Events and Advisory Notices Reporting***

If the organization has taken field action on products already distributed, confirm that the appropriate MDSAP regulatory authorities have been notified, as necessary.

### 10. Verify that internal audits of the quality management system are being conducted according to planned arrangements and documented procedures to ensure the quality management system is in compliance with the established quality management system requirements and applicable regulatory requirements, and to determine the effectiveness of the quality system. Confirm that the internal audits include provisions for auditor independence over the areas being audited, corrections, corrective actions, follow-up activities, and the verification of corrective actions.

*Clause and Regulation:* [ISO 13485:2003: 4.2.1, 8.2.2; RDC ANVISA 16/2013: 7.3; MHLW MO169: 6, 56; 21 CFR 820.22, 820.100]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Verify that quality audits are conducted by trained people in accordance with established audit procedures [RDC ANVISA 16/2013: 7.3.2].

*United States (FDA):*

Verify that resources include the assignment of trained personnel to meet the requirements of 21 CFR Part 820, including management, performance of work, assessment activities, and internal quality audits [21 CFR 820.20(b)(2)].

*Assessing conformity:*

## **Internal audits**

Internal audits are systematic, independent examinations of an organization's quality management system that are performed at defined intervals and at sufficient frequency to determine whether both quality management system activities and the results of such activities comply with quality management system procedures. Internal audits should also determine whether these procedures are implemented effectively and whether they are suitable to achieve quality management system objectives.

## **Auditors**

Internal audits are to be conducted according to established procedures by appropriately trained individuals not having direct responsibility for the matters being audited. If possible, interview auditors and ask how audits are conducted, how long audits typically last, what documents are typically reviewed, etc.

## **Requirements**

Internal audit procedures typically include requirements for auditor qualifications, requirements for the frequency of audits, specified functional areas to be audited, and audit plans (or the requirement to establish audit plans prior to the audit). Procedures should also include requirements for how audit activities and results are to be communicated, addressed, and followed up (including re-audit, if necessary) and for how audit activities are to be documented.

## **Review and documentation**

Management having responsibility for the matters audited must review the report of the quality audit. The dates and results of all quality audits (and subsequent re-audits, if necessary) must be documented, as well as any corrective or preventive actions resulting from the internal audits.

### ***Link: Management***

During the audit of the Management process, the audit team should confirm that the output of internal audits is an input to management review.

## **11. Determine if relevant information regarding nonconforming product, quality management system nonconformities, corrections, corrective actions, and preventive actions has been supplied to management for management review.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 5.6.2; TG(MD)R Sch3 P1 1.4(5)(b)(iii); RDC ANVISA 16/2013: 2.2.6, 7.1.1.7; MHLW MO169: 6, 19; 21 CFR 820.100 (a)(7)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Confirm that relevant information about quality problems is identified and corrective and preventive actions are submitted to executive management for information and monitoring, as well as the competent health authority, if applicable [RDC ANVISA 16/2013: 7.1.1.7].



## Management review

During the performance of this audit task, the auditor(s) may choose to select a recent, significant corrective or preventive action and determine which records or information regarding the event was submitted for management review.

### **Link: Management**

During the audit of the Management process, the audit team should have confirmed that the status of corrective and preventive actions is an input to the management review. During the audit of the Measurement, Analysis and Improvement process, determine that top management is aware of higher-risk quality problems, as well as significant corrective and preventive actions, when necessary.

## **12. Confirm that the manufacturer has made effective arrangements for gaining experience from the post-production phase, handling complaints, and investigating the cause of nonconformities related to advisory notices with provision for feedback into the Measurement, Analysis and Improvement process. *Verify that information from the analysis of production and post-production quality data was considered for amending the analysis of product risk, as appropriate.***

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.2.3, 8.2.1; TG(MD)R Sch1 P1 2, Sch3 P1 1.4(3), 1.4(5)(b)(iii) & 1.4(5)(f); RDC ANVISA 16/2013: 7.2; CMDR 57-58; MHLW MO169: 6, 29, 55; 21 CFR 820.198]

*Additional country-specific requirements:*

### *Australia (TGA):*

Verify that the organization has procedures for a post-marketing system that includes a systematic review of post-production experience (e.g. from; expert user groups, customer surveys, customer complaints and warranty claims, service and repair information, literature reviews, post-production clinical trials, user feedback other than complaints, device tracking and registration schemes, user reactions during training, adverse event reports). Investigation should take place in a timely manner to ensure that reporting timeframes for adverse events or advisory notices may be met [TG(MD)R Sch3 P1 1.4(3)(a)].

Note: Investigation should take place in a timely manner to ensure that reporting time-frames for adverse events or advisory notices can be met by the Australian Sponsor. The manufacturer should be aware that recalls are to be conducted in Australia by the Australian Sponsor in accordance with the Australian Uniform Recall Procedure for Therapeutic Goods.

### *Brazil (ANVISA):*

Verify that each manufacturer has established and maintains procedures to receive, examine, evaluate, investigate and document complaints. Such procedures must ensure that:

- (1) Complaints are received, documented, analyzed, evaluated, investigated and documented by a formally designated unit;
- (2) Where applicable, complaints must be reported to the competent health authority;
- (3) Complaints must be examined to determine whether an investigation is necessary. When an investigation is not done, the unit must maintain a record that includes the reason that the investigation was not performed and the name of the responsible for that decision;
- (4) Each manufacturer must examine, evaluate and investigate all complaints involving possible nonconformities of the product. Any claim for death, injury or threat to public health must be immediately reviewed, evaluated and investigated.



(5) The records of the investigation must include:

- Product name;
- Date of receipt of the complaint;
- Any control number used;
- Name, address and telephone number of the complainant;
- Nature of complaint; and
- Data and research results including actions taken [RDC ANVISA 16/2013: 7.2].

*Canada (HC):*

Verify that the manufacturer maintains records of reported problems related to the performance characteristics or safety of a device, including any consumer complaints received by the manufacturer after the device was first sold in Canada, and all actions taken by the manufacturer in response to the problems referred to in the complaints [CMDR Section 57].

Verify that the manufacturer has established and implemented documented procedures that will enable it to carry out an effective and timely investigation of the problems reports through the customer complaints, and to carry out an effective and timely recall of the device [CMDR Section 58].

*Japan (MHLW):*

Confirm that the personnel operating the Registered Manufacturing Site has determined and implemented effective arrangements for communicating with the Japanese Marketing Authorization Holder in relation to customer feedback, including customer complaints, and advisory notices [MHLW MO169: 29].

*United States (FDA):*

Verify procedures have been defined, documented, and implemented for receiving, reviewing, and evaluating complaints by a formally designated unit. Procedures must ensure that:

- (1) All complaints are processed in a uniform and timely manner
- (2) Oral complaints are documented upon receipt
- (3) Complaints are evaluated to determine whether the complaint represents an event which is required to be reported to FDA

Each manufacturer must review and evaluate all complaints to determine whether an investigation is necessary. When no investigation is made, the manufacturer must maintain a record that includes the reason no investigation was made and the name of the individual responsible for the decision not to investigate.

Any complaint of the failure of the device, labeling, or packaging to meet any of its specifications must be reviewed, evaluated, and investigated, unless such investigation has already been made for a similar complaint and another investigation is not necessary.

Any complaint that represents an event which must be reported to FDA must be promptly reviewed, evaluated, and investigated by a designated individual(s) and must be maintained in a separate portion of the complaint files or otherwise clearly identified. Records of investigation must include a determination of:

- (1) Whether the device failed to meet specifications
- (2) Whether the device was being used for treatment or diagnosis
- (3) The relationship, if any, of the device to the reported incident or adverse event

When an investigation is made, a record of the investigation must be maintained by the formally designated unit. The record of investigation must include:

- (1) The name of the device;

- (2) The date the complaint was received;
- (3) Any device identification(s) and control number(s) used;
- (4) The name, address, and telephone number of the complainant;
- (5) The nature and details of the complaint;
- (6) The dates and results of investigation; and
- (7) Any corrective action taken.

When the manufacturer's formally designated unit is located at a site separate from the manufacturing establishment, the investigated complaint(s) and the record(s) of investigation must be reasonably accessible to the manufacturing establishment [21 CFR 820.198].

*Assessing conformity:*

## Evaluation of post-production data

During the review of quality data sources that serve as inputs to the Measurement, Analysis and Improvement process, the audit team may choose to review complaints and customer feedback. Confirm that complaints are handled as required by the MDSAP participating regulatory authorities. Complaints can be an important source of information regarding quality problems and are often indicative that distributed devices (or their packaging or labeling) did not meet specified requirements.

## Selecting records

One method to analyze complaints and customer feedback is to review the analysis of complaint data and select one or more complaint failure modes, **preferably failure modes associated with higher risk to the patient or user**. Once the audit team has selected complaint failure modes, the auditor(s) can select a sample of complaints from those failure modes and confirm the complaints are handled appropriately, including investigation and implementation of corrective action when necessary.

## Risk management

Information from post-production sources, including complaints and customer feedback, can provide important information for the risk management activities for the device. In particular, previously unidentified risks discovered during the post-production monitoring may indicate a need for improving the risk management process or may indicate a need for design changes. Additionally, on the basis of post-production quality data, the organization may choose to enact new or more stringent controls to maintain an acceptable level of product risk.

### ***Link: Medical Device Adverse Events and Advisory Notices Reporting***

During the review of complaints and feedback, confirm that individual medical device reports were made to the appropriate regulatory authorities when necessary.

## **13. Where investigation determines that activities outside the organization contributed to a customer complaint, verify that records show that relevant information was exchanged between the organizations involved.**

*Clause and regulation:* [ISO 13485:2003; 4.1, 4.2.1, 7.2.3, 8.5.1; RDC ANVISA 16/2013: 7.1.1.6; MHLW MO169: 5, 6, 29, 62; 21 CFR 820.100(a)(6)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Verify that the manufacturer has ensured that information about quality problems or nonconforming products are properly disseminated to those directly involved in the maintenance of product quality and to prevent occurrence of such problems [RDC ANVISA 16/2013: 7.1.1.6].

*United States (FDA):*

Verify that information related to quality problems or nonconforming product is disseminated to those directly responsible for assuring the quality of such product or the prevention of such problems [21 CFR 820.100(a)(6)].

*Assessing conformity:*

## **Complaints and nonconformities attributed to supplied product**

Confirm that information related to quality problems or nonconforming product, including complaints, is disseminated to those directly responsible for assuring the quality of product. This includes instances where investigation reveals the underlying cause of the complaint or nonconforming product to be related to supplied product. The organization should notify the supplier of the quality problem and appropriate corrective action must be taken when necessary. Failure of an outside organization to provide products that meet specified requirements may disqualify them as an acceptable or approved supplier.

### **Link: Purchasing**

During the audit of the Measurement, Analysis and Improvement process, if significant nonconformities are related to supplied product, the audit team should consider selecting those suppliers for evaluation during the audit of the organization's Purchasing process.

## **14. Verify that the organization has defined and documented procedures for the notification of adverse events. Confirm adverse event reporting is performed according to the applicable regulatory requirements.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 8.5.1; TG(MD)R Sch3 P1 1.4(3)(c); RDC ANVISA 16/2013: 7.1.1.8, RDC ANVISA 67/2009; CMDR 59-61.1; MHLW MO169: 6, 62; 21 CFR 803]

*Additional country-specific requirements:* Refer to MDSAP process Medical Device Adverse Events and Advisory Notices Reporting

*Assessing conformity:*

### **Individual adverse event reports**

An output of the activities associated with the Measurement, Analysis and Improvement process, such as complaint handling, may be the reporting of individual adverse events to regulatory authorities in which the device is marketed. When applicable, select complaint records that meet criteria for reporting and confirm the appropriate reports and information was provided to the regulatory authority. Ensure the individual adverse event reports contain accurate information by comparing the submitted reports to the associated complaint and complaint investigation.

Reportable events are often an important Measurement, Analysis and Improvement process quality data source since these events are indicative that the finished device has caused death, serious injury, or has malfunctioned in a manner such that if the malfunction were to recur, the result could be death or serious injury. Any death, even if the organization attributes it to user error, is considered to have potentially high risk associated with it. Confirm that reportable events were evaluated for corrective action when necessary.

**15. Confirm that the manufacturer has made effective arrangements for the timely issuance and implementation of advisory notices. Confirm that reporting of advisory notices is performed according to the applicable regulatory requirements.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 8.5.1; TG(MD)R Sch3 P1 1.4(3)(c); RDC ANVISA 16/2013: 7.1.1.8, RDC ANVISA 23/2012; CMDR 63-65.1; MHLW MO169: 6, 62; 21 CFR 806]

*Additional country-specific requirements:* Refer to MDSAP process Medical Device Adverse Events and Advisory Notices Reporting

*Assessing conformity:*

**Advisory notices**

An output of the activities associated with the Measurement, Analysis and Improvement process, including complaint handling and the discovery of nonconforming product that has been distributed, may be the reporting of advisory notices to regulatory authorities in which the device is marketed. When applicable, select advisory notices that meet criteria for reporting and confirm that the appropriate reports and information were provided to the regulatory authority.

The quality problems that led to an advisory notice is often an important quality data source for the corrective actions process since these events are indicative that the finished device does not meet specified requirements and has the potential for unreasonable risk to the user. Confirm that quality problems that resulted in advisory notices were evaluated for corrective action. If corrective action was taken, evaluate the mechanism by which the organization assured the action is effective and does not adversely affect the ability of the device to meet specified requirements. If corrective action was not taken for quality problems associated with a correction, removal, or advisory notice, review the organization's rationale for not undertaking corrective action and confirm that the decision is appropriate using a risk-based decision making process.

**Decisions to not report a correction, removal, or advisory notice**

The audit team may encounter instances where the organization has performed activities involving issuance of advisory notices without notifying regulatory authorities in the markets in which the device is marketed. In these situations, review the organization's rationale for not reporting these actions and ensure that the rationale is appropriate. Verify that records of the action are maintained.

**16. Determine, based on the assessment of the Measurement, Analysis and Improvement process overall, whether management provides the necessary commitment to detect and address product and quality management system nonconformities, and ensure the continued suitability and effectiveness of the quality management system.**

*Clause and regulation:* [ISO 13485:2003: 4.1; RDC ANVISA 16/2013: 2.2.1; MHLW MO169: 5]

# Medical Device Single Audit Program

## Chapter 4

### Process: Medical Device Adverse Events and Advisory Notices Reporting

The Medical Device Adverse Events and Advisory Notices Reporting process may be audited as a linkage from the Measurement, Analysis and Improvement process.

**Purpose:** The purpose of auditing the Medical Device Adverse Events and Advisory Notices Reporting is to verify that the organization's processes ensure that individual device-related adverse events and advisory notices involving medical devices are reported to regulatory authorities within required timeframes.

**Outcomes:** As a result of the audit of the Medical Device Adverse Events and Advisory Notices Reporting process, objective evidence will show whether the organization has:

- A) Defined processes to ensure individual device-related adverse events are reported to regulatory authorities as required
- B) Ensured that advisory notices are reported to regulatory authorities and authorized representatives when necessary
- C) Maintained appropriate records of individual device-related adverse events and advisory notices

#### ***Links to Other Processes: Measurement, Analysis and Improvement***

#### **Audit Tasks and Links to Other Processes:**

- 1. Verify that the organization has a process in place for identifying device-related events that may meet reporting criteria as defined by participating regulatory authorities. Verify that the complaint process has a mechanism for reviewing each complaint to determine if a report to a regulatory authority is required. Confirm that the organization's processes meet the timeframes required by each regulatory authority where the product is marketed.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 8.5.1; see the country-specific requirements below]

*Country-specific requirements:*

*Australia (TGA):*

Manufacturers are required to implement a post-marketing system that includes provisions for adverse event reporting – e.g. Therapeutic Goods (Medical Devices) Regulations 2002 Schedule 3 Part 1 Clause 1.4(3)(c)(i). In view of the written agreement between Manufacturers and the Australian Sponsor [TG Act 41FD], events must be reported by the manufacturer to the TGA, or to the Sponsor in a timely manner to ensure that a Sponsor can meet their reporting obligations under the Therapeutic Goods (Medical Devices) Regulation 5.7:

- Verify that the manufacturer or other person becoming aware of an event that represents a serious threat to public health provides information as soon as practicable. The Sponsor is to report the event within 48 hours.
- Verify that the manufacturer or other person becoming aware of an event that led to the death or serious deterioration in the state of health of a patient, a user, or other person provides information as soon as practicable. The Sponsor is to report the event within 10 days.



- Verify that the manufacturer or other person becoming aware of an event that the recurrence of which might lead to the death or serious deterioration in the state of health of a patient, a user, or other person provides information as soon as practicable. The Sponsor is to report the event within 30 days.

Note: An event that leads to a serious threat to human health is a hazard arising from a systematic failure of the devices or an event or other occurrence that may lead to death or serious injury.

Note: It is a condition on Australian Sponsors of Class AIMD, Class III and Implantable Class IIb devices that they provide three consecutive annual reports to the TGA following inclusion of the device in the ARTG. Annual reports are due 1 October each year. Reports should be for the period 1 July to 30 June. The report is to include:

- ARTG no.
- Product name
- Model no(s)
- Number supplied in Australia
- Number supplied worldwide (Numbers should include devices that are the same but supplied under a different name in another jurisdiction)
- Number of complaints in Australia
- Number of complaints worldwide
- Number of adverse events and incident rates in Australia (Rate= No. of events/ No. Supplied x 100 = Rate%)
- Number of adverse events and incident rates world wide
- A list of the more common complaints and all of the adverse events
- Device Incident Report (DIR) number of those adverse events reported to the TGA
- Regulatory/corrective action/notification by manufacturer

Note: Australian Sponsors are required to provide manufacturers with any information that will assist the manufacturer to comply with the obligations of a conformity assessment procedure (e.g. information in relation to adverse events) [TG(MD)R Reg 5.8].

#### *Brazil (ANVISA):*

Verify that a post-market surveillance system is established and implemented in the organization and integrated into the Quality System, with procedures and work flows established to ensure the correct and the prompt identification of adverse events, the performance of investigations and use of the results to improve the safety and effectiveness of the device when necessary [RDC ANVISA 67/2009 – Art. 6º].

For domestic manufacturers (also applies to legal representatives in Brazil) - verify that top management has designated a professional to be responsible for the post-market surveillance system. This designation shall be documented [RDC ANVISA 67/2009 – Art. 5º].

Verify that the organization has mechanisms for processing and recording complaints, conducting investigations, and providing feedback directly to the complainant, or in the case of an international manufacturer, to their legal representative in Brazil, as necessary [RDC ANVISA 67/2009 – Art. 6º, Art. 7º, Art. 9º].

Verify that the organization has notified the regulatory authority about problems associated with their devices, including adverse events (critical or non-critical), any technical defect that was identified regarding products already marketed, anything that can cause a serious hazard to public health, or cases of counterfeit [RDC ANVISA 67/2009 – Art. 8º].

For international manufacturer, verify that the legal representative in Brazil is aware about the occurrence of possibility of death, serious hazard to public health or cases of counterfeit, associated with their products exported to Brazil [RDC ANVISA 67/2009 – Art. 8º].

*Canada (HC):*

Medical Device Regulations SOR/98-282, Section 59-61.1:

Verify that the manufacturer and the importer of a medical device make a preliminary and final report to the minister concerning any incident occurring inside or outside Canada involving a device sold in Canada.

- a. Related to the failure of the device or deterioration in its effectiveness or any inadequacy in its labeling or in its directions for use.
- b. Has led to death or serious deterioration in the state of health of a patient, user, or other person, or could do so if it were to occur [CMDR 59].

Verify that the manufacturer or other person becoming aware of an event that led to the death or serious deterioration in the state of health of a patient, a user, or other person provides information in a preliminary report within 10 days after the person becomes aware of the event or occurrence [CMDR 60 (1) (a) (i)].

Verify that the manufacturer or other person becoming aware of an event that the recurrence of which might lead to the death or serious deterioration in the state of health of a patient, a user, or other person provides information in a preliminary report within 30 days after the person becomes aware of the event or occurrence [CMDR 60 (1) (a) (ii)].

Verify that manufacturer has made effective arrangements to submit preliminary reports to the Minister and that the reports contain [CMDR 60 (2)]:

- (a) the identifier of any medical device that is part of a system, test kit, medical device group, medical device family or medical device group family;
- (b) if the report is made by
  - (I) the manufacturer: the name and address of that manufacturer and of any known importer, and the name, title and telephone and facsimile numbers of a representative of the manufacturer to contact for any information concerning the incident, or
  - (II) the importer of the device: the name and address of the importer and of the manufacturer, and the name, title and telephone and facsimile numbers of a representative of the importer to contact for any information concerning the incident;
- (c) the date on which the incident came to the attention of the manufacturer or importer;
- (d) the details known in respect of the incident, including the date on which the incident occurred and the consequences for the patient, user or other person;
- (e) the name, address and telephone number, if known, of the person who reported the incident to the manufacturer or importer;
- (f) the identity of any other medical devices or accessories involved in the incident, if known;
- (g) the manufacturer's or importer's preliminary comments with respect to the incident;
- (h) the course of action, including an investigation, that the manufacturer or importer proposes to follow in respect of the incident and a timetable for carrying out any proposed action and for submitting a final report; and
- (i) a statement indicating whether a previous report has been made to the Minister with respect to the device and, if so, the date of the report.

If a preliminary report required by section 60 is submitted to the Minister and/or Importer, verify that the manufacturer has submitted a final report to the Minister in writing in accordance with the timetable established under CMDR 60(2)(h) and the final report contains [CMDR 61(1)]:

- (a) a description of the incident, including the number of persons who have experienced a serious deterioration in the state of their health or who have died;
- (b) a detailed explanation of the cause of the incident and a justification for the actions taken in respect of the incident; and
- (c) any actions taken as a result of the investigation, which may include: (i) increased post-market surveillance of the device,  
(ii) corrective and preventive action respecting the design and manufacture of the device, and  
(iii) recall of the device.

If the reports required by section 60 and 61 are submitted to the Minister just by the Importer, verify that the manufacturer has advised the Minister in writing that the reports the manufacturer and importer would have submitted were identical and that the manufacturer has permitted the importer to prepare and submit reports to the Minister on the manufacturer's behalf [CMDR 61.1].

*Japan (MHLW):*

Marketing Authorization Holders are required to implement post market safety activities in accordance with domestic (Japanese) regulatory requirements in addition to the QMS requirements.

The personnel operating the Registered Manufacturing Sites are not required to report any adverse event directly to a Regulatory Authority, but shall report any adverse event which meets the criteria specified by the Ordinance for Enforcement of PMD Act Article 228-20 (2) to the Marketing Authorization Holder [MHLW MO169: 62.6] .

Verify that the person operating the Registered Manufacturing Site provides events which meet the following criteria defined by the Ordinance for Enforcement of PMD Act Article 228-20 (2) (see below) to the Marketing Authorization Holder in a timely manner.

- (a) The following malfunction events which may cause or may have caused health damage:
  - (i) Serious event (domestic and foreign)
  - (ii) Unlabeled non-Serious event (domestic)
- (b) The following Adverse Reaction events which were caused by or may have been caused by the malfunction of a medical device.
  - (i) Serious event (domestic and foreign)
  - (ii) Unlabeled non-Serious event (domestic)
- (c) Any action taken for preventing the occurrence or expansion of a public health hazard in relation to a medical device which is marketed in foreign countries and is equivalent to the one marketed in Japan. These actions include but are not limited to:
  - (i) Suspension of manufacturing, importing or selling,
  - (ii) Recall and
  - (iii) Abolishment.
- (d) Study report that indicates:

- (i) The possibility of the event of cancer or other serious illnesses, injury or death caused by malfunction of a medical device (domestic and foreign), or by infectious disease arising from usage of a device (domestic and foreign),
- (ii) A significant occurrence rate change of event etc. caused by malfunction of a medical device (domestic and foreign),
- (iii) A significant occurrence rate change of infectious disease caused by usage of a medical device (domestic and foreign) and
- (iv) The fact that a medical device is less effective than claimed when approved.

*United States (FDA):*

21 CFR 803: Medical Device Reporting

Determine whether the manufacturer has developed a process for reporting to FDA incidents involving device-related deaths, serious injuries, and reportable malfunctions that occur within and outside the United States if the same or similar device is marketed to the United States.

Confirm that the manufacturer has developed, maintained, and implemented written medical device reporting (MDR) procedures for the following:

- (a) Internal processes that provide for:
  - (1) Timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements;
  - (2) A standardized review process or procedure for determining when an event meets the criteria for reporting; and
  - (3) Timely transmission of complete medical device reports to FDA
- (b) Documentation and recordkeeping requirements for:
  - (1) Information that was evaluated to determine if an event was reportable;
  - (2) (2) All medical device reports and information submitted to FDA
  - (3) Processes that ensure access to information that facilitates timely follow-up and audit.

Verify that any reports are made within 30 calendar days after the day that the manufacturer receives or otherwise becomes aware of information, from any source, that reasonably suggests that a device that is marketed:

- (1) May have caused or contributed to a death or serious injury; or
- (2) Has malfunctioned and this device or a similar device that is marketed would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur.

Confirm the manufacturer's MDR files contain the following:

- (1) Information (or references to information) related to the adverse event, including all documentation of deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable to FDA.
- (2) Copies of all MDR forms (form 3500A) and other information related to the event submitted to FDA.
- (3) If the manufacturer maintains MDR event files as part of the complaint file, ensure that the manufacturer has prominently identified these records as MDR reportable events. FDA will not consider a submitted MDR report to comply with 21 CFR 803 unless the manufacturer evaluates an event in accordance with the quality management system requirements. Confirm that the

manufacturer has documented and maintained in the MDR event files an explanation of why the manufacturer did not submit or could not obtain any information required by 21 CFR 803, as well as the results of the evaluation of each event.

Compare the information submitted on the individual medical device report to the information contained in the associated complaint and confirm the medical device report contains all information related to the event that is reasonably known to the manufacturer.

Verify the manufacturer has submitted reports to FDA, on form 3500A or an electronic equivalent approved under 803.14, no later than 5 work days after the day that the manufacturer becomes aware that:

- (a) An MDR reportable event necessitates remedial action to prevent an unreasonable risk of substantial harm to the public health. The manufacturer may become aware of the need for remedial action from any information, including any trend analysis; or
- (b) FDA has made a written request for the submission of a 5-day report. If the manufacturer receives such a written request from FDA, the manufacturer must submit, without further requests, a 5-day report for all subsequent events of the same nature that involve substantially similar devices for the time period specified in the written request. FDA may extend the time period stated in the original written request if FDA determines it is in the interest of the public health.

Verify the manufacturer submitted supplemental reports within one month of obtaining information that was not submitted in an initial report.

***Link: Measurement, Analysis and Improvement***

Reports of individual adverse events are a form of feedback and must be analyzed as appropriate for trends requiring improvement or corrective action. During the audit of the Measurement, Analysis and Improvement process, confirm that the organization has considered individual adverse events and trends of adverse events in the analysis of data.

**2. Verify that advisory notices are reported to regulatory authorities when necessary and comply with the timeframes and recordkeeping requirements established by participating regulatory authorities.**

Clause and regulation: [ISO 13485:2003: 4.2.1, 8.5.1; see the country-specific requirements below]

Country specific requirements:

*Australia (TGA):*

Manufacturers are required to implement a post-marketing system that includes provisions for the recovery of devices – e.g. Therapeutic Goods (Medical Devices) Regulations 2002 Schedule 3 Part 1 Clause 1.4(3)(c)(ii). In view of the written agreement between Manufacturers and the Australian Sponsor [TG Act 41FD] proposed recalls must be reported by the manufacturer to the TGA, or to the Sponsor in a timely manner to ensure that a Sponsor can meet their reporting obligations [Therapeutic Goods (Medical Devices) Regulation 5.7, *Therapeutic Goods Act Part 4-9* and the Uniform Recall Procedure for Therapeutic Goods (URPTG)].

Note: Australian Sponsors are required to provide manufacturers with any information that will assist the manufacturer to comply with the obligations of a conformity assessment procedure (e.g. information in relation to the recovery of devices) [TG(MD)R Reg 5.8].

*Brazil (ANVISA):*

Verify that procedures and work flows were established in order to identify when field actions (recalls and corrections) are necessary, in accordance with the organization's post-market surveillance system and quality system [RDC ANVISA 67/2009 - Art. 6º; RDC ANVISA 23/2012 – Art. 1º, Art. 5º].



Verify that the organization keeps records regarding field actions performed, including those that do not need to be reported to regulatory authorities [RDC ANVISA 23/2012 – Art. 4º; Art. 6º, Art. 10, Art. 11, Art. 16].

For domestic manufacturers (also applies to legal representatives in Brazil) - verify that the organization has sent to the regulatory authority the reports requested, according Brazilian regulation [RDC ANVISA 23/2012 – Art. 10, Art. 11].

Verify that the organization has performed field actions based on potential or concrete evidence that their product does not comply with essential requirements of safety and effectiveness [RDC ANVISA 23/2012 – Art. 4º, Art. 6º, Art. 7º, Art. 13, Art. 14, Art. 15].

For domestic manufacturers (also applies to legal representatives in Brazil) - verify that the organization has performed field actions when required by the regulatory authority [RDC ANVISA 23/2012 – Art. 6º].

For domestic manufacturers (also applies to legal representatives in Brazil) - verify that the organization notified the regulatory authority regarding field actions, in accordance with requirements and deadlines established per Brazilian regulation [RDC ANVISA 23/2012 – Art. 7º, Art. 8º].

For international manufacturers, verify that the legal representative in Brazil was aware about the occurrence of field actions performed on products exported to Brazil [RDC ANVISA 67/2009 – Art. 8º].

#### *Canada (HC):*

Medical Device Regulations SOR/98-282, Section 63 – 65.1:

Verify that the manufacturer and the importer of a medical device, on or before undertaking a recall of a device provide the minister with the following information [CMDR 64]:

- (a) the name of the device and its identifier, including the identifier of any medical device that is part of a system, test kit, medical device group, medical device family or medical device group family;
- (b) the name and address of the manufacturer and importer, and the name and address of the establishment where the device was manufactured, if different from that of the manufacturer;
- (c) the reason for the recall, the nature of the defectiveness or possible defectiveness and the date on and circumstances under which the defectiveness or possible defectiveness was discovered;
- (d) an evaluation of the risk associated with the defectiveness or possible defectiveness;
- (e) the number of affected units of the device that the manufacturer or importer
  - (i) manufactured in Canada,
  - (ii) imported into Canada, and
  - (iii) sold in Canada;
- (f) the period during which the affected units of the device were distributed in Canada by the manufacturer or importer;
- (g) the name of each person to whom the affected device was sold by the manufacturer or importer and the number of units of the device sold to each person;
- (h) a copy of any communication issued with respect to the recall;
- (i) the proposed strategy for conducting the recall, including the date for beginning the recall, information as to how and when the Minister will be informed of the progress of the recall and the proposed date for its completion;

- (j) the proposed action to prevent a recurrence of the problem; and
- (k) the name, title and telephone number of the representative of the manufacturer or importer to contact for any information concerning the recall.

Verify that as soon as possible after the completion of the recall the manufacturer and the importer reports to the minister the results of the recall and the action taken to prevent a recurrence of the problem [CMDR 65].

If the reports required by section 64 and 65 are submitted to the Minister just by the Importer, verify that the manufacturer has advised the Minister in writing that the reports the manufacturer and importer would have submitted were identical and that the manufacturer has permitted the importer to prepare and submit reports to the Minister on the manufacturer's behalf [CMDR 65.1].

*Japan (MHLW):*

Marketing Authorization Holders are required to report advisory notices to Regulatory Authorities [PMD Act 68-11].

Confirm that the personnel operating the Registered Manufacturing Site have determined and implemented effective arrangements for communicating with the Marketing Authorization Holder in relation to advisory notices [MHLW MO169: 29].

Note: Personnel operating Registered Manufacturing Sites are not required to report any advisory notice directly to the regulatory authority but shall communicate with the Marketing Authorization Holder, so the MAH can take any necessary regulatory actions.

*United States (FDA):*

21 CFR 806: Medical Devices; Reports of Corrections and Removals

Verify that the manufacturer has a process in place to notify FDA in the event of actions concerning device corrections and removals and to maintain records of those corrections and removals.

Verify that the written report to FDA of any correction or removal initiated to reduce a risk to health or remedy a violation of the U.S. Food, Drug and Cosmetic Act is reported within 10 working days of initiating the correction or removal.

Confirm that the manufacturer maintains records of any correction and removal not required to be reported to FDA (e.g. corrections and removals conducted to correct a minor violation of the U.S. Food, Drug and Cosmetic Act or no risk to health)

***Link: Measurement, Analysis and Improvement***

Corrections and removals are indicative that the product or process does not meet specified requirements or planned results and the nonconformity was not detected prior to distribution. When specified requirements or planned results are not achieved, correction and corrective action must be taken as necessary. During the audit of the Measurement, Analysis and Improvement process, confirm the organization has taken appropriate correction regarding devices already distributed, and taken appropriate corrective action to prevent recurrence of the condition(s) that caused the nonconformity.

# Medical Device Single Audit Program

## Chapter 5

### Process: Design and Development

The purpose of the Design and Development process is to control the design process and to assure that devices meet user needs, intended uses, and specified requirements. Attention to design and development planning, identifying design inputs, developing design outputs, verifying that design outputs meet design inputs, validating the design, controlling design changes, reviewing design results, transferring the design to production, and compiling the appropriate records will help an organization assure that resulting designs will meet user needs, intended uses, and requirements.

The **management representative** is responsible for ensuring that the requirements of the quality management system have been effectively defined, documented, implemented, and maintained. Prior to the audit of any process, interview the management representative (or designee) to obtain an overview of the process and a feel for management's knowledge and understanding of the process.

Audit of the Design and Development process will follow audit of the Measurement, Analysis and Improvement process per the MDSAP audit sequence. Information regarding product or quality system nonconformities noted during audit of the Measurement, Analysis and Improvement process should be considered when making decisions as to the design and development projects, including design changes resulting from corrective actions, to be reviewed during the audit of the Design and Development process. Review of the Design and Development process will also provide an opportunity to evaluate how the organization has utilized risk management activities to ensure design inputs are comprehensive and meet user needs, to confirm that risk control measures that were planned have been implemented in the design, and to verify that risk control measures are effective in controlling or reducing risk. Additionally, review of design and development activities will assist the audit team during the audit of the organization's Purchasing process because the auditor(s) has an opportunity to select suppliers for review whose activities are associated with higher risk to the product or whose activities are critical to the essential design outputs. The review of design and development activities also provides information to assist the audit team in performing a final evaluation of the Management process at the conclusion of the audit.

### Auditing the Design and Development Process

**Purpose:** The purpose of auditing the Design and Development process is to verify that the organization establishes, documents, implements, and maintains controls to ensure that medical devices meet user needs, intended uses, and specified requirements.

**Outcomes:** As a result of the audit of the Design and Development process, objective evidence will show whether the organization has:

- A) Defined, documented and implemented procedures to ensure medical devices are designed according to specified requirements
- B) Effectively planned the design and development of a device
- C) Established mechanisms, including systematic review, for addressing incomplete, ambiguous or conflicting requirements

- D) Determined the internally or externally imposed requirements for safety, function, and performance for the intended use, including regulatory requirements, risk management, and human factors requirements
- E) Verified that design outputs satisfy design input requirements
- F) Identified and mitigated, to the extent practical, the risks associated with the device, including the device software
- G) Ensured that changes to the device design are controlled, the risks associated with the design change are identified and mitigated, to the extent practical, and that the device will continue to perform as intended
- H) Performed design validation to ensure devices conform to user needs and intended use
- I) Confirmed that the design is correctly translated into production methods and procedures

***Links to Other Processes: Purchasing; Production and Service Controls; Measurement, Analysis and Improvement; Device Marketing Authorization and Facility Registration.***

## **Audit Tasks and Links to Other Processes:**

### **1. Verify that those devices that are, by regulation, subject to design and development procedures have been identified.**

*Clause and regulation:* [ISO 13485:2003: 4.1, 4.2.1, 7.1, 7.3.1; TG(MD)R Regs Division 3.2; MHLW MO169:5, 6, 26, 30; 21 CFR 820.30(a)]

*Additional country-specific requirements:*

#### *Australia (TGA):*

Verify that the manufacturer prepares and maintains complete and current objective evidence that demonstrates compliance with the Essential Principles of Safety and Performance [TG(MD)R Sch3 P1 1.4(5)(c) & 1.9].

Verify that devices to be sold in Australia have labeling and instructions for use that comply with the Essential Principles for information that is to be provided with a device [TG(MD)R Sch1 P2 13].

When the Therapeutic Goods (Medical Devices) Regulations 2002 does not require a manufacturer to apply design and development controls for the Class of the medical device (Class IIa, Class I Measuring, Class I Sterile), the manufacturer shall prepare and maintain complete and current objective evidence that demonstrates compliance with the Essential Principles of Safety and Performance [see TG(MD)R Sch3 P6 6.4 - Required Technical Documentation].

#### *Brazil (ANVISA):*

According to Brazilian legislations, there is no exception to design control.

If design activities are outsourced, verify that the manufacturer has a complete device master record for the device and records of the design transfer to production [RDC ANVISA 16/2013: 4.1.7, 4.2].

#### *Canada (HC):*

With respect to Class II devices that are not subject to Design and Development controls, verify that the manufacturer has objective evidence to establish that Class II devices meet the safety and effectiveness requirements of section 10 to 20 [CMDR 9, 10 to 20].

*Japan (MHLW):*

Class 1 devices are not required to comply with the requirements of MHLW MO169:30-36, which are equivalent to the requirements of ISO 13485: 7.3.1-7.3.7. [MHLW MO169:4.1]

*Assessing conformity:*

### **Absence of design activity**

The audit team may encounter situations where the organization has not completed any design projects, has no ongoing or planned design projects, and has not made any design changes (i.e., there has been no design activity). At the minimum, verify that the organization maintains a defined and documented design change procedure. An organization may also have defined and documented other design control procedures. For that type of organization — an organization with no design activity, including no design changes — assess the procedures the organization has in place. The audit team can then proceed to the audit of the next process.

### **Outsourced design activities**

In cases where design activities (development and changes) are completely outsourced by the organization, the audit team must verify (at a minimum) that the controls and records related to the design transfer to production have been determined and that the production line, implemented in the manufacturer site, meets the production requirements established during the design and development of the device. In these cases, the manufacturer shall ensure that the contracted organization complies with the requirements of design and development, established by Medical devices – Quality management systems – Requirements for regulatory purposes (ISO 13485:2003), Brazilian Good Manufacturing Practices (RDC ANVISA 16/2013), Japanese QMS Ordinance (MHLW MO 169), the Quality System Regulation (21 CFR Part 820), and any other specific requirements of medical device regulatory authorities participating in the MDSAP program.

#### ***Link: Purchasing***

If the organization outsources design and development activities, or any portion of the design and development, confirm that the organization treats the outsourced firm as a supplier, has appropriately qualified and maintains control over the supplier, communicates requirements to the supplier, including regulatory requirements, and has arrangements to verify that the design and development activities satisfy those requirements.

## **2. Select a completed (where applicable) design and development project for review.**

Priority criteria for selection:

- complaints or known problems with a particular device
- *product risk*
- recent design changes, particularly design changes made to correct quality problems associated with the device design
- age of design (prefer most recent)
- designs that have not been recently audited



### ***Link: Measurement, Analysis and Improvement***

At this point in the audit, the audit team will have already reviewed the Measurement, Analysis and Improvement process. If the auditors noted corrective actions that resulted in design changes, or noted product nonconformities that have been attributed to the design of the device, the audit team should consider selecting those designs for review. The audit team should be particularly mindful of how the identified quality problems from the Measurement, Analysis and Improvement process are related to specific aspects of the design and development of the device. For example, if the auditors review complaints related to a safety feature of the device that is not performing as intended, the audit team should consider selecting for review the design verification of that safety feature and determine whether appropriate risk control methods were confirmed to be effective.

- 3. Verify that the design and development process is planned and controlled. Review the design plan for the selected design and development project to understand the design and development activities; including the design and development stages, the review, verification, validation, and design transfer activities that are appropriate at each stage; and the assignment of responsibilities, authorities, and interfaces between different groups involved in design and development.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.1, 7.3.1; TG(MD)R Sch3 P1 CI 1.4(4)&(5)(c); RDC ANVISA 16/2013: 4.1.2, 4.1.11; MHLW MO169: 6, 26, 30; 21 CFR 820.30(b), 820.30(j)]

*Additional country-specific requirements:*

*Australia (TGA):*

Verify that effective planning for design and development is documented, typically as part of a Quality Plan [TG(MD)R Sch3 P1 CI 1.4(4)].

*Canada (HC):*

Verify that manufacturers of Class IV devices maintain a quality plan that sets out the specific quality practices, resources, and sequence of activities relevant to the device [CMDR 32].

*Assessing conformity:*

### **Reviewing the design plan**

Review the design plan for the selected project to understand the layout of the design and development activities, including assigned responsibilities and interfaces.

The design plan for the selected project can be used by the audit team as a roadmap for the review of the project. Plans may vary depending on the type or size of the project. Some design plans may be expressed as simple flowcharts, or for larger projects, Gantt or Program Evaluation Review Technique (PERT) charts may be used. Plans do not have to show starting or completion dates for activities covered. However, plans must define responsibility for implementation of the design and development activities and describe the interfaces with different groups or activities. Expect to see interfacing between research and development, marketing, regulatory, manufacturing, and quality departments. The audit team might also see interfacing with purchasing, installers, and servicers. When external institutions (e.g. universities or research and development centers) are involved in the design and development activities, the interfaces between the organization and those external institutions must also be defined.

Design and development plans may change while the design and development process evolves; however, all changes on the plan must be documented and approved.

**4. For the device design and development record(s) selected, verify that design and development procedures have been established and applied. Confirm the design and development procedures address the design and development stages, review, verification, validation, design transfer, and design changes.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.3.1; TG(MD)R Sch3 P1 Cl 1.4(4)&(5)(c); RDC ANVISA 16/2013: 4.1.1; MHLW MO169: 6, 30; 21 CFR 820.30(a), 820.30(j)]

*Additional country-specific*

*requirements: United States (FDA):*

Verify that the design input procedures contain a mechanism for addressing incomplete, ambiguous, or conflicting requirements [21 CFR 820.30(c)].

*Assessing conformity:*

### **Review of procedures**

Design and development procedures set the structure, provide the framework, and support the organization's Design and Development process. The purpose of auditing the procedures is to determine if the organization has that framework in place. If procedures have not been defined and documented, or are deficient, the organization's devices may not meet user needs and intended use.

In accomplishing this audit task, the audit team is to review the organization's procedures and verify that the procedures address the requirements of the Medical devices – Quality management systems – Requirements for regulatory purposes (ISO 13485:2003), Brazilian Good Manufacturing Practices (RDC ANVISA 16/2013), Japanese QMS Ordinance (MHLW MO 169), the Quality System Regulation (21 CFR Part 820), and specific requirements of medical device regulatory authorities participating in the MDSAP program. For example, verify that the design input procedure includes a mechanism for addressing incomplete, ambiguous, or conflicting requirements. Verify that the output procedure ensures that essential outputs are identified. Verify that the design review procedure ensures that each design review includes an individual who does not have responsibility for the design stage being reviewed.

### **Minimum requirement**

If the organization has no ongoing or planned design projects, has not made any design changes, then ensure that, at a minimum, the organization maintains defined and documented design change procedures.

**5. Verify that design and development inputs were established, reviewed and approved; and that they address customer functional, performance and safety requirements, intended use, applicable regulatory requirements, and other requirements including those arising from human factors issues, essential for design and development. *Verify that any risks and risk mitigation measures identified during the risk management process are used as an input in the design and development process.***

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 5.2, 7.2.1, 7.3.2; TG(MD)R Sch1 P1 2, Sch3 P1 Cl 1.4(2)&(5)(c); RDC ANVISA 16/2013: 2.4, 4.1.3, 4.1.11; CMDR 10-20, 21-23; MHLW MO169: 6, 11, 27, 31; 21 CFR 820.30(c), 820.30(g)]

*Additional country-specific requirements:*

*Australia (TGA):*

Verify that the manufacturer has identified the relevant Essential Principles that apply to the medical device [TG(MD)R Sch1 Essential Principles].

*United States (FDA):*

For the selected device(s), verify that the firm has the appropriate marketing clearance [510(k)] or pre-market approval (PMA) if distributing the devices in the United States [21 CFR 807].

*Assessing conformity:*

## Design inputs

Inputs are the physical and performance requirements of a device that are used as a basis for device design. Inputs must be documented and approved by appropriate personnel. The audit team should review the sources used to develop the inputs and determine that relevant aspects of the requirements for the device were covered. These sources must include the relevant regulations where safety and performance criteria have been defined (e.g. safety and efficacy requirements or Essential Principles of Safety and Performance). Examples of relevant aspects include intended use, performance characteristics, intended user, risk mitigation, biocompatibility, compatibility with the environment of intended use (including electromagnetic compatibility), software, radiation protection, human factors, and sterility. Organizations must take into account the current thinking of experts where published information is available (e.g. Standards).

Design inputs are the basis of the design verification and validation; therefore, design inputs need to be defined and recorded as formal requirements that allow for confirmation to the design outputs.

Relevant information for design input can also come from post-production data or experience from similar devices. Complaints and adverse events form a feedback system that can help drive quality improvements in new designs and changes to current designs.

***Link: Device Marketing Authorization and Facility Registration***

Confirm the organization has considered regulatory requirements for registration, listing, notification and licensing; and has complied with these requirements prior to marketing the device in the applicable regulatory jurisdictions.

## 6. Confirm that the design and development inputs are complete, unambiguous, and not in conflict with each other.

*Clause and regulation:* [ISO 13485:2003: 7.3.2; TG(MD)R Sch 3 Part 1.4(4), RDC ANVISA 16/2013: 4.1.3; MHLW MO169: 31; 21 CFR820.30(c)]

*Additional country-specific requirements:* None

*Assessing conformity:*

## Design inputs

Design inputs must be defined and recorded as verifiable requirements, approved by the appropriate personnel. If the organization does not have accurate and complete design inputs, the final design may not meet user needs and intended use.

A common method for an organization to confirm the design inputs for a design and development project are complete, unambiguous, and not in conflict with each other is to perform a design review after the initial requirements are determined.

**7. Review medical device specifications to confirm that design and development outputs are traceable to and satisfy design input requirements. Verify that the design and development outputs essential for the proper functioning of the medical device have been identified. Outputs include, but are not limited to, device specifications, specifications for the manufacturing process, the quality assurance testing, and device labeling and packaging.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.3.3; 7.3.5; TG(MD)R Sch3 P1 CI 1.4(5)(c); RDC ANVISA 16/2013: 4.1.5, 4.1.4, 4.1.11; MHLW MO169: 6, 32, 34; 21 CFR 820.30(d), 820.30(f)]

*Additional country-specific requirements:*

*Australia (TGA):*

Confirm that documentation identifies whether relevant state of the art standards have been applied in full or in part. If standards have not been applied, ensure that the manufacturer has documented a rationale to explain why alternative methods have been applied to demonstrate compliance with the Essential Principles [TG(MD)R Sch3 Part 1.4(5)(c)(iii)(C)].

For devices incorporating a medicinal substance, verify that documentation also identifies the data to be derived from tests conducted in relation to the substance, and its interaction with the device [TG(MD)R Sch 3 Part 1.4(5)(c)(v)].

*Assessing conformity:*

## **Design outputs**

Design outputs are the work products or deliverables of a design stage. Design outputs can include documents such as diagrams, drawings, specifications, and procedures. The outputs from one stage may become inputs to the next stage. The total finished design output consists of the specifications for the device, its packaging and labeling, quality management system requirements, the manufacturing process, and if applicable, installation and servicing requirements. During this design stage, a tremendous number of records, or outputs, can be produced. Only the approved outputs need to be retained. However, if an organization chooses to retain other records, for historical or other purposes, they may do so.

## **Essential outputs**

Outputs that are essential for the proper functioning of the device must be identified. Typically, an organization can use a risk management tool to determine the essential outputs. To verify that this has been done, the auditor(s) may review the organization's process for determining how the essential outputs were identified and if it was done in accordance with their design output procedures. The identification of essential outputs may influence other quality system activities. For example, the establishment of manufacturing process tolerances, the degree of purchasing controls and acceptance activities applied to a supplier or the priority and depth of a failure investigation may be influenced by whether or not the component (assembly, material, etc.) is considered an output essential for the proper functioning of the device.

## **Design verification**

In design verification, the organization obtains objective evidence (i.e., data) that design outputs



meet design inputs. An organization generates this objective evidence by conducting verification activities such as tests, measurements, and analyses. These activities should be explicit and thorough in their execution. An organization's verification activities should be predictive, not empiric. In other words, acceptance criteria need to be stated in advance of the verification activity. The establishment of pre-determined acceptance criteria may be found in a verification protocol or similar document. During the review of design verification activities, the auditor(s) will determine if the design verification data confirms that design outputs met the design input requirements.

## Verification techniques

Complex designs will require more and different types of verifications than simple designs. Sometimes an organization has to use its own expertise to develop (in-house) a way to verify a particular aspect of a design. Any approach selected by an organization is acceptable as long as it provides reliable objective evidence that the output met the input.

## Choosing verification activities for review

In accomplishing this audit task, select records generated from design verification activities associated with a number of design inputs and design outputs. The review of these records will determine whether design outputs met design input requirements. When possible, select documentation of design verification activities that are associated with outputs that are considered essential for the proper functioning of the device.

### ***Links: Purchasing, Production and Service Controls***

During the review of a design project, the audit team should be mindful of production processes and supplied products that are essential to the proper functioning of the device. Production processes can include not only the manufacturing instructions, but also internal controls, such as the type and extent of acceptance activities, equipment calibration and maintenance intervals, environmental controls, and personnel controls. For suppliers that provide products and services related to the essential design outputs, the degree of purchasing controls necessary is commensurate with the effect of the supplied product on the proper functioning of the finished device.

During the audits of the Purchasing process and Production and Service Controls process, the audit team should consider reviewing production processes and supplied products that have the highest risk or greatest effect on the essential design outputs.

8. *Verify that risk management activities are defined and implemented for product and process design and development. Confirm that risk acceptability criteria are established and met throughout the design and development process.* **Verify that any residual risk is evaluated and, where appropriate, communicated to the customer (e.g., labeling, service documents, advisory notices, etc.).**

### **Note:**

In some instances, it may be necessary for the manufacturer to conduct a risk/benefit analysis to justify a risk that cannot be mitigated to an acceptable level.



Additionally, *it may be necessary to audit other processes (e.g. Production and Service Controls, Purchasing) to verify that risk acceptability criteria are met, risk is controlled or reduced, and residual risk is communicated if necessary.*

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.1, 7.3.2; TG(MD)R Sch1 P1 2, Sch3 P1 Cl 1.4(5)(c)(iii); RDC ANVISA 16/2013: 2.4, 4.1.11, RDC ANVISA 56/2001; CMDR 10, 11, 16; MHLW MO169: 6, 26, 31; 21 CFR 820.30(g)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Verify that the manufacturer has established and maintains a continuous process of risk management which covers the entire life cycle of the product. Possible hazards must be identified in both normal and fault conditions, including those arising from human factors issues. The risk associated with those hazards, shall be calculated. Risks must be analyzed, evaluated and controlled, as necessary. Effectiveness of risk controls implemented shall be evaluated [RDC ANVISA 56/2001, RDC ANVISA 16/2013: 2.4].

*United States (FDA):*

Confirm that the manufacturer has identified the possible hazards associated with the device in both normal and fault conditions. The risks associated with the hazards, including those resulting from user error, should be calculated in both normal and fault conditions. If any risk is judged to be unacceptable, it should be reduced to acceptable levels by the appropriate means. Ensure changes to the device to eliminate or minimize hazards do not introduce new hazards [21 CFR 820.30(g); preamble comment 83].

*Assessing conformity:*

## **Risk management**

Each organization must determine how much risk is acceptable. The actual use of any medical device includes some measure of risk to users or patients. Determining an acceptable level of risk depends on the intended use of the device, including the particular health concern of the patient population, the training of the users involved, and the use environment. For example, pediatric patients may have less ability to detect a device malfunction. A device used by consumers generally has less medical oversight than a device used in a hospital setting. The goal of a risk management program is to ensure the device is as safe as practical and the safety of the device is acceptable for the intended use.

Effective risk management usually starts in conjunction with the design and development process, proceeds through product realization, including the selection of suppliers, and continues until the time the product is decommissioned. Risk management should be initiated at a point early in the design and development process. This includes defining the intended use of the device, considering risk under normal use and reasonably foreseen misuse. Starting the risk management process after the design has progressed beyond a point where reasonable risk mitigation features can be included in the design can lead to devices that do not meet customer needs and the organization's requirements for safety. Records of risk management should demonstrate that risks that have been identified as unacceptable have been mitigated to an acceptable level.

## **Mitigation of risks**

There are a number of mechanisms that can be used to mitigate product risk. These risk mitigation mechanisms, in descending order of effectiveness, include safety features inherent in the device design, protective measures in the design (e.g. alarms), and user notifications (e.g. labeled warnings).

## Review of risk management activities

During the review of the design project selected, verify that risk management is initiated early in the design and development process. Confirm that the organization's risk management process involves the proactive evaluation, control, and monitoring of product risk, followed by the reactive response to quality data that indicates new or changing product risk.

### 9. *Confirm that design verification and/or design validation includes assurances that risk control measures are effective in controlling or reducing risk.*

*Clause and regulation:* [ISO 13485:2003: 7.1, 7.3.5, 7.3.6; TG(MD)R Sch1 P1 2, Sch3 P1 CI 1.4(5)(c); RDC ANVISA 16/2013: 2.4, 4.1.4, 4.1.8, 4.1.11; CMDR 10,16; MHLW MO169: 26, 34, 35; 21 CFR 820.30(f), 820.30(g)]

*Additional country-specific requirements:* None

*Assessing conformity:*

## Verification of risk control measures

During the review of design verification activities for the chosen design project, confirm that the identified risk control measures are actually effective in reducing or controlling risk. For example, a design for an enteral feeding tube may have a unique connector to prevent the potential for misconnection to other types of devices, such as suction catheters. Design verification should show that it is difficult or impossible to connect non-related devices to the enteral feeding tube.

### 10. **Verify that design and development validation data show that the approved design meets the requirements for the specified application or intended use(s).** *Verify that design validation testing is adjusted according to the risk of the product and element being validated.*

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.3.6; TG(MD)R Sch1 P1 2; Sch3 P1 CI 1.4(5)(d); RDC ANVISA 16/2013: 2.4, 4.1.8, 4.1.11; CMDR 12; MHLW MO169: 6, 35; 21 CFR 820.30(g)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Verify that design validation has been performed under defined operating conditions on initial production units, lots, or batches. Validation shall include device testing under real or simulated conditions of use. Design validation shall include software validation, as necessary. Stability studies shall be performed as necessary [RDC ANVISA 16/2013: 4.1.8].

*United States (FDA):*

Verify that design validation has been performed on initial production units, lots, or batches, or their equivalents. When equivalent devices are used in the final validation, the manufacturer must document in detail how the device was manufactured and how the device is similar to and possibly different from initial production. When there are differences, the manufacturer must justify why design validation results are valid for the production units, lots, or batches. Verify that design validation includes testing of production units under actual or simulated use conditions [21 CFR 820.30(g)].

*Assessing conformity:*

## Design validation

Design validation is performed to provide objective evidence that design specifications (outputs) conform to user needs and intended uses. Design validation must be completed before commercial distribution of the product.

The design validation activities should be predictive, not empiric. In other words, acceptance criteria need to be stated in advance of the validation activity. The establishment of pre-determined acceptance criteria may be found in a validation protocol or similar document.

Design validation must be performed under defined operating conditions on initial production units, lots, or batches, or their equivalents. Design validation shall ensure that devices conform to defined user needs and intended uses and includes testing of production units under actual or simulated use conditions. The results of the design validation, including identification of the design, method(s), the date, and the individual(s) performing the validation, must be recorded.

### **Needs, environment and uses**

Design validation must address the needs of all relevant parties, such as the patient, healthcare worker, biomedical engineer, and storage clerk. Consideration must be given to the environment in which the device will be stored, transported, and used. Design validation needs to be performed for each intended use. Design validation must also confirm that user needs and intended uses associated with the device's packaging and labeling are met. These outputs have human factors implications and unless they are adequately considered during design validation, they may adversely affect the device and its use. Confirm that design validation data show that the approved design met the predetermined user needs and intended uses. The intended uses must include the purpose of the device, patient type (adults, pediatrics or newborn) and the environment in which the device is to be transported and used (domestic use, hospitals, ambulances, etc.).

## **11. Verify that clinical evaluations and/or evaluation of the medical device safety and performance were performed as part of design validation if required by national or regional regulations.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.3.6; TG(MD)R Reg 3.11, Sch3 P1 CI 1.4(5)(c)(vii), Sch3 P8; RDC ANVISA 16/2013: 4.1.8, 4.1.11, RDC ANVISA 56/2001; CMDR 12; MHLW MO169: 6, 35; 21 CFR 820.30(g)]

*Additional country-specific requirements:*

*Australia (TGA):*

Verify that records of the validation include clinical evidence as required by the clinical evidence procedures [TG(MD) Sch3 P1 CI 1.4(5)(c)(vii) and TG(MD) Sch3 P8].

*Assessing conformity:*

### **Clinical evaluations and testing**

Design validation may involve the performance of some sort of clinical evaluation, including testing under actual or simulated use conditions. Clinical evaluations may involve full clinical studies. Clinical evaluations may also consist of other evaluations in a clinical or non-clinical setting, provision of historical evidence that similar designs are clinically safe, or reviews of scientific literature.

The audit team should limit their review of clinical evaluations to verifying whether clinical evaluations have been performed as part of design validation, when necessary, and whether the organization has established acceptance criteria for the results in order to validate the device and that the results obtained meet the defined acceptance criteria.

When applicable, review the clinical evaluations, if performed, to validate the design. The audit team should confirm that the data from clinical evaluations demonstrates that the user needs and intended uses for the device and its packaging and labeling were met.

**12. If the medical device contains software, verify that the software was subject to the design and development process. *Confirm that the software was included within the risk management process.***

*Clause and regulation:* [ISO 13485:2003: 7.3.1, 7.3.6; TG(MD)R Sch1 P1 2, Sch1 EP12.1; RDC ANVISA 16/2013: 2.4, 4.1.8, 4.1.11; CMDR 20; MHLW MO169: 30, 35; 21 CFR 820.30(g)]

*Additional country-specific requirements:* None

*Assessing conformity:*

### **Software development**

Many devices are at least partially controlled by software. Some devices consist almost entirely of software. For the device software, confirm that the software is part of the design and development plan for the device. The life cycle requirements for medical device software must be defined, including the intended use.

### **Software verification**

“Software verification” is a term often used to describe the testing of the software. During the review of the software development, confirm that the organization has conducted appropriate verification activities. Verification is often accomplished by performing test cases at the unit, subsystem, and integration levels; as well as system functional testing. Software verification can include the testing of the software product installed on the target hardware. As with other types of design verification, verification of software is a predictive activity. The acceptance criteria must be determined prior to performing the testing. The predetermined acceptance criteria are often found in a verification protocol or similar document. Confirm that the predetermined acceptance criteria have been met by reviewing the actual results of the selected software tests. The risk management activities for the device and software can help guide the audit team as to which verification tests involve the essential design outputs of the device and software.

### **Software validation**

Software validation is a “confirmation by examination and provision of objective evidence that software specifications conform to user needs and intended uses, and that the particular requirements implemented through software can be consistently fulfilled.” It involves checking for proper operation of the software in its actual or simulated use environment, including integration into the final device where appropriate. Testing of device software functionality in a simulated use environment, and user site testing are typically included as components of an overall design validation program for a software automated device.

The audit team may encounter times when the software has been installed at user sites as part of validation, often referred to as “beta testing”. Beta testing can be a method to confirm the device, including the software, meets the user needs and intended uses.

**13. Verify that design and development changes were controlled, verified (or where appropriate validated), and approved prior to implementation. *Confirm that any new risks associated with the design change have been identified and mitigated to the extent practical.***

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.1, 7.3.7; TG(MD)R Sch1 P1 2, Sch3 P1 Cl 1.4(5)(f), Sch3 P1 Cl1.5(4); RDC ANVISA 16/2013: 2.4, 4.1.4, 4.1.8, 4.1.10, 4.1.11, Brazilian Law 6360/76 - Art. 13; CMDR 1, 34; MHLW MO169: 6, 26, 36; 21CFR 820.30(i)]



#### *Additional country-specific requirements:*

##### *Australia (TGA):*

Verify that the manufacturer has a process or procedure for notifying the auditing organization of a substantial change to the design process or the range of products to be manufactured [TG(MD)R Sch3 Cl1.5].

Verify that the manufacturer has a process or procedure for identifying a proposed substantial change to the design, or the intended performance, of a Class AIMD or Class III device, and to notify the assessment body prior to implementing the change [TG(MD)R Sch3 P1 Cl 1.6(4)].

##### *Brazil (ANVISA):*

If the medical device evaluated is already registered/notified with ANVISA, verify that the design change was correctly and promptly submitted to ANVISA for approval, when applicable [Brazilian Law 6360/76 - Art. 13].

##### *Canada (HC):*

Verify that the manufacturer has a process or procedure for identifying a “significant change” to a Class III or IV medical device. Verify that information about “significant changes” is submitted in a medical device license amendment application [CMDR 1, 34].

##### *Japan (MHLW):*

For the Marketing Authorization Holder: When applicable, confirm the Marketing Authorization Holder has submitted a new application, a change application, or a change notification to PMDA/ a Registered Certification Body. [PMD Act 23-2-5 (1), 23-2-5 (11), 23-2-5 (12), 23-2-23 (1), 23-2-23 (6), 23-2-23 (7)].

For the Registered Manufacturing Site: Confirm the site has a mechanism to communicate with the Marketing Authorization Holder about device modifications so the Marketing Authorization Holder can take appropriate actions when necessary. If a critical medical device modification has occurred at the Registered Manufacturing Site, confirm if the Registered Manufacturing Site has communicated the change to the Marketing Authorization Holder. [MHLW MO169: 29]

##### *United States (FDA):*

Verify that the firm obtained a new 510(k) or supplement to the pre-market approval if required [21 CFR 807].

#### *Assessing conformity:*

### **Procedures**

An organization may have separate change control procedures to handle the post-production and pre-production changes, or an organization may have one procedure that handles both.

### **Nature of change**

The documentation and control of changes begins when the initial design inputs are approved and continues for the life of the product. Design change control applies to changes to inputs or outputs as a result of design verification or design validation, changes to labeling or packaging, changes to enhance a product's performance, changes of production process(es), and changes that result from product complaints. Change can be acceptable as long as it is controlled.

### **Records**

The control of changes is not complete until the results of the review of changes and any updates to product specifications or changed processes are documented or amended.

### **Communication and consequential actions**

Changes need to be effectively communicated and requirements for any consequential actions should be defined (e.g. training or communication to design or production staff).



***Link: Measurement, Analysis and Improvement process (if a design change was made to correct a quality problem with the device); Device Marketing Authorization and Facility Registration***

During the audit of the Measurement, Analysis and Improvement process, the auditors may encounter corrective actions or preventive actions that resulted in design changes. When corrective action or preventive action involves changing the design, confirm that design controls have been applied to the change, in accordance with the organization's procedures. Confirm these design changes were effective in addressing the quality issues or potential quality issues identified in corrective or preventive action. In addition, the design change should be evaluated under the organization's risk management process to ensure that changes do not introduce new hazards. Some changes may require revalidation where it is not possible to verify that requirements have been met after the change has been implemented.

The audit team should also confirm the organization has considered regulatory requirements for registration, listing, notification and licensing; and has complied with these requirements prior to marketing the changed device in the applicable regulatory jurisdictions.

**14. Verify that design reviews were conducted at suitable stages as required by the design and development plan. Confirm that the participants in the reviews include representatives of functions concerned with the design and development stage being reviewed, as well as any specialist personnel needed.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.3.1, 7.3.4; TG(MD)R Sch3 P1 C1.4(5)(c)(i); RDC ANVISA 16/2013: 4.1.6, 4.1.11; MHLW MO169: 6, 30, 33; 21 CFR 820.30(e)]

*Additional country-specific requirements:*

*United States (FDA):*

Verify that procedures ensure that participants include representatives of all functions concerned with the design stage being reviewed and an individual(s) who does not have direct responsibility for the design stage being reviewed, as well as any specialists needed [21 CFR 820.30(e)].

*Assessing conformity:*

**Design reviews**

Design reviews typically occur at the end of each design stage or phase or after the completion of project milestones. The number of design reviews can vary, but at a minimum, one formal review must be conducted. Reviews should provide feedback to the design team on emerging problems, assess the progress of the design and development project, and confirm that the design is ready to move to the next phase of development or for transfer to the manufacturing phase.

It is not necessary to have fully convened meetings for all design reviews. For simple designs or minor changes, desk reviews and sign-offs may be adequate. Design reviews must include an individual who does not have direct responsibility for the design stage being reviewed and representation from manufacturing to ensure that design and development outputs are verified as suitable for manufacturing before becoming final production specifications.

During the review of design review activities for the selected design project, confirm that the reviews included an individual who did not have direct responsibility for the design stage being reviewed. The audit team should also confirm that outstanding action items are being resolved or have been resolved.

## 15. Verify that design changes have been reviewed for the effect on products previously made and delivered, and that records of review results are maintained.

*Clause and regulation:* [ISO 13485:2003: 7.3.7; RDC ANVISA 16/2013: 4.1.10; MHLW MO169: 36; 21 CFR 820.30(i)]

*Additional country-specific requirements:* None

*Assessing conformity:*

### Effects on constituent parts and products already delivered

There are situations where a design change can affect constituent parts. For example, a change to a disposable portion of an aspiration system might affect the ability of the disposable to connect to the console. When necessary, ensure the design change does not negatively impact products in distribution.

## 16. Determine if the design was correctly transferred to production.

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.1, 7.3.1; RDC ANVISA 16/2013: 4.1.7, 4.1.9, 4.1.11, 4.2; MHLW MO169: 6, 26, 30; 21 CFR 830.30(h)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Verify that procedures ensure that the device design is correctly translated into production specifications [RDC ANVISA 16/2013: 4.1.7].

Confirm that the manufacturer ensures that the design release occurs only after the approval(s) of a designated person. Before the final release, design and development records must be reviewed to confirm that the design is complete and that the final design meets the approved design. Final release, including signature(s) (manual or electronic) and dates, shall be documented [RDC ANVISA 16/2013: 4.1.9, 4.1.11].

Verify that production specifications are documented (e.g. Device Master Record – DMR). The record shall include or make reference to: a) device specifications, including software source code (if applicable), drawings, composition (BOM – bill of materials), etc.; b) production specifications (ex. work instructions, environmental controls, measurement equipment, etc.); c) labeling and packaging specifications; c) measurements, inspections, and tests, with acceptance criteria; and d) methods and procedures for installation and servicing (if applicable) [RDC ANVISA 16/2013: 4.2].

*Assessing conformity:*

### Transferring the design to production

During this phase, the design is translated into production specifications. This can take place in steps or phases. The audit team should review how the design for the selected project was transferred into production specifications. Based on the organization's identification of essential outputs and risk management activities, review significant elements of the manufacturing processes, including products from suppliers and the established tolerances for processes, and compare them with the approved design outputs contained within the design records. These activities can confirm whether or not the design was correctly transferred.

Design transfer is a process that may be initiated not only at the end of the design and development process, but may also be initiated immediately before validation stages and may continue as design and development evolves. This early initiation of design transfer is helpful in order to have production processes and device validations conducted properly and allow for corrections during the process. At the end, design and development process is "finalized" by a "final design transfer."

**Link: Production and Service Controls, Purchasing**

Verify that production processes for the device, including process validation (if required) have been defined, documented, and implemented. Confirm that potential hazards that could be introduced or exacerbated by the production process have been identified, and production controls have been established. Production processes include not only the manufacturing instructions, but also internal controls, such as the type and extent of acceptance activities, equipment calibration and maintenance intervals, environmental controls, and personnel controls.

Confirm that the manufacturer has determined the type and extent of supplier controls based on the relationship between the supplied products and services and product risk.

**17. Determine, based on the assessment of the design and development process overall, whether management provides the necessary commitment to the design and development process.**

*Clause and regulation:* [ISO 13485:2003: 4.1, 5.1, 5.5.1; TG(MD)R Sch3 P1 Cl 1.4(5)(b)(ii); RDC ANVISA 16/2013: 2.2.1; MHLW MO169: 5, 10, 15]

# Medical Device Single Audit Program

## Chapter 6

### Process: Production and Service Controls

The purpose of the Production and Service Controls process is to manufacture products that meet specifications. Developing processes that are adequate to produce devices that meet specifications, validating (or fully verifying the results of) those processes, and monitoring and controlling those processes are all steps that help assure the result will be devices that meet specified requirements. After completing the audit of the organization's Production and Service Controls process, the audit team will return to the Management process to make a final decision of whether top management ensures that an adequate and effective quality management system has been established and maintained at the organization.

In order to meet the Production and Service Controls requirements of Medical devices – Quality management systems – Requirements for regulatory purposes (ISO 13485:2003), Brazilian Good Manufacturing Practices (RDC ANVISA 16/2013), Japanese QMS Ordinance (MHLW MO 169), the Quality System Regulation (21 CFR Part 820), and specific requirements of medical device regulatory authorities participating in the MDSAP program, the organization must understand when deviations from device specifications could occur as a result of the production process or environment.

The **management representative** is responsible for ensuring that the requirements of the quality management system have been effectively defined, documented, implemented, and maintained. Prior to the audit of any MDSAP process, interview the management representative (or designee) to obtain an overview of the process and a feel for management's knowledge and understanding of the process.

Audit of the Production and Service Controls process will follow audit of the Measurement, Analysis and Improvement process and the Design and Development process per the MDSAP audit sequence. Information the audit team has learned about device and quality management system nonconformities during audit of the Measurement, Analysis and Improvement process, as well as higher risk elements and essential design outputs from the design projects reviewed during audit of the Design and Development process, should be used to make decisions as to the production processes to be reviewed during the audit of the Production and Service Controls process.

### Auditing the Production and Service Controls Process

**Purpose:** The purpose of auditing the production and service controls process (including testing, infrastructure, facilities, equipment, and servicing) is to verify that the organization's processes are capable of ensuring that products will meet specifications.

**Outcomes:** As a result of the audit of the Production and Service Controls process, objective evidence will show whether the organization has:

- A) Defined, documented and implemented procedures to ensure production and service processes are planned, developed, conducted, controlled, and monitored to ensure conformity to specified requirements
- B) Developed production and service process controls commensurate with the potential effect of the process on product risk

- C) Ensured that when the results of a process cannot be verified by subsequent monitoring or measurement, the process is validated with a high degree of assurance that the process will consistently achieve the planned result
- D) Implemented procedures for the validation of the application of computer software for production and service processes that affect the ability of the product to conform to specified requirements, including validation of computer software used in the quality management system
- E) Maintained records for each batch of medical devices that provides information for traceability and confirmation that the batch meets specified requirements
- F) Implemented controls to protect customer property, including intellectual property, confidential health information, and other forms of customer property that is used or incorporated into products

***Links to Other Processes: Management; Design and Development; Measurement, Analysis and Improvement; Purchasing.***

### **Audit Tasks and Links to Other Processes:**

1. **Verify that the product realization processes are planned, including any necessary controls, controlled conditions, and risk management activities required for the product to meet the specified or intended uses and the statutory and regulatory requirements related to the product. Confirm that the planning of product realization is consistent with the requirements of the other processes of the quality management system and performed in consideration of the quality objectives.**

*Clause and regulation:* [ISO 13485:2003: 7.1, 7.2.1, 7.5.1.1; TG(MD)R Sch 1 P1 2, Sch3 P1 Cl1.4(4), Sch3 P1 Cl1.4(5)(d)&(e); RDC ANVISA 16/2013: 2.2.1, 2.4, 4.1.2, 4.1.7, 5.1; MHLW MO169: 26, 27, 40; 21 CFR 820.30(b), 820.20(a), 820.30(h), 820.70(a)]

*Additional country-specific requirements:* None

*Assessing conformity:*

### **Planning**

In planning product realization, the organization must determine as appropriate the quality objectives and requirements for the product, the processes, documents, and resources specific to the product, the criteria for product acceptance, and the required verification, monitoring, inspection, and test activities specific to the product. Planning of product realization often begins in the design and development of the product, including the translation of the design into production specifications.

The planning of product realization should be consistent with the risk control and mitigation strategies identified by the organization during risk management activities.

During the audit, be mindful of requirements for the product that relate to statutory and regulatory requirements, requirements necessary for the product to meet specified or intended uses, and requirements for safe and efficacious use of the product. The organization must ensure their processes, and the monitoring of processes, inspection, and test activities are planned and developed to ensure these requirements are met.



## Quality objectives

Quality objectives are typically expressed as a measurable target or goal. The planning of product realization should include consideration of how the production processes, the criteria for product acceptance, and the required verification, validation, monitoring, inspection, and test activities specific to the product will achieve the quality objectives. Confirm that the organization has defined quality objectives for the device.

### ***Link: Management***

Confirm when necessary that the quality objectives related to the product were considered for inclusion in management review.

## **2. Review production processes considering the following criteria. Select one or more production processes to audit.**

**Reminder:** Information the audit team has learned about device and quality management system nonconformities during audit of the Measurement, Analysis and Improvement process, as well as higher risk elements and essential design outputs from the design projects reviewed during audit of the Design and Development process should be used to make decisions as to the production processes to be reviewed.

### **Priority criteria for selection:**

- Corrective and preventive action indicators of process problems or potential problems
- *Use of the production process for higher risk products*
- Use of production processes that directly impact the ability of the device to meet its essential design outputs
- New production processes or new technologies
- Use of the process in manufacturing multiple products
- Processes that operate over multiple shifts
- Processes not covered during previous audits

## **3. For each selected process, determine if the production and service process is planned and conducted under controlled conditions that include the following:**

- the availability of information describing product characteristics
- the availability of documented procedures, requirements, work instructions, and reference materials, reference measurements, and criteria for workmanship
- the use of suitable equipment
- the availability and use of monitoring and measuring devices
- the implementation of monitoring and measurement of process parameters and product characteristics during production
- the implementation of release, delivery and post-delivery activities

- the implementation of defined operations for labeling and packaging
- the establishment of documented requirements for changes to methods and processes

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.5.1.1, 8.2.3, 8.2.4; TG(MD)R Sch3 P1 Cl1.4(5)(d)&(e); RDC ANVISA 16/2013: 3.1.3, 4.2, 5.1, 5.2, 5.3, 5.4, 5.6; 5.6.1; 5.6.2; MHLW MO169: 6, 40, 57, 58, 59; 21 CFR 820.70(a), 820.70(b), 820.75, 820.120, 820.130]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Determine whether the manufacturer has established and maintained a procedure for change control in order to track changes in auxiliary systems, software, equipment, processes, methods or other changes that may affect the quality of products, including risk assessment within the risk management process. The procedure must describe the actions to be taken, including, when appropriate, the need for re-qualification or re-validation. Verify that changes are formally requested, documented and approved before implementation [RDC ANVISA 16/2013: 5.6; 5.6.1; 5.6.2].

*Assessing conformity:*

## **Establishment of work instructions, procedures, and production processes**

Production processes that may cause a deviation to a device specification and all validated processes must be controlled and monitored. The planning of production includes the establishment of procedures and work instructions for the control and monitoring of the production processes, including service controls when necessary. Control and monitoring procedures may include in-process and finished device acceptance activities as well as environmental and contamination control measures. The establishment of procedures and work instructions to control the production of the device should provide the controls and tolerances necessary to ensure finished devices conform to product specifications.

### **4. Determine if the organization has established documented requirements for product cleanliness including any cleaning prior to sterilization, cleanliness requirements if provided non-sterile, and assuring that process agents are removed from the product if required.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.5.1.2.1; TG(MD)R Sch3 P1 Cl1.4(5)(d); RDC ANVISA 16/2013: 5.1.3.1, 5.1.3.4, 5.1.5.3; MHLW MO169: 6, 41; 21 CFR 820.70(c), 820.70(d), 820.70(e), 820.70(h)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Confirm that a pest control program has been established and where chemicals are used as part of the pest control program, the company must ensure that they do not affect product quality [RDC ANVISA 16/2013: 5.1.3.4].

Verify that the manufacturer has established and maintains housekeeping procedures and schedules for production areas and warehouses, in conformance with production specifications [RDC ANVISA 16/2013: 5.1.3.1].

*Assessing conformity:*

## **Cleanliness requirements**

The goal of establishing requirements for product cleanliness is to minimize contamination of the finished device and the manufacturing environment. Sterile devices may require a higher level of control in terms of minimizing the bioburden and particulate contamination in order to assure the desired sterility assurance level is met. Each organization must evaluate the extent of cleanliness required for the proper functioning and intended use of the finished device and implement the necessary control measures. Examples of control measures include, but are not limited to,

cleaning procedures, environmental controls (e.g. cleanrooms, or other controlled environments), requirements for attire, and training of personnel. When necessary, confirm the organization has identified the cleanliness requirements for the finished device and the proper controls to achieve the required level of cleanliness.

## Process agents

Process agents, also known as manufacturing materials, are generally defined as materials or substances used to facilitate the manufacturing process, which are present in or on the finished devices as a residue or impurity. Examples of process agents include cleaning agents, mold-release agents, lubricating oils, latex proteins, sterilant residues, etc. The organization must evaluate process agents used during the manufacturing process when the process agent could potentially have an adverse effect on the product. During the design of the product and the development of the manufacturing process, the potential effect of process agents should be considered. If the audit team encounters situations where process agents are being utilized in the manufacturing of the product, and the process agent could potentially have an adverse effect on the product, confirm that the organization has made effective arrangements to control the process agent in a manner commensurate with the risk the agent poses to the finished device. For example, the organization may need to validate a cleaning process to ensure cutting oil is removed from an orthopedic implant prior to packaging and sterilization.

- 5. Verify that the organization has determined and documented the infrastructure requirements to achieve product conformity, including buildings, workspace, process equipment, and supporting services. Confirm that buildings, workspaces, and supporting services allow product to meet requirements. Verify that there are documented and implemented requirements for maintenance of process equipment where important for product quality, and that records of maintenance are maintained.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 6.3; RDC ANVISA 16/2013: 5.1.2, 5.1.5; CMDR 14; MHLW MO169: 6, 24; 21 CFR 820.70(g), 820.70(f)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Verify that manufacturing facilities are configured in order to provide adequate means for production, avoid mix-ups or contamination of components, raw materials, in process products and finished devices; and to ensure the correct handling of the devices and production flow [RDC ANVISA 16/2013: 5.1.2].

*Assessing conformity:*

## Infrastructure requirements

The organization is responsible for evaluating the manufacturing facility to ensure that the buildings, utilities, and space allow for the achievement of product conformity. The organization is responsible for ensuring adequate space to prevent mix-ups and ensure orderly handling of products.

## Equipment maintenance

The organization must consider whether maintenance of production equipment may affect product quality. Procedures, including the frequency of maintenance and the records of maintenance must be available for these items of equipment.

## 6. Verify documented requirements have been established, implemented and maintained for:

- health, cleanliness, and clothing of personnel that could have an adverse effect on product quality
- monitoring and controlling work environment conditions that can have an adverse effect on product quality
- training or supervision of personnel who are required to work under special environmental conditions
- controlling contaminated or potentially contaminated product (including returned products) in order to prevent contamination of other product, the work environment, or personnel

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 6.4; TG(MD)R Sch1 P2 7.2, 8; RDC ANVISA 16/2013: 5.1.3; MHLW MO169: 6, 25; 21 CFR 820.70(c), 820.70(d), 820.70(e)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Verify that biosafety standards are used, when applicable [RDC ANVISA 16/2013: 5.1.3.6].

*Assessing conformity:*

### Contamination control

The organization is responsible for establishing and maintaining procedures to prevent contamination of products, equipment, and personnel by substances that could adversely affect the device. If contamination control measures are necessary to meet specified requirements, cleaning and sanitation procedures and schedules may be required to ensure the contamination control measures are properly functioning. The organization should consider the segregation and decontamination of returned product.

### Personnel practices

Personnel practices must address personnel health, cleanliness, and attire if these could adversely affect product quality or the work environment. In the event that maintenance or other personnel are required to work temporarily under special environmental conditions, these individuals must be appropriately trained or supervised by a trained individual.

## 7. Determine if the selected process(es) and sub-process(es) have been reviewed, including any outsourced processes, to determine if validation of these processes is required.

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.5.2.1; TG(MD)R Sch1 P2 8.2, 8.3; Sch3 P1 1.4(5)(d), RDC ANVISA 16/2013: 5.5.2, 5.5.3; MHLW MO169: 6, 45; 21 CFR 820.75(a)]

*Additional country specific requirements:*

*Brazil (ANVISA):*

Verify that analytical methods, utilities, computer systems and automated software that can adversely affect product quality or the quality system are validated, periodically reviewed and, when necessary, revalidated [RDC ANVISA 16/2013: 5.5.2, 5.5.3].

*Canada (HC):*

Verify that sterilization methods for devices sold in a sterile state are validated [CMDR 17].

*United States (FDA):*

Process validation is required for sterilization, aseptic processing, injection molding, and welding [21 CFR 820.75; preamble comment 143].

*Assessing conformity:*

## **Process validation**

During the planning of product realization, the organization must determine which production processes require validation and which processes can be verified. Process validation may apply to processes that generate components, subassemblies, or finished devices. Process validation is required for processes where the results of the process cannot be fully verified. Processes that cannot be fully verified include processes where clinical or destructive testing is necessary to show that the process produced the desired result, where routine inspection and/or testing does not examine quality attributes essential to the proper functioning of the finished device, or where routine testing has insufficient sensitivity to verify the desired safety and efficacy of the finished product.

Examples of processes that require validation include, but are not limited to sterilization, aseptic processing, welding, and injection molding. When applicable, confirm that the organization has identified processes which require validation, including validation requirements for any outsourced processes.

When validating processes, organizations must take into account the current thinking of experts where published information is available (e.g. though the application of ISO standards for sterilization validation).

### ***Link: Purchasing***

The audit team may encounter situations where the organization outsources processes that require validation. During the review of the Purchasing process, review the controls the organization has instituted over suppliers that perform validated processes. This can be particularly important for higher risk validated processes performed by suppliers, since the finished device manufacturer does not have immediate control over those processes.

- 8. Verify that the selected process(es) has been validated if the result of the process cannot be fully verified. Confirm that the validation demonstrates the ability of the process(es) to consistently achieve the planned result. In the event changes have occurred to a previously validated process, confirm that the process was reviewed and evaluated, and re-validation was performed where appropriate.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.5.2.1; TG(MD)R Sch1 P1 2(1), Sch3 P1 1.4(5)(d); RDC ANVISA 16/2013: 1.2.18, 5.5.1; MHLW MO169: 6, 45; 21 CFR 820.75(a), 820.75(c)]

*Additional country-specific requirements:*

*Australia (TGA):*

Confirm that methods of validation have regard to the generally acknowledged state of the art (e.g. current Medical Device Standard Orders - MDSO, ISO/IEC Standards, BP, EP, USP etc.) [TG Act s41CB, TG(MD)R Sch 1 P1 2(1)].



#### *Brazil (ANVISA):*

Verify that processes requiring validation are validated according to previously established protocols. The results of validations, including date and identification of the person responsible for its approval, must be recorded [RDC ANVISA 16/2013: 5.5.1].

#### *United States (FDA):*

Confirm that the validation activities and results, including the date and signature of the individual approving the validation and where appropriate the major equipment validated, have been documented [21 CFR 820.75(a)].

#### *Assessing conformity:*

### **Process validation**

Process validation means establishing by objective evidence (i.e. data) that a process **consistently** produces a **result** (e.g., sterility assurance level) or **product** meeting predetermined specifications. Remember that the term “**product**” applies to components and in-process devices as well as finished devices. Therefore, process validation may apply to processes that generate components, in-process devices, or finished devices.

### **Process validation procedures**

Some organizations have general process validation procedures. Other organizations establish separate procedures for each individual process validation study. Both methods for establishing process validation procedures are acceptable.

### **Reviewing a validation**

During review of a validation study, determine when applicable whether:

- 1) The instruments used to generate the data were properly calibrated and maintained;
- 2) Predetermined product and process specifications were established;
- 3) Sampling plans used to collect test samples are based on a statistically valid rationale;
- 4) Data demonstrates predetermined specifications were met consistently;
- 5) Process tolerance limits were challenged;
- 6) Process equipment was properly installed, adjusted, and maintained;
- 7) Process monitoring instruments were properly calibrated and maintained;
- 8) Changes to the validated process were appropriately challenged (if applicable); and
- 9) Process operators were appropriately qualified.

### **Achieving the planned result**

Process validation activities are predictive, rather than empiric. In order for a process validation study to show the process achieves the planned result, the acceptance criteria must be stated in advance of performing the validation. The data from the process validation study must show the predetermined acceptance criteria have been met.

## Evidence of nonconformities

Process validation studies may also provide valuable insight into process or product nonconformities. For example, the process validation study must demonstrate not only that the process can produce a result or product meeting predetermined specifications but also that the process will consistently produce a result or product meeting predetermined specifications. If process or product nonconformities related to a validated process are encountered at a higher than anticipated rate, it may indicate the process validation study did not confirm that the process could consistently produce a result or product meeting predetermined specifications. Unless the organization recognized this during the process validation study, they may not have investigated the cause of the process inconsistency.

### 9. If product is supplied sterile:

- **Verify the sterilization process is validated, periodically re-validated, and records of the validation are available**
- **Verify that devices sold in a sterile state are manufactured and sterilized under appropriately controlled conditions**
- **Determine if the sterilization process and results are documented and traceable to each batch of product**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.5.1.3, 7.5.2.2; TG(MD)R Sch1 2(1) & 8.3, Sch3 P1 1.4(5)(d); RDC ANVISA 16/2013: 5.1.6, 5.5; CMDR 17; MHLW MO169: 6, 44, 46; 21 CFR 820.75, 820.184(d)]

*Additional country-specific requirements:*

*Australia (TGA):*

Verify that methods of sterilization validation have regard to the generally acknowledged state of the art (e.g. current Australian Medical Device Standard Orders - MDSO, ISO 11135, ISO 11137) [TG(MD)R Sch1 P1 2(1)].

*Assessing conformity:*

### Validation of sterilization processes

Sterilization processes include terminal sterilization methods (such as radiation and ethylene oxide) as well as aseptic processing methods. Sterilization processes must be validated, with periodic revalidation as required by established standards or requirements established by the organization.

### 10. Verify that the system for monitoring and measuring of product characteristics is capable of demonstrating the conformity of products to specified requirements. *Confirm that product risk is considered in the type and extent of product monitoring activities.*

*Clause and regulation:* [ISO 13485:2003: 7.1, 7.5.1.1, 8.1; 8.2.4; TG(MD)R Sch1 P1 2, Sch3 P1 1.4(5)(b)&(e); RDC ANVISA 16/2013: 2.4, 5.1.1, 9.1; MHLW MO169: 26, 40, 54, 58; 21 CFR 820.70(a), 820.250(a)]

*Additional country-specific requirements:* None

*Assessing conformity:*

### Monitoring systems

The general goal of monitoring processes and product characteristics during production is to ensure that products conform to the specified requirements defined and approved during the

design and development of the device. The organization has the flexibility to determine the controls that are necessary, commensurate with the risk to the finished device if processes or product characteristics do not meet specified requirements. During the audit of production processes, confirm that the control measures are suitable for detecting process or product nonconformities.

**11. Verify that the processes used in production and service are appropriately controlled, monitored, and operated within specified limits. *In addition, verify that risk control measures identified by the manufacturer for production processes are implemented, monitored and evaluated.***

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.1, 7.5.1.1, 8.1, 8.2.3; TG(MD)R Sch1 P1 2, Sch3 P1 1.4(5)(b)&(e); RDC ANVISA 16/2013: 2.4, 5.1.1, 5.1.6, 8.2, 9.1; MHLW MO169: 6, 26, 40, 54, 57; 21 CFR 820.70(a), 820.75(b), 820.250]

*Additional country specific requirements:*

*Brazil (ANVISA):*

Verify that processes which cannot be fully verified are conducted in accordance with established procedures and parameters to ensure conformance to specifications. Critical parameters should be monitored and recorded in the batch record [RDC ANVISA 16/2013: 5.1.6].

*United States (FDA):*

Verify that the manufacturer has established and maintains procedures for identifying valid statistical techniques required for establishing, controlling and verifying the acceptability of process capability and product characteristics, where appropriate [21 CFR 820.250(a)].

*Assessing conformity:*

## **Process control and monitoring**

Processes that may cause a deviation to device specifications and validated processes must be controlled and monitored. Control and monitoring procedures may include in-process and finished device acceptance activities as well as environmental and contamination control measures.

Compare the process monitoring and acceptance procedures contained or referenced within the records of production specifications with those available to the production personnel. Confirm that the procedures available to the production personnel are the most current approved revisions.

While in the production area, verify that the building is of suitable design and contains sufficient space to perform necessary operations. Also, verify that the results of control and monitoring activities demonstrate that the process is currently operating in accordance with applicable procedures. This can be done by comparing work instructions with what is actually being done, comparing product acceptance criteria with acceptance activity results, reviewing control charts against specified requirements, etc.

### ***Link: Design and Development***

The design outputs for a device include documents such as diagrams, drawings, specifications, procedures, and the production processes that are essential to the proper manufacturing of the device. Production processes can include not only the manufacturing instructions, but also internal controls, such as the type and extent of acceptance activities, equipment calibration and maintenance intervals, environmental controls, and personnel controls. During the audit of the Production and Service Controls process, consider reviewing production processes that have the highest risk or greatest effect on the essential design outputs.

## 12. Verify that personnel are competent to implement and maintain the processes in accordance with the requirements identified by the organization.

*Clause and regulation:* [ISO 13485:2003: 6.2.2; RDC ANVISA 16/2013: 2.3.2; MHLW MO169: 23; 21 CFR 820.25, 820.70(d), 820.75(b)]

*Additional country-specific requirements:* None

*Assessing conformity:*

### Personnel training and qualification

Production processes must be performed by adequately trained personnel. The organization must establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities. This training must be documented. In addition, personnel who perform validated processes must be qualified. It is management's responsibility to determine what qualifications are necessary for personnel who perform validated processes.

#### **Link: Management**

During the audit of the Production and Service Controls process, ensure that employees who are involved in key operations that affect product realization and product quality have been trained in their specific job tasks, as well as the quality policy and objectives. When appropriate, review the training records for those employees whose activities have contributed to process nonconformities.

## 13. Confirm that the organization has determined the monitoring and measuring devices needed to provide evidence of conformity to specified requirements. Verify that the monitoring and measuring equipment used in production and service control has been identified, adjusted, calibrated and maintained, and capable of producing valid results.

*Clause and regulation:* [ISO 13485:2003: 7.5.1.1, 7.6; TG(MD)R Sch3 P1 1.4(5)(e); RDC ANVISA 16/2013: 5.1.5, 5.4; MHLW MO169: 40, 53; 21 CFR 820.70(g), 820.72]

*Additional country-specific requirements:* None

*Assessing conformity:*

### Maintenance and calibration

While reviewing the selected production process, make note of significant pieces of process equipment and significant pieces of measuring or test equipment. Consider selecting process and test equipment that, if not properly controlled, could cause devices to not meet specified requirements; or produce inaccurate results that could lead to unrecognized nonconformities. Confirm that the production and test equipment selected for review is suitable for its intended purpose and capable of giving valid results.

Review the maintenance, control, and calibration procedures (and records) for the equipment selected for review. The initial frequency with which measuring and test equipment is calibrated and maintained is usually based on the equipment manufacturer's recommendations. As the organization gains experience with the piece of equipment, the frequency of calibration and maintenance may be adjusted, based on a documented rationale.

## Accuracy and precision

When accuracy and precision is a factor in the validity of the result of the measuring equipment, the required accuracy and precision should be defined during the planning of product realization to ensure the equipment is suitable and capable of providing valid results.

## Reviewing records

If production equipment or test equipment is found to be outside of its maintenance or calibration requirements, verify that the organization made an assessment of the effect of the out-of-tolerance situation on in-process, finished, or released devices, based on risk. Equipment adjustment, calibration, and maintenance procedures and records may provide insight into nonconformities. Review these procedures and records to determine whether inadequate procedures or the organization's failure to comply with adequate procedures contributed to the nonconformity. For example, determine whether the lack of specified equipment adjustment or maintenance contributed to the production of nonconforming product.

- 14. Confirm that the organization assesses (and records) the validity of previous measurements when equipment is found not to conform to specified requirements, and takes appropriate action on the equipment and any product affected. Verify that the control of the monitoring and measuring devices is adequate to ensure valid results. Confirm that monitoring and measuring devices are protected from damage or deterioration.**

*Clause and regulation:* [ISO 13485:2003: 7.6; TG(MD)R Sch3 P1 1.4(5)(e); RDC ANVISA 16/2013: 5.4; MHLW MO169: 53; 21 CFR 820.72(a)]

*Additional country-specific requirements:* None

*Assessing conformity:*

## Control of monitoring and measuring devices

Organizations must maintain proper calibration, storage, and handling controls for measuring, monitoring, and test equipment used in the development, production, installation, and servicing of product. Calibration must be traceable to a national or international measurement standard if one is available. If calibration services are provided by a supplier, the supplier controls are to be applied to ensure calibration is performed competently. Proper controls will help instill confidence in results obtained from the use of the equipment.

## Procedures

Organizations must define, implement, and maintain procedures for the control of monitoring and measuring devices. The organization may choose to develop general policies for the control of monitoring and measuring devices, along with separate, more specific procedures for the actual calibration and control of each piece of equipment. Procedures must account for any environmental controls necessary for the equipment to produce valid results, as well as any specific storage or handling requirements when necessary. For example, a set of calibrated calipers may require storage in a padded case to maintain the required accuracy and precision. Confirm that the organization has the proper procedures and controls in place to preserve the proper functioning of monitoring, measuring, and test equipment.



## When equipment is found to be out-of-tolerance

The organization may discover that monitoring or measuring equipment is no longer within its adjustment or calibration tolerance. In these situations, the organization must assess and record the validity of previous measuring results and take appropriate action on the equipment and any product affected.

### **15. If the selected process is software controlled or if software is used in production equipment or the quality management system, verify that the software is validated for its intended use. Software validation may be part of equipment qualification.**

*Clause and regulation:* [ISO 13485:2003: 7.5.2.1, 7.6; RDC ANVISA 16/2013: 5.5.2; MHLW MO169: 45, 53; 21 CFR 820.70(i)]

*Additional country-specific requirements:* None

*Assessing conformity:*

## **Validation of production and quality system software**

Production process control software (and any other software used in the organization's quality system) must be validated for its intended use according to an established protocol. If the production process the audit team selected for review is controlled with software, review the software validation documents and records. Software validation documents and records should include:

- a) A software requirements document describing the intended use(s) and user needs associated with the software.
- b) An established validation protocol or similar document describing the activities necessary to demonstrate that the software requirements can be met.
- c) Records of the results of the software validation activities described in the software validation protocol or similar document.
- d) Records that software changes are appropriately controlled (where applicable).

For off-the-shelf quality management system software and software-controlled production or test equipment, it may not be possible, practical, or necessary for the device manufacturer to review the software code or the various software verification test cases that are typically performed by the software or equipment manufacturer. However, the device manufacturer must still ensure the software is capable of functioning according to the device manufacturer's needs. The validation to confirm the software meets the device manufacturer's needs must be performed according to a protocol or similar document with predetermined acceptance criteria.

If multiple software driven systems are used in the production process, be sure to assess the system(s) most likely to have an impact on the finished device's ability to meet specified requirements. Not all software driven systems used in a production process will need to be audited during each audit.

### **16. Determine if the manufacturer has established and maintained a file for each type of device that includes or refers to the location of device specifications, production process specifications, quality assurance procedures, traceability requirements, and packaging and labeling specifications. *Confirm that the manufacturer determined the extent of traceability based on the risk posed by the device in the event the device does not meet specified requirements.***

*Clause and regulation:* [ISO 13485:2003: 4.2.1; 4.2.4; 7.1; 7.5.3.2.1; TG(MD)R Sch3 P1 1.4(5) (c),(d),(e) & 1.9; RDC ANVISA 16/2013: 1.2.26, 2.4, 4.2, 5.2, 6.4; CMDR 9(2), 21-23, 52-56, 66-68; MHLW MO169: 6, 9, 26, 48; 21 CFR 820.65, 820.181]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Verify that the manufacturer has established and maintains procedures to ensure integrity and to prevent accidental mixing of labels, instructions, and packaging materials [RDC ANVISA 16/2013: 5.2.2.1].

Confirm that the manufacturer has ensured that labels are designed, printed and, where applicable, applied so that they remain legible and attached to the product during processing, storage, handling and use [RDC ANVISA 16/2013: 5.2.2.2].

*Canada (HC):*

Verify that the manufacturer maintains objective evidence that devices meet the safety and effectiveness requirements of the CMDR [CMDR 9(2)].

Verify that devices sold in Canada have labeling that conforms to Canadian English and French language requirements and contains the manufacturer's name and address, device identifier, control number (for Class III and IV devices), contents of packaging, sterility, expiry, intended use, directions for use and any special storage conditions [CMDR 21-23].

Verify that the manufacturer maintains distribution records in respect of a device that will permit a complete and rapid withdrawal of the device from the market [CMDR 52-56].

*United States (FDA):*

If a control number is required for traceability, confirm that such control number is on or accompanies the device throughout distribution [21 CFR 820.120(e)].

*Assessing conformity:*

## **Records**

The required records for each type or model of device include documents such as diagrams, drawings, specifications, and procedures associated with the device, its packaging and labeling; as well as, quality management system and production process requirements; and if applicable, installation and servicing requirements. Documents and records associated with production processes can include not only the manufacturing instructions, but also internal controls, such as the type and extent of acceptance activities, equipment calibration and maintenance intervals, environmental controls, and personnel controls. These documents and records provide the requirements and instructions for the proper manufacturing, labeling, packaging, and testing of the device to assure specified requirements are met during the production of each batch of devices. For the device(s) the audit team has selected to review, confirm that the required records have been established.

## **General traceability**

It is the responsibility of the organization to establish procedures for traceability. For devices that are not implanted and are not life-supporting or life-sustaining, the organization has the flexibility to determine which raw materials and components are required to be traceable, commensurate with the risk posed by the device in the event the component does not meet specified requirements.

Traceability systems commonly include elements such as written procedures describing the control numbering system to be used, as well as the documentation of lot numbers, control numbers, or serial numbers identifying the batch of components, subassemblies, finished devices, packaging, and labeling in order to aid their identification in the manufacturing process.

***Link: Design and Development***

During the design and development of the device, the essential design outputs for the proper functioning of the device should have been identified. Raw materials, components, and subassemblies should have been considered for traceability if their nonconformity could result in the finished device not meeting its specified requirements and essential functions.

**17. Determine if the manufacturer has established and maintained a record of the amount manufactured and approved for distribution for each batch of medical devices, the record is verified and approved, and the device is manufactured according to the file referenced in task 16.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.5.1.1; 8.2.4.1; RDC ANVISA 16/2013: 3.2, 5.2, 6.4; MHLW MO169: 6, 40, 58; 21 CFR 820.184]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Verify that the device history record of the product includes or refers to the following information: date of manufacture; components used; quantity manufactured; results of inspections and tests; parameters of special processes; quantity released for distribution; labeling; identification of the serial number or batch of production; and final release of the product [RDC ANVISA 16/2013: 3.2.1].

Verify that labeling has not been released for storage or use until a designated individual has examined the labeling for accuracy. The approval, including the date, name, and physical or electronic signature of the person responsible, must be documented in the device history record [RDC ANVISA 16/2013: 5.2.2.3].

*United States (FDA):*

Verify that labeling is not released for storage or use until a designated individual has examined the labeling for accuracy. The release, including the date and signature of the individual performing the examination must be documented in the device history record (i.e. batch record) [21 CFR 820.120(b)].

Confirm that labeling is stored in a manner that provides proper identification and prevents mix-ups. Verify labeling and packaging operations are controlled to prevent labeling mix-ups [21 CFR 820.120(c) and (d)].

Verify that the label and labeling used for each production unit, lot, or batch are documented in the batch record, as well as any control numbers used [21 CFR 820.120(e), 820.184(e)].

*Assessing conformity:*

**Verify manufacturing of the device**

Verify that each batch of devices was manufactured in accordance with product and production specifications, being mindful that in some instances, a batch can be a single device. This verification should include a review of the purchasing controls and receiving acceptance activities applied to at least one significant component or raw material, in-process and final finished device acceptance activities and results, environmental and contamination control records (if applicable), and sampling plans for process and environmental controls and monitoring.

The record for each batch of devices must include, or refer to the location of, the following information:

- (a) The dates of manufacture;
- (b) The quantity manufactured;
- (c) The quantity released for distribution;

- (d) The acceptance records which demonstrate the device has been manufactured in accordance with the planned arrangements and defined product specifications;
- (e) The primary identification label and labeling used for each production unit;
- (f) Any device identification(s) and control number(s) used; and
- (g) A provision to indicate that the record has been verified and approved

### **Determine if there are problems**

If, during the accomplishment of this audit task, the audit team observes evidence that the process is outside the organization's acceptance range for operating parameters or that product nonconformities exist, confirm that the nonconformities were handled appropriately, with input into the Measurement, Analysis and Improvement process when appropriate.

**18. If the organization manufactures active or nonactive implantable medical devices, life-supporting or life-sustaining devices, confirm that the manufacturer maintains traceability records of all components, materials, and work environment conditions (if these could cause the medical device to not satisfy its specified requirements) in addition to records of the identity of personnel performing any inspection or testing of these devices. Confirm that the organization requires that agents or distributors of these devices maintain distribution records and makes them available for inspection. Verify that the organization records the name and address of shipping consignees for these devices.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.5.3.2.2, 8.2.4.2; MHLW MO169: 6, 49, 59; 21 CFR 820.65]

*Additional country-specific requirements:*

#### *Canada (HC):*

Verify that the manufacturer has identified Schedule 2 implants and provides implant registration cards with devices or employs another suitable system approved by Health Canada [CMDR 66-68].

Verify that the manufacturer of devices that are listed on Schedule 2 of the Medical Devices Regulations maintains distribution records of these devices as well as any information received on implant registration cards related to these Schedule 2 devices [CMDR 54].

#### *United States (FDA):*

Verify that the manufacturer has implemented a tracking system for devices for which the manufacturer has received a tracking order from FDA. The tracking system must ensure the manufacturer is able to track the device to the end-user. The manufacturer must conduct periodic audits of the tracking system [21 CFR 821].

*Assessing conformity:*

### **Traceability of implantable, life-supporting or life-sustaining devices**

Manufacturers of finished devices whose failure could result in serious injury or harm to the user must implement a traceability system. The traceability system must allow for each batch of finished devices to be traced by a control number or similar mechanism throughout the distribution chain. Organizations must also provide for the control and traceability of components and materials used in the manufacture of the device, as well as documentation of the manufacturing conditions when manufacturing conditions could cause the finished device to not meet specified requirements (e.g. cleanroom conditions)

The determination of which components and raw materials may be required to be traceable may be made by the organization using risk management tools, such as risk analysis, or by identification of the components and processes used to fulfill the essential design outputs.

## Tracking

Some regulatory authorities participating in the MDSAP have requirements for tracking certain types of devices to the end-user. For regulatory authorities that have tracking requirements, these requirements generally apply to a small subset of devices that are life-sustaining or life supporting, intended for implant longer than one year, or are considered by the regulatory authority to be high risk. If the organization manufactures or distributes a device that falls under a tracking requirement, confirm that the organization has the necessary systems in place to provide for tracking each device to the end-user. The organization's tracking system must be periodically reviewed and audited by the organization to confirm that the tracking system is effective.

### **19. Verify that product status identification is adequate to ensure that only product which has passed the required inspections and tests is dispatched, used, or installed.**

*Clause and regulation:* [ISO 13485:2003: 7.5.3.3; RDC ANVISA 16/2013: 6.1.2, 6.4; MHLW MO169: 50, 21 CFR 820.86]

*Additional country-specific requirements:* None

*Assessing conformity:*

## Identification

Identification is generally defined as the description of the product that distinguishes it from other product. Organizations must define, document, and implement processes for the identification and control of product, including components, process agents, subassemblies, finished devices, packaging, and labeling. This can be accomplished through the use of part numbers, lot numbers, batch numbers, work order numbers, quantities, supplier name, as well as other means. The extent of identification activities should be based on the complexity and risk of the product.

### **20. Verify that the organization has implemented controls to identify, verify, protect, and safeguard customer property provided for use or incorporation into the product. Verify that the organization treats patient information and confidential health information as customer property.**

*Clause and regulation:* [ISO 13485:2003: 7.5.4; MHLW MO169: 51]

*Additional country-specific requirements:* None

*Assessing conformity:*

## Safeguarding customer property

The organization is responsible for safeguarding customer property while it is under the organization's control. If any customer property is lost, damaged, or otherwise unsuitable for use, this must be reported to the customer and records maintained.



**21. Verify that acceptance activities assure conformity with specifications and are documented.** *Confirm that the extent of acceptance activities is commensurate with the risk posed by the device.*

**Note:** Acceptance activities apply to any incoming component, subassembly, or service, regardless of the manufacturer's financial or business arrangement with the supplier.

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.4.3, 8.2.4.1, 8.2.4.2; TG(MD)R Sch1 P1 2, Sch3 P1 Cl1.4(5)(d); RDC ANVISA 16/2013: 5.3.1, 5.3.2, 5.3.3, 5.3.4, 9.2; MHLW MO169: 6, 39, 58, 59; 21 CFR 820.80, 820.250(b)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Verify that sampling plans are defined and based on valid statistical rationale. Each manufacturer must establish and maintain procedures to ensure that sampling methods are suitable for their intended use and are reviewed regularly. A review of sampling plans should consider the occurrence of nonconforming product, quality audit reports, complaints and other indicators [RDC ANVISA 16/2013: 9.2].

*United States (FDA):*

Verify that the manufacturer establishes and maintains procedures to ensure that sampling methods are adequate for their intended use and ensure that when changes occur, the sampling plans are reviewed [21 CFR 820.250(b)].

*Assessing conformity:*

## **Recognized acceptance activities**

Organizations are expected to define, document, and implement systems and procedures for acceptance activities to verify that products, including finished devices, in-process devices, components, packaging, and labeling conform to specified requirements. Recognized acceptance activities include, but are not limited to, inspections, tests, review of certificates of analysis, and supplier audits. Effective acceptance procedures and systems directly affect the ability of an organization to demonstrate that the process and product meets specifications. During the audit of acceptance activities for the devices selected for audit, confirm that the organization has defined processes for receiving, in-process, and final acceptance activities. Determine if the acceptance activities have been implemented. One way to accomplish this audit task is to review a sample of batch records and confirm that the acceptance activities have been documented and that the acceptance activities show specified requirements have been met. Records should identify who conducted acceptance activities.

The acceptance status of incoming, in-process, and finished devices must be identified. The identification of acceptance status must be maintained throughout manufacturing, packaging, labeling, and where applicable, installation and servicing to ensure that only product which has passed the required acceptance activities is distributed, used, or installed.

## **Acceptance activities involving related firms**

The audit team may encounter situations where the organization receives incoming product from a financial or corporate affiliate. It is the receiving organization's responsibility to perform and record the necessary acceptance activities to ensure the received product conforms to specified requirements, as well as applying the necessary purchasing controls to the supplier. Acceptance activities and purchasing controls apply to all product received from outside of the finished manufacturer, whether a payment occurs or not, and regardless of the corporate or financial relationship of the supplier to the finished device manufacturer.

## Sampling

The audit team may encounter the use of sampling during acceptance activities. For example, an organization might choose to use sampling to perform receiving acceptance on a large lot of incoming components. When used, sampling plans must be written and based on a valid statistical rationale and a risk-based methodology.

## Combination of controls

An important concept to remember is that quality cannot be inspected or tested into products. Organizations must establish an appropriate mix of acceptance activities and purchasing controls to ensure products will meet specified requirements. The type and extent of acceptance activities can be based in part on the amount of purchasing controls applied to the supplier, the demonstrated capability of the supplier to provide quality products, and the potential impact of the product on the finished device, including the risk the device poses to the patient or user if specified requirements are not met. Organizations that conduct quality control solely in-house must still assess the capability of suppliers to provide acceptable products.

## Evidence of inadequate acceptance activities

The audit team may encounter instances where product has been deemed acceptable by the successful completion of acceptance activities but the product is later shown to not meet specified requirements (i.e. failure of the device leading to product complaint). This can be an indication that the acceptance activities are not sufficient to identify nonconformities. Confirm that the organization has taken the appropriate action to determine the suitability of the acceptance activities.

### **Link: Purchasing, Design and Development**

The audit team should consider reviewing the purchasing controls and requirements for suppliers of higher risk products. The audit team should also consider reviewing the purchasing controls and requirements for suppliers of products that undergo minimal acceptance activities at the device manufacturer, particularly if the supplied product is manufactured using a process that requires validation. During the review of acceptance activities, if the audit team encounters situations where records of acceptance activities for supplied product reveal products that do not meet specified requirements, consider selecting those suppliers for review during the audit of the organization's Purchasing process.

The establishment of the necessary purchasing controls and required acceptance activities is a design output. The degree of the purchasing controls necessary and extent of acceptance activities should be based on the risk posed by the product not meeting its specified requirements and essential design outputs.

## **22. Verify that the identification, control, and disposition of nonconforming products is adequate, *based on the risk the nonconformity poses to the device meeting its specified requirements.***

*Clause and regulation:* [ISO 13485:2003: 7.5.3.1, 8.3; TG(MD)R Sch1 P1 2, Sch3 P1 Cl1.4(5)(b); RDC ANVISA 16/2013: 6.5.1, 6.5.2; MHLW MO169: 47, 60; 21 CFR 820.60, 820.90(a), 820.86, 820.100(a)]

*Additional country-specific requirements:* None

## Procedures

The purpose of controlling nonconforming product is to prevent the unintended use and distribution of nonconforming product, including components, processing agents, in-process devices, and finished devices. Confirm that the organization has defined and implemented procedures for the identification, control, segregation, evaluation, and disposition of nonconforming product.

## Handling nonconforming product

The organization can address nonconforming product by taking action to eliminate the detected nonconformity (e.g. sorting an incoming lot of components to remove components that do not meet specifications), authorizing its use, release, or acceptance under concession, or by taking action to prevent its original intended use (e.g. allowing the components or devices to be used as demonstration units at marketing conferences).

Until a disposition can be made, the organization must have a process to properly identify nonconforming product to prevent its accidental or unauthorized use. One example is tagging and moving the nonconforming product to a controlled enclosure away from the production area.

If nonconforming product is accepted under concession, the records of the identity of the person authorizing the concession must be maintained.

If nonconforming product has been detected after a product has been released and put into use the organization must consider the risks associated with the device and may need to consider an advisory notice or recall.

## Evaluation of nonconforming product

The evaluation of a nonconformity must include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformity, such as a supplier. Ensure that the organization has adequately established an interface / interaction between the processes for the identification of non-conforming product and the processes for corrective action. These interactions should be evident in the quality manual.

### ***Link: Measurement, Analysis and Improvement***

The audit team should be mindful of any instances where the acceptance of nonconforming product has led to finished devices not meeting specified requirements. This information can often be found in records of acceptance activities and complaint records. During the review of the organization's corrective and preventive actions, the auditors may have noted instances where nonconforming products were found to be the underlying cause of quality problems and complaints. The audit team should consider reviewing the organization's handling and evaluation of nonconforming products that were determined to be the underlying cause of quality problems. Ensure that the analysis of data regarding nonconforming product is considered as an input to the organization's Measurement, Analysis and Improvement process and that corrective or preventive actions have been implemented when necessary.

**23. If a product needs to be reworked, confirm that the manufacturer has made a determination of any adverse effect of the rework upon the product. Verify that the rework process has been performed according to an approved procedure, that the results of the rework have been documented, and that the reworked product has been re-verified to demonstrate conformity to requirements.**

*Clause and regulation:* [ISO 13485:2003: 8.3; RDC ANVISA 16/2013: 6.5.3; MHLW MO169: 60; 21 CFR 820.90(b)]

*Additional country-specific requirements:* None

*Assessing conformity:*

**Reworking nonconforming product**

The audit team may encounter instances where the organization has chosen to address nonconforming product by means of reworking the component, subassembly or finished device. The organization must have suitable approved procedures in place to address nonconforming product destined for rework. Reworked product must be re-evaluated or re-tested to ensure it meets its original specified requirements. Rework must be documented.

Be mindful of instances where the underlying cause of quality problems, such as complaints that finished devices do not meet specified requirements, are traced to devices that have been reworked. This can be an indication that the rework process was not adequate to ensure the finished device meets specifications.

Additionally, rework of products manufactured using validated processes can be an indication that the process cannot consistently produce product that meets specified requirements. If the audit team notes a pattern of reworking products that are manufactured using a validated process, consider reviewing the process validation to confirm that the organization has data to show the process is effective, reproducible, and stable; and that the organization is operating the process within the validated parameters.

**24. Verify that procedures are established and maintained for preserving the conformity of product and constituent parts of a product during internal processing, storage, and transport to the intended destination. This preservation encompasses identification, handling, packaging, storage, and protection, including those products with limited shelf-life or requiring special storage conditions.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.5.3.1, 7.5.5; TG(MD)R Sch1 P1 5; RDC ANVISA 16/2013: 5.2.1, 6.1.1, 6.2.1; CMDR 14; MHLW MO169: 6, 47, 52; 21 CFR 820.130, 820.140, 820.150, 820.160(a)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Verify that the manufacturer has established procedures for the packaging of products in order to protect the product from deterioration, damage, or contamination during processing, storage, handling, and distribution [RDC ANVISA 16/2013: 5.2.1].

*United States (FDA):*

Confirm that the manufacturer established and maintains procedures that describe the methods for authorizing receipt from and dispatch to storage areas and stock rooms [21 CFR 150(b)].

Verify that the manufacturer established and maintains procedures for control and distribution of finished devices to ensure that only those devices approved for release are distributed and that purchase orders are reviewed to ensure ambiguities and errors are resolved before devices are released for distribution [21 CFR 820.160(a)].



*Assessing conformity:*

## **Ensuring proper handling**

The organization must have a documented system that defines product handling requirements at all stages of manufacturing to prevent mix-ups, damage, and deterioration. This can include specified requirements for storage and shipping to ensure the preservation of the product to its destination. For example, an in-vitro diagnostic device may need to be stored and shipped in a frozen state to maintain proper shelf-life of the reagents. These handling requirements should have been considered during the planning of product realization for the device. When necessary, confirm that the needed control measures are implemented to ensure the conformity of product to its specified requirements.

### **25. Confirm that the organization performs a review of the customer's requirements, including the purchase order requirements, prior to the organization's commitment to supply a product to a customer. Verify that the organization maintains documentation required by regulatory authorities regarding maintenance of distribution records.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1; 5.2, 7.2.2, RDC ANVISA 16/2013: 6.3; MHLW MO169: 6, 11, 28; 21 CFR 820.160(a)]

*Additional country specific requirements:*

*Brazil (ANVISA):*

Verify that the manufacturer maintains distribution records which include or make reference to: the name and address of the consignee, the identification and quantity of products shipped, the date of dispatch, and any numerical control used for traceability [ANVISA RDC 6.3].

*Canada (HC):*

Verify that the manufacturer maintains distribution records that contain sufficient information to permit complete and rapid withdrawal of the medical device from the market [CMDR 52-53].

Verify that distribution records of a device are retained by the manufacturer in a manner that will allow for timely retrieval, for the longer of (a) the projected useful life of the device; and (b) two years after the date the device was shipped [CMDR 55-56].

*United States (FDA):*

Verify that the manufacturer maintains distribution records which include or refer to the location of the name and address of the initial consignee, the identification and quantity of devices shipped; and any control numbers used [21 CFR 820.160(b)].

*Assessing conformity:*

## **Distribution records**

The organization must maintain distribution records which include or refer to the location of the initial consignee, the identification and quantity of devices shipped, the date shipped, and any control numbers used.

### **26. If installation activities are required, confirm that records of installation and verification activities are maintained.**

*Clause and regulation:* [ISO 13485:2003: 7.5.1.2.2; RDC ANVISA 16/2013: 8.1; MHLW MO169: 42; 21 CFR 820.170]

*Additional country-specific requirements:* None



*Assessing conformity:*

## **Installation activities**

When a device must be installed for suitable functioning, the organization must establish procedures and instructions to ensure proper installation. These instructions must be made available to personnel performing the installation. Installation activities must be documented.

## **Determining the extent of review**

In the absence of identified quality problems related to the installation of the selected device, the audit team may choose to limit the review of the installation process to confirming the necessary procedures are in place.

## **27. Determine if servicing activities are conducted and documented in accordance with defined and implemented instructions and procedures. Confirm that service records are used as a source of quality data in the Measurement, Analysis and Improvement process.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.5.1.2.3, 8.4; RDC ANVISA 16/2013: 8.2; MHLW MO169: 6, 43, 61; 21 CFR 820.200]

*Additional country specific requirements:*

*Brazil (ANVISA):*

Confirm that the manufacturer has established and maintains procedures to ensure that records of servicing activities are kept with the following information: the product serviced; the control number of the product serviced; the date of completion of service; identification of the service provider; description of service performed; and results of inspections and tests performed [RDC ANVISA 16/2013: 8.2.1].

Verify that the manufacturer periodically reviews the records of servicing activities. In cases where the analysis identifies trends that pose danger or records involving death or serious injury, a corrective or preventive action must be initiated [RDC ANVISA 16/2013: 8.2.2].

*United States (FDA):*

Verify that each manufacturer who receives a service report that represents an event that must be reported to FDA as a medical device report automatically considers the report a complaint [21 CFR 820.200(c)].

Confirm that service reports are documented and include the name of the device serviced, any device identification(s) and control number(s) used, and the date of service [21 CFR 820.200(d)].

*Assessing conformity:*

## **Procedures**

When servicing is a specified requirement, the organization must define and maintain procedures, instructions, and processes for performing and verifying that servicing activities meet specified requirements.

## **Servicing process**

When organizations implement servicing programs, the organization must ensure components used for repair are acceptable for the intended use, inspection and test procedures are available, and test equipment is properly maintained to ensure serviced devices will perform as intended after servicing. Personnel performing service activities must have the appropriate training.

The audit team may observe instances where nonconformities occurred and/or complaints were received after the servicing of the device. This can be an indication that the service activity was not properly controlled or that service personnel do not have the proper equipment, instructions, or training to perform the required service.

### Analysis of service reports

Service reports can be an important source of quality data for input into the organization's Measurement, Analysis and Improvement process. When necessary, confirm data regarding service reports is analyzed for possible corrective action or preventive action. Service reports must also be analyzed to determine if the service event represents an adverse event that is reportable to regulatory authorities.

In some instances, product complaints may be initially recorded by the organization as a service report. For example, a user may report to the device manufacturer that a patient blood parameter monitoring device is not working correctly and requires service. Upon receipt of the device from the user by the organization's service function, the service function notes the reason the monitoring device is not working is that an essential component within the device failed prematurely. This service report should be considered by the organization to be a complaint and analyzed by the manufacturer to determine if an adverse event report needs to be submitted to regulatory authorities.

#### ***Link: Measurement, Analysis and Improvement***

During the audit of the organization's Measurement, Analysis and Improvement process, the audit team may have already confirmed that quality data from the analysis of servicing activities is analyzed for possible corrective or preventive action. When reviewing the organization's service reports, the audit team should be mindful of service reports that appear to be product complaints. Ensure that service reports that appear to be complaints have been appropriately addressed. In some instances, a similar quality problem for a particular device may be found in the service reports and the complaint records. In these instances, confirm that the organization is taking appropriate corrections and/or corrective actions considering a similar quality problem is observed in multiple data sources.

### **28. *When appropriate, verify that risk control and mitigation measures are applied to transport, installation and servicing, in accordance with the organization's risk management practices.***

*Clause and regulation:* [ISO 13485:2003: 7.1, 7.5.1.1, 7.5.1.2.2, 7.5.1.2.3; TG(MD)R Sch1 P1 2; RDC ANVISA 16/2013: 2.4; MHLW MO169: 26, 40, 42, 43; 21 CFR 820.160(a), 820.170(a), 820.200(a)]

*Additional country-specific requirements:* None

*Assessing conformity:*

#### **Risk control**

The requirements for delivery, installation, and servicing of a particular device should have already been evaluated and addressed by the organization during design and development and planning for product realization. If risk control measures were identified involving the delivery, installation, and servicing for a particular device, confirm that the necessary processes have been implemented to ensure the risk control measures are in place. For example, an organization may have identified that in order for a medical imaging device to give accurate images, servicing must be performed by trained personnel according to specific instructions. Risk control measures

might include warnings on the imaging device that only authorized personnel should service the device and the design of a unique tool to access the inside of the device that is only provided to authorized service personnel.

**29. Determine, based on the assessment of the production and service control process overall, whether management provides the necessary commitment to the production and service control process to ensure devices meet specified requirements and quality objectives.**

Clause and regulation: [ISO 13485:2003: 4.1; RDC ANVISA 16/2013: 2.2.1; MHLW MO169: 5]

# Medical Device Single Audit Program

## Chapter 7

### Process: Purchasing

The intent of the Purchasing process is to ensure that purchased, subcontracted, or otherwise received products and services conform to specified requirements. The organization is expected to establish and maintain documented controls for planning and performing purchasing activities. The controls necessary depend on the effect of the product on the quality, safety, and effectiveness of the finished device. Effective purchasing processes incorporate purchasing requirements and specifications, the selection of acceptable suppliers based on the capability of the suppliers to provide acceptable product, the performance of necessary acceptance activities, and maintenance of the required quality records.

The management representative is responsible for ensuring that the requirements of the quality management system have been effectively defined, documented, implemented, and maintained. Prior to the audit of any MDSAP process, interview the management representative (or designee) to obtain an overview of the process and a feel for management's knowledge and understanding of the process.

The Purchasing process is integral to the other processes of the MDSAP audit sequence. As the audit is being performed of the organization's Measurement, Analysis and Improvement process, Design and Development process, and Production and Service Controls process, the audit team should be assessing the affect purchased product has on the quality of the finished device. The audit team should be using information learned about actual and potential product and process nonconformities during the audit of the Measurement, Analysis and Improvement process, higher risk elements and essential design outputs from the design projects reviewed during audit of the Design and Development process, in addition to significant outsourced product and production processes identified during the audit of the Production and Service Controls process to make decisions as to supplier evaluation files to be reviewed during the audit of the Purchasing process.

The organization's Purchasing process may be reviewed in conjunction with the Measurement, Analysis and Improvement process, the Design and Development process, and the Production and Service Controls process, being mindful of the MSDAP process linkages. The Purchasing process should be considered a critical process for those organizations that outsource essential activities such as design and development and/or production to one or more suppliers.

**Purpose:** The purpose of auditing the Purchasing process is to verify that the manufacturer's processes ensure that products (e.g. components, materials and services provided by suppliers, including contractors and consultants) are in conformance with specified purchase requirements, including quality management system requirements. This is particularly important for those organizations who outsource activities such as design and development and/or production to one or more suppliers, and when the supplied product or service cannot be verified by inspection (e.g. sterilization services). Suppliers include those providers of any product received from outside the manufacturer, including corporate or financial affiliates, where the product has an effect on subsequent product realization or the final product.

**Outcomes:** As a result of the audit of the Purchasing process, objective evidence will show whether the manufacturer has:

- A) Defined, documented and implemented procedures to ensure purchased or otherwise supplied products conform to specified purchase requirements
- B) Established criteria for the selection, evaluation and re-evaluation of suppliers based on the type and significance of the product purchased and the impact of the supplied product on subsequent product realization or the quality of the finished device
- C) Performed the evaluation and selection of suppliers based on the capability of the supplier to meet specified requirements
- D) Ensured the continued capability of suppliers to provide quality products that meet specified purchase requirements through re-evaluation
- E) Determined and implemented an appropriate combination of controls applied to suppliers in conjunction with acceptance verification activities to ensure conformity to product and quality management system requirements, based on the impact of the supplied product on the finished device

***Links to Other Processes: Management; Design and Development; Measurement, Analysis and Improvement; Production and Service Controls***

## **Audit Tasks and Links to Other Processes:**

1. **Verify that planning activities describe or identify products to purchase and processes to outsource, the specified requirements for purchased products, the requirements for purchasing documentation and records, purchasing resources, the activities for purchased product acceptance, and *risk management* in supplier selection and purchasing.**

*Clause and regulation:* [ISO 13485:2003: 4.1, 7.1, 7.4.1; TG(MD)R Sch1 P1 2, Sch3 P1 Cl1.4(5)(d)(ii); RDC ANVISA 16/2013: 2.5.1, 2.4; MHLW MO169: 5, 26, 37; 21 CFR 820.20, 820.50]

*Additional country-specific requirements:* None

*Assessing conformity:*

## **Planning**

In planning product realization, the organization must determine as appropriate the quality objectives and requirements for the purchased products, the processes, documents, and resources specific to the purchased products, the criteria for purchased product acceptance, and the required verification, monitoring, inspection, and test activities specific to the purchased products. Planning of product realization often begins in the design and development of the product, including the translation of the design into production specifications. The translation of the design into production specifications includes the establishment of specified requirements for purchased product.

## **Quality objectives**

Quality objectives are typically expressed as a measurable target or goal. The planning of product realization should include consideration of how the purchased product, the criteria for purchased product acceptance, and the required verification, monitoring, inspection, and test activities specific to the purchased product will achieve the quality objectives.



***Links: Design and Development, Management***

During the review of a design project, confirm that the organization has considered the effect of purchased product on the essential design outputs. For suppliers that provide product and services related to the essential design outputs, the degree of purchasing controls necessary is commensurate with the effect of the supplied product on the proper functioning of the finished device. During the audit of the Purchasing process, confirm when necessary that the degree of control over suppliers of purchased product has been made based on the risk the supplied product poses to the ability of the finished device to meet specified requirements.

Additionally, confirm when necessary that the quality objectives related to the purchased product were considered for inclusion in management review.

**2. Select one or more supplier evaluation files to audit.**

Priority criteria for selection:

- Indications of problems with supplied products or processes from audit of the Measurement, Analysis and Improvement process
- *Suppliers of higher risk products or processes*
- Suppliers who provide products or services that directly impact the design outputs required for proper functioning of the device
- Suppliers of processes that require validation or revalidation
- Newly approved suppliers of products or services
- Suppliers of products or services used in the manufacturing of multiple products
- Suppliers of components or services not covered during previous audits

**3. Verify that procedures for ensuring purchased product conforms to purchasing requirements have been established and documented.**

*Clause and regulation:* [ISO 13485:2003: 7.4.1; TG(MD)R Sch3 P1 Cl1.4(5)(d)(ii); RDC ANVISA 16/2013: 2.5.1; MHLW MO169: 37; 21 CFR 820.50]

*Additional country-specific requirements:* None

*Assessing conformity:*

**Procedures**

The organization must define, document, and implement procedures to ensure that purchased product conforms to specified requirements. These procedures commonly contain information as to the mechanisms by which the organization is going to categorize suppliers based on the risk the supplied product has on the ability of the finished device to meet specified requirements, the criteria the organization intends to use to evaluate the suppliers, the means of determination that a supplier is acceptable, the methods for supplier monitoring, the requirements for re-evaluating suppliers, and the means by which a supplier might be determined to be unacceptable.

It is important to remember that the requirements for purchasing controls apply to all product received from an outside source by the finished device manufacturer that have an impact on product realization, whether a payment occurs or not, and regardless of the corporate or financial affiliation between the supplier and finished device manufacturer.

**4. Verify that the procedures assure the type and extent of control applied to the supplier and the purchased product is dependent upon the effect of the purchased product on subsequent product realization or the final product.**

*Clause and regulation:* [ISO 13485:2003: 7.4.1; RDC ANVISA 16/2013: 2.5.2; MHLW MO169: 37; 21 CFR 820.50]

*Additional country-specific requirements:* None

*Assessing conformity:*

**Extent of control**

The type and extent of control applied to the supplier must take into consideration the affect the supplied product has on the finished device. Procedures commonly contain methods to categorize suppliers, based on the importance of the supplied product to the proper functioning of the finished device and the past history (if applicable) of the supplier.

Be mindful of organizations that use a “one-size-fits-all” approach to managing their suppliers, as these systems may not provide the necessary amount of evaluation and oversight over suppliers of products essential for the proper functioning of the finished device.

**5. Verify that criteria for the selection, evaluation and re-evaluation of suppliers have been established.**

*Clause and regulation:* [ISO 13485:2003: 7.4.1; RDC ANVISA 16/2013: 2.5.2, 2.5.3; MHLW MO169: 37; 21 CFR 820.50(a)]

*Additional country-specific requirements:* None

*Assessing conformity:*

**Evaluation criteria**

The organization must define, document, and implement procedures outlining the criteria for the selection, evaluation and re-evaluation of suppliers. The procedures for supplier evaluation and selection typically include such items as the methods by which suppliers will be evaluated and the means and frequency by which supplier performance will be monitored.

The evaluation of suppliers must provide a means to assess the capability of the supplier to supply products that meet specified requirements. The organization can assess a supplier's capability to supply quality product in a number of ways, including but not limited to performing supplier audits, first-article inspections, supplier surveys, and reviewing the supplier's past history in supplying a similar product or service if applicable.

The organization may also choose to consider the supplier's conformity with quality management system requirements through third party certifications; however, third party certification should not be relied on exclusively in initially evaluating a supplier.

**6. Verify that suppliers are selected based on their ability to supply product or services in accordance with the manufacturer's specified requirements. *Confirm that the degree of control applied to the supplier is commensurate with the significance of the supplied product or service on the quality of the finished device, based on risk.***

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.1, 7.4.1; TG(MD)R Sch1 P1 2; RDC ANVISA 16/2013: 2.5.3, 2.4;MHLW MO169: 6, 26, 37; 21 CFR 820.50(a)]

*Additional country-specific requirement*

*Australia (TGA):*

If the manufacturer outsources to the Australian Sponsor a quality management system requirement or an obligation on the manufacturer from the Australian regulations, verify that the manufacturer treats the Sponsor as a supplier and has adequate supplier controls for those activities. For example, making applications on behalf of the manufacturer to the TGA [TG Act s41EB], representing the manufacturer in interactions with the TGA [41FN(3)], adverse event reporting, as the first point for handling customer complaints, as an intermediary in recalls of products [TG(MD) Regs Schedule 3 - Part 1:1.4(3)], or in the notification of substantial changes to the quality management system or product range or the provision of records [TG(MD) Regs Schedule 3 - Part 1:1.5, 1.9].

*Canada (HC)*

Verify that any regulatory correspondent used by the manufacturer is treated as a supplier and is adequately qualified.

*Japan (MHLW):*

For Marketing Authorization Holder: If the Marketing Authorization Holder (MAH) has outsourced to a Registered Manufacturing Site (RMS) any process that affects product conformity with requirements, verify the MAH has performed the necessary verification that the RMS has an appropriate quality management system. If the site of a supplier is a Registered Manufacturing Site, verify the MAH has performed the necessary verification that the supplier has an appropriate quality management system [MHLW MO169: 65].

For Registered Manufacturing Sites: If the RMS has outsourced to another RMS any process that affects product conformity with requirements, confirm the outsourcing RMS has performed the necessary verification that the outsourced RMS has an appropriate quality management system. If the site of a supplier is an RMS, verify the purchase controlling RMS has performed the necessary verification that the supplier has an appropriate quality management system [MHLW MO169: 65].

*Assessing conformity:*

## **Supplier selection**

The selection of suppliers must be based on defined criteria. An important concept to remember is that quality cannot be inspected or tested into products. Finished device manufacturers who choose to conduct product quality control solely in-house must still assess the capability of suppliers to provide acceptable product.

Some organizations require suppliers to maintain various types of certifications or registrations. While registrations and third-party certifications may be considered in supplier evaluations, the organization should not exclusively rely on these methods to perform the initial evaluation of suppliers.

For the supplier(s) the audit team has chosen to review, confirm that the organization's selection of the supplier was based on defined criteria commensurate with the risk posed if the supplied product causes the finished device to not meet specified requirements.

***Links: Design and Development, Production and Service Controls***

The establishment of the necessary purchasing controls and required acceptance activities is a design output. The degree of the purchasing controls necessary and extent of acceptance activities should be based on the risk posed by the product not meeting its specified requirements and essential design outputs.

Auditors may encounter situations where the organization outsources processes that require validation. During the review of the Purchasing process, review the controls the organization has instituted over suppliers that perform validated processes. This typically includes confirming that the finished device manufacturer has reviewed the process validation data generated by the supplier to ensure the process is effective, reproducible, and stable. This can be particularly important for higher risk validated processes performed by suppliers, since the finished device manufacturer does not have immediate control over those processes.

The audit team should also consider reviewing the purchasing controls and requirements for suppliers of products that undergo minimal acceptance activities at the device manufacturer.

## **7. Verify that records of supplier evaluations are maintained.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.4.1; RDC ANVISA 16/2013: 2.3.3, 2.5.3; MHLW MO169: 6, 37; 21 CFR 820.50(a)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Confirm that the manufacturer establishes and maintains records of approved suppliers, contractors, and consultants [RDC ANVISA 16/2013: 2.3.3, 2.5.3].

*United States (FDA):*

Confirm that the manufacturer establishes and maintains records of acceptable suppliers, contractors, and consultants [21 CFR 820.50(a)(3)].

*Assessing conformity:*

### **Records of supplier evaluations**

The organization must maintain records of the evaluation of the capability of the supplier to meet specified requirements. The records should include the mechanism by which the supplier was evaluated, the results of the evaluation, and the determination of whether the supplier was deemed to be acceptable.

For the supplier(s) the audit team has selected, review the organization's evaluation of the supplier(s). Confirm that the evaluation was made according to defined criteria and is commensurate with the effect the supplied product has on the essential design outputs.

## **8. Verify that the manufacturer maintains effective controls over suppliers and product, so that specified requirements continue to be met.**

*Clause and regulation:* [ISO 13485:2003: 7.4.1; RDC ANVISA 16/2013: 2.5.3; MHLW MO169: 37; 21 CFR 820.50(a)]

*Additional country-specific requirements:* None

*Assessing conformity:*

### **Monitoring supplier performance**

The organization must define and implement processes to monitor the performance of suppliers. The monitoring of supplier performance should not be based solely on cost considerations or on- time deliveries. The monitoring of suppliers should take into consideration the actual performance of the supplier in terms of providing products that meet specified requirements. Examples of supplier monitoring activities may include, but are not limited to supplier re-audits, statistical analysis of incoming acceptance results, monitoring of complaints and nonconformities related to supplied product, independent confirmation of certificate of conformance data, and consideration of the supplier's responses to requests for corrective action.

In order for the supplier to maintain a status as an acceptable supplier, the supplier must be capable of supplying product that consistently meets the manufacturer's specified requirements. If supplier monitoring does not demonstrate that the supplier has the capability to provide acceptable products, the organization must have a means to undertake appropriate action, including such activities as requesting corrective action from the supplier, and in some cases, removing the supplier from records of acceptable suppliers.

For the supplier(s) the audit team has chosen to review, confirm that the supplier monitoring is documented and reviewed by the appropriate individuals responsible for supplier selection. Be particularly mindful of instances where supplied product has caused complaints and/or product nonconformities. Verify that the organization has performed the appropriate monitoring of the supplier and taken actions when necessary, such as requesting the supplier undertake a corrective action.



**Links: Production and Service Controls, Measurement, Analysis and Improvement**

Organizations are expected to define, document, and implement systems and procedures for acceptance activities to verify that supplied products conform to specified requirements. Effective acceptance procedures and systems directly affect the ability of an organization to demonstrate that supplied products meets specifications. During the audit of the Production and Service Controls process, confirm that the appropriate acceptance activities have been implemented and monitored to ensure the received product meets specified requirements.

Additionally, organizations are required to determine, collect, and analyze appropriate data to demonstrate the ability of suppliers to provide acceptable product. During the audit of the Measurement, Analysis and Improvement process, confirm that analysis of supplier performance data has been performed and considered for corrective or preventive action when necessary.

**9. *Confirm that the re-evaluation of the capability of suppliers to meet specified requirements is performed at intervals consistent with the significance of the product on the finished device.***

Clause and regulation: [ISO 13485:2003: 7.4.1; TG(MD)R Sch1 P1 2; RDC ANVISA 16/2013: 2.5.2, 2.4; MHLW MO169: 37; 21 CFR820.50(a)]

Additional country-specific requirements: None

Assessing conformity:

**Supplier re-evaluation intervals**

Organizations must implement the appropriate combination of supplier evaluation, supplier monitoring, and acceptance activities to provide the necessary confidence in the acceptability of supplied product. However, supplier evaluation is not a “one-time” assessment. The organization must ensure the continued capability of the supplier to provide product that meets specified requirements. The frequency of re-evaluation must be performed according to the organization’s procedures and at intervals consistent with the significance of the product or service on the finished device. The frequency of re-evaluation may change based on identified quality problems with the supplied product.

For the supplier(s) the audit team has chosen to review, confirm that the re-evaluation of the supplier was performed commensurate with the risk the supplied product poses to the ability of the finished device to meet specifications.

**Link: Measurement, Analysis and Improvement**

The frequency and extent of supplier re-evaluation activities may be based, in part, on the performance of the supplier as demonstrated by such activities as statistical monitoring of the supplier, monitoring of complaints and nonconformities related to supplied product, and corrective or preventive actions related to the supplier.

**10. *Verify that the organization assures the adequacy of purchasing requirements for products and services that suppliers are to provide, and defines risk management activities and any necessary risk control measures.* Confirm that the manufacturer ensures the adequacy of specified purchase requirements prior to their communication to the supplier.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.4.2, TG(MD)R Sch1 P1 2; RDC ANVISA 16/2013: 2.4, 2.5.4, 2.5.6; MHLW MO169: 6, 38; 21 CFR 820.50(b)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Confirm that purchase orders are approved by a designated person. This approval, including date and signature, shall be documented [RDC ANVISA 16/2013: 2.5.4].

*Assessing conformity:*

### **Adequacy of purchasing information**

Purchasing information is commonly provided to suppliers in documents such as, but not limited to, specification sheets, drawings, contracts, purchase orders, and quality agreements. The amount of detail required in the purchasing information must be commensurate with the effect of the supplied product on the performance of the finished device.

### **Risk control measures**

The finished device manufacturer is responsible for the quality and performance of the finished device. The specified requirements for the finished device cannot be met unless the individual parts of the finished device meet specifications. While the finished device manufacturer may require certain risk management activities to be adopted by the supplier to help ensure acceptability of incoming product, the ultimate responsibility for the finished device is borne by the finished device manufacturer. The finished device manufacturer is responsible for identifying any risk control measures that are required for the supplied product. For suppliers that provide product and services related to the essential design outputs, the degree of necessary risk control measures is commensurate with the effect of the supplied product on the proper functioning of the finished device.

Some examples of risk control measures related to supplied product include, but are not limited to, requiring the supplier to use quality assurance procedures approved by the device manufacturer, the establishment of inspections or testing of supplied product before shipment to the manufacturer, requiring each incoming shipment be accompanied by a certificate of conformance, periodic verification of the certificate of conformance by third-party laboratory analysis, implementation of acceptance activities at the finished device manufacturer based on the risk the supplied product poses to the ability of the finished device to meet specifications, and the verification of validation data by the finished device manufacturer for validated processes performed by a supplier.

For the supplier(s) files the audit team has selected for review, confirms that risk control measures have been identified when appropriate and the risk control measures have been implemented and are effective. If the auditor(s) observe that supplied product has been identified as an underlying cause of complaints and nonconformities, this can be an indication that the risk control measures are inadequate or ineffective.

**11. Verify that the organization documents purchasing information, including where appropriate the requirements for approval of product, procedures, processes, equipment, qualification of personnel, and other quality management system requirements.**

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.4.2; RDC ANVISA 16/2013: 2.5.4, 2.5.5; MHLW MO169: 6, 38: 21 CFR 820.50(b)]

*Additional country-specific requirements:*

*Brazil (ANVISA):*

Confirm that an agreement is established and documented in which suppliers agree to notify the manufacturer of any change in the product or service, so that the manufacturer can determine whether the change affects the quality of the finished product [RDC ANVISA 16/2013: 2.5.5].

*United States (FDA):*

Verify that purchasing documents contain, where possible, an agreement that the supplier agrees to notify the manufacturer of changes in products or services that may affect the quality of a finished device [21 CFR 820.50(b)].

*Assessing conformity:*

**Documenting purchasing information**

Purchasing information must describe the product to be purchased, including (when appropriate) the requirements for approval of product, procedures, processes, and equipment, the requirements for qualification of personnel, and quality management system requirements related to the purchased product. Where possible, the purchasing information must contain an agreement that the supplier agrees to notify the manufacturer of changes in products or services that may affect the quality of the finished device. The manufacturer should approve or reject these changes, based on the impact of the change on the essential design outputs of the finished device.

Purchasing information may be recorded in written or electronic format, but must be documented.

**12. Verify that documents and records for purchasing are consistent with traceability requirements where applicable.**

*Clause and regulation:* [ISO13485:2003 7.4.2, 7.5.3.2; RDC ANVISA 16/2013: 2.5.4, 6.4; MHLW MO169: 38, 48, 49; 21 CFR 820.65, 820.160]

*Additional country-specific requirements:* None

*Assessing conformity:*

## Traceability

It is the responsibility of the organization to establish procedures for traceability. For devices that are not implanted and are not life-supporting or life-sustaining, the organization has the flexibility to determine which raw materials and components are required to be traceable, commensurate with the risk posed by the device in the event the component does not meet specified requirements.

Manufacturers of finished devices whose failure could result in serious injury or harm to the user, or are implanted or life-supporting or life-sustaining must implement a traceability system. The traceability system must allow for each batch of finished devices to be traced by a control number or similar mechanism throughout the distribution chain. Organizations must provide for the control and traceability of components and materials used in the manufacture of the device when these could cause the finished device to not meet specified requirements.

The determination of which components and raw materials may be required to be traceable may be made by the organization using risk management tools, such as risk analysis, or by the identification of the components and processes used to fulfill the essential design outputs.

**13. Confirm that the verification (inspection or other activities) of purchased products is adequate to ensure specified requirements are met. *Confirm that the manufacturer has implemented an appropriate combination of controls applied to the supplier, the specification of purchase requirements, and acceptance verification activities that are commensurate with the risk of the supplied product upon the finished device.***

*Clause and regulation:* [ISO 13485:2003: 4.2.1, 7.1, 7.4; TG(MD)R Sch1 P1 2; RDC ANVISA 16/2013: 2.4, 2.5.2, 5.3.1, 5.3.2, 5.3.3; MHLW MO169: 6, 26, 37, 38, 39; 21 CFR 820.50, 820.80(b)]

*Additional country specific requirements:*

*Brazil (ANVISA):*

Verify that the manufacturer has established and maintains procedures to ensure the retention of components, raw materials, in-process products and returned products until inspections, tests or other specified verifications have been performed and documented [RDC ANVISA 16/2013: 5.3.3].

*Assessing conformity:*

## Establishment of acceptance activities

The organization must establish an appropriate combination of supplier assessment and receiving acceptance activities to ensure products and services are acceptable for their intended use. After a supplier has been approved, the necessary acceptance activities for the supplied product must be implemented. The degree of acceptance activities may vary with the type and significance of the product or service on the quality of the finished device and the extent of measures performed by the supplier to ensure product acceptability.

Organizations are expected to define, document, and implement processes and procedures for acceptance activities to verify that supplied products conform to specified requirements. Recognized acceptance activities include, but are not limited to, inspections, tests, reviews of certificates of analysis, and supplier audits. Effective acceptance procedures and systems directly affect the ability of an organization to demonstrate the process and product meet specifications.

It is important to remember that acceptance activities apply to any incoming component, subassembly, or service, whether a payment occurs or not, and regardless of the manufacturer's financial or business arrangement with the supplier.

#### **14. Verify that records of verification activities are maintained.**

*Clause and regulation:* [ISO 13485:2003: 7.4.3; RDC ANVISA 16/2013: 5.3.1; MHLW MO169: 39; 21 CFR 820.80]

*Additional country-specific requirements:* None

*Assessing conformity:*

##### **Records of verification activities**

The records of verification activities must show the supplied product is in conformity with specified requirements. If nonconformities are found by the organization, confirm the organization has appropriately handled the nonconformity according to the organization's established procedures.

The organization can address nonconforming product by taking action to eliminate the detected nonconformity (e.g. sorting an incoming lot of components to remove components that do not meet specifications), authorizing its use, release, or acceptance under concession, or by taking action to prevent its original intended use (e.g. allowing the components to be used as training aids to show production personnel the difference between an acceptable and unacceptable component).

For the supplied product(s) the audit team has chosen to review, confirm the records of verification activities have been maintained. One way to perform this task is to request a sample of verification records for the chosen product and confirm the acceptance activities have been documented, including the documentation and appropriate disposition of nonconforming product.

##### ***Link: Production and Service Controls***

The audit team may encounter instances where product has been deemed acceptable by the successful completion of acceptance activities but the product is later shown to not meet specified requirements (e.g. failure of the device due to nonconforming component leading to product complaint). This can be an indication that the acceptance activities are not sufficient to identify nonconformities; or were not appropriately conducted. Confirm that the organization has taken the appropriate action to determine the suitability of the acceptance activities. For example, the organization may need to validate the test method used for incoming acceptance to ensure the test method is actually capable of identifying nonconforming product.



**15. Verify that data from the evaluation of suppliers, verification activities, and purchasing are considered as a source of quality data for input into the Measurement, Analysis and Improvement process.**

*Clause and regulation:* [ISO 13485:2003: 8.4; RDC ANVISA 16/2013: 7.1.1.1; MHLW MO169: 61; 21 CFR 820.100]

*Additional country-specific requirements:* None

*Assessing conformity:*

**Collection and analysis of data**

The organization is responsible for assuring the supplied product meets specified requirements. In addition to supplier evaluation, the assurance that the supplied product meets specified requirements is accomplished with the implementation of appropriate acceptance activities and monitoring complaints and nonconformities associated with purchased product. The data regarding acceptance activities and nonconformities must be analyzed as appropriate to determine the need for corrective or preventive action.

***Links: Measurement, Analysis and Improvement***

The organization must determine the appropriate acceptance activities for supplied product, based on the essential design outputs of the device and the risk the device poses if specified requirements are not met. Confirm as necessary that supplied product was evaluated as to the effect on the essential design outputs. Additionally, verify that the appropriate acceptance activities were implemented based on the potential effect the supplied product poses to the essential design outputs.

Organizations are required to determine, collect, and analyze appropriate data to demonstrate the ability of suppliers to provide acceptable product. During the audit of the Measurement, Analysis and Improvement process, confirm that analysis of supplier performance data from evaluation and monitoring supplier process activities has been performed and considered for corrective or preventive action when necessary.

**16. Determine, based on the assessment of the overall purchasing, whether management provides the necessary commitment to the purchase process.**

*Clause and regulation:* [ISO 13485:2003: 4.1; RDC ANVISA 16/2013: 2.2.1; MHLW MO169: 5]